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ABSTRACT 
 
This study investigated the underlying mechanisms of outer membrane homeostasis in Gram-
negative bacteria. Using both the evolved laboratory strain E. coli K12 and the broad host 
range pathogen Salmonella enterica serovar Typhimurium, we have identified and 
characterised a series of non-essential genes responsible for the maintenance of the outer 
membrane barrier function. We have revealed their importance for bacterial pathogenesis 
suggesting their use as novel targets for drug development. This study has provided the first 
description of a pathway for phospholipid transport from the inner membrane to the outer 
membrane via the lipoprotein PlpA, a gene previously of unknown function. As several of the 
genes highlighted by our initial studies were associated with the biogenesis of virulence 
factors, we complemented our investigations by characterising the contributions of the S. 
Typhimurium Type V proteins to virulence in a murine model. These investigations have 
provided the first peer reviewed characterisation of a trimeric autotransporter from 
Salmonella, has identified a mechanism by which Salmonella can survive on tomatoes, and 
has highlighted the functional redundancy of these proteins in Salmonella infection. These 
findings have significantly advanced our understanding of the mechanisms mediating outer 
membrane homeostasis and the biogenesis and functions of virulence factors.  
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1.1. STRUCTURE OF THE GRAM NEGATIVE ENVELOPE  
The structure of the Gram-negative cell envelope is strikingly different to that of Gram 
positive bacteria, which have a single cytoplasmic membrane surrounded by the 
peptidoglycan (1). In contrast, Gram negative organisms contain an additional outer 
membrane (OM) surrounding a thinner layer of peptidoglycan, enclosing this within a 
periplasmic space (1-3).   
 
1.1.1. The structure and composition of the OM 
The OM of Gram negative bacteria is selectively permeable, preventing entry of toxic 
and bactericidal compounds, including hydrophobic substances and anionic detergents (4, 5). 
The membrane forms an asymmetric bilayer, comprised of lipopolysaccharide (LPS) on the 
outer leaflet, transported and inserted by the lipopolysaccharide transport (Lpt) pathway and 
phospholipids on the inner leaflet (1, 2, 4). LPS is comprised of three sections, consisting of 
lipid A providing a membrane anchor for the attachment of core and O- polysaccharides (6). 
Lipid A is comprised of fatty acids with ester amine linkages to glucosamine disaccharides, 
containing six to seven acryl chains, attaching the core polysaccharide structures via 
ketodeoxyoctanoate (KDO) (1, 2). This structure induces a strong anionic charge, connected 
by cationic interactions, creating an impermeable barrier (1). The inner leaflet is comprised of 
phospholipids including phosphatidylethanolamine (PE), phosphatidylglycerol (PG) and 
cardiolipin (CL) (2).  
The membrane is further punctuated with an array of β-barrel proteins, inserted by the 
β-barrel assembly machinery (BAM) complex and lipoproteins that are attached to the inner 
leaflet, via the localisation of lipoproteins (Lol) pathway (1, 2).  The integral β-barrel outer 
membrane proteins (OMPs) span the OM bilayer functioning as porins, membrane 
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stabilisation factors, efflux components or OM assembly complexes (1, 2). OMPs form 
monomers or trimers, comprised of between eight and 24 β-strands (dependant on the 
protein). The most common OMPs include the OmpF and OmpC trimers, with each monomer 
comprised of 16 β-strands. They are abundant with up to 250,000 copies per cell, allowing for 
the diffusion of small hydrophilic molecules <600 Da into the cell (1, 2). Other OMPs include 
LamB and OmpA, which are required for diffusion of maltose, maltodextrins and anions (1). 
In contrast, OmpA, can exist in a second non-porin form, which non-covalently binds 
peptidoglycan, stabilising the OM (1).  
OM lipoproteins in E. coli can be either surface exposed on the outer leaflet or 
protrude into the periplasm from the N-terminal cysteine residue, anchoring them to the inner 
leaflet, as shown for Braun’s lipoprotein Lpp (7).  To date over 100 different lipoproteins 
have been identified in E. coli (1). In many instances the function has yet to be determined, 
though Pal and Lpp are required to maintain cell shape and stabilise the OM through covalent 
attachments to the peptidoglycan (specifically the diaminopimelic acid [DAP] residue in the 
case of Lpp)(1). Pal also interacts indirectly with the inner membrane (IM) protein TolA via 
interaction with the periplasmic TolB, which also directly interacts with TolA, providing an 
additional stabilising interaction with the IM, thought to be critical for correct invagination of 
the OM during daughter cell separation (8). 
 
1.1.2. Periplasmic Space & Peptidoglycan 
The periplasmic space is an oxidising environment, absent of ATP which enables 
Gram negative bacteria to sequester harmful compounds, restricting their entry to the 
cytoplasm (1). The periplasmic space encloses the rigidly structured peptidoglycan between 
the two membranes. Comprised of multiple layers of glycosaminoglycan, a few nanometres 
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thick, cross linking N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) through a 
1-4 β link between DAP and D-alanine residues of the L-alanine, D-alanine, D-glutamic acid 
and DAP repeating structures, the peptidoglycan provides rigidity and cell shape. Preventing 
lysis due to changes in pressure (1, 9). 
The biosynthesis of peptidoglycan has been relatively well characterised and shown to 
progress in a methodical manner as shown in figure 1.1. The first steps in the biosynthetic 
pathway are performed by cytoplasmic enzymes, commencing with MurA catalysing the 
transfer of a enolpyruvyl modiety to uridine diphosphate (UDP)-N-acteylglucosamine 
(GlcNAc) to generate enolpyruvyl UDP-GlcNAc, this is then converted to UDP-MurNAc 
through an NADPH dependant reaction, catalysed by the reductase MurB. MurC-F 
subsequently catalyse the ATP-dependant ligation of amino acid side chains, L-Ala, D-Glu, 
DAP and D-Ala-D-Ala, respectively to UDP-MurNAc, generating the UDP-MurNAc-L-Ala-
D-Glu-DAP-D-Ala-D-Ala (MurNAc-pentapeptide)(10). Following the production of the 
MurNAc-pentapeptide, the IM localised MurY catalyses its transfer to the undecaprenyl 
phosphate carrier (C55-P or UP) creating lipid I. This reaction is thought to be coupled to that 
of the MurG catalysed conversion of lipid I to lipid II, via the transfer of UDP-activated N-
acteyl-D-glucosamine. Lipid II is then flipped across the IM by an as of yet unidentified 
flippase to the periplasmic face (10). The lipid II moiety is linked to the peptidoglycan strand 
by glycosyltransferase (GT) and transpeptidase (TP) enzymes, GTPGP and TPPGP, respectively, 
where the lipid II undergos initiation (combining two lipid II moieties) followed by 
elongation (adding a further two lipid moieties, ready for transpeptidation. Binding to the 
transpeptidase, converts the D-Ala-D-Ala to an acyl-enzyme intermediate, which can be then 
cross linked to the amino group of the peptidoglycan strands (10).   
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Figure 1.1. Peptidoglycan biosynthesis 
Pathway of peptidoglycan biosynthesis, with individual components shown at each stage, and 
the enzymes catalysing each reaction shown in blue. Arrows depict the order of sequence, 
with the first six reactions catalysed in the cytoplasm of cell, before the MurNAc-
pentapeptide is transferred to the inner leaflet of the IM membrane, where the addition of C55-
PP converts the molecule to lipid I, couple to MurG reaction converting lipid I to lipid II. The 
lipid moiety component is flipped across the membrane to the periplasmic face where it 
undergoes initiation and elongation reactions, combining multiple lipid II components, 
through the activity of PBP –GT (Glycosyltransferase) and TP (Transpeptidase). 
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Several OM components including, OMPs (OmpA), lipoproteins (MipA and Lpp) and 
cell envelope spanning complexes (Tol-Pal) can bind and associate directly with the 
peptidoglycan, acting as stabilisation factors, through tethering to both the OM and IM. In the 
case of OmpA and Pal, these interactions have been shown to be a result of non covalent 
interactions with the DAP residues of peptidoglycan (11, 12) . While the interaction with Lpp 
is mediated via a peptide bond, between the C-terminal Lys residue and DAP (13).  
Numerous murine hydrolyase enzymes have also been identified for the degradation 
and hydrolysis of peptidoglycan, with variations in their specific target site. For example, 
amidases required for hydrolysis during daughter cell separation specifically target the N-
MurNAc-L-Ala linkage, while muramidases such as MltA/MltB, cleave the linkages between 
MurNAc and GlcNAc components (13). The activity and expression of murine hydrolases is 
tightly regulated to prevent autolysis.   
 
1.1.2.1. Periplasmic Chaperones.  
 Despite the absence of ATP, numerous proteins including chaperones, proteases, 
isomerases and disulfide bond catalysts function to deliver, degrade, fold and modify proteins 
destined for the OM. Chaperones including SurA, Skp and DegP (to name but a few), 
transport polypeptides from the Sec translocon at the IM to the BAM complex, catalysing 
their folding, and/or degradation as required (1, 2). 
SurA, a peptidyl-prolyl isomerase (PPIase) forms the major chaperone pathway, with 
substrates including OmpA, OmpF, LamB and autotransporters (ATs) (14-16). The protein is 
composed of a 20 residue N-terminal region, two PPIase domains and a 35 residue C-terminal 
domain. Studies have shown the PPIase I domain is devoid of activity, and has more recently 
been suggested to form the binding site for OMP precursors during transit. In contrast, earlier 
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reports indicating the N-terminal region of the protein was required specifically for OMP 
precursor binding (17, 18). Deletion of surA induces serve membrane defects, resulting in 
elevated sensitivity to a range of compounds including vancomycin and SDS-EDTA (14, 15). 
In addition, abrogation of surA expression attenuates virulence in a range of pathogens, 
including Salmonella enterica serovar Typhimurium (S. Typhimurium), Uropathogenic 
Escherichia coli (UPEC) and Shigella flexneri, purportedly through disruption in the 
biogenesis of type 1 and P-fimbriae and the AT IcsA, respectively (18). 
DegP and Skp comprise an alternative chaperone pathway, predicted to function in 
parallel to SurA, while double mutants of degP and skp show only minor defects in OMP 
biogenesis, double mutants of either skp or degP with surA are synthetically lethal (3, 19). 
Transcriptionally activated by the Cpx and Sigma E (σE) pathways, DegP has long been 
known to function in a temperature dependant manner, alternating between serine protease 
and chaperone activity when the temperatures drop below 28
o
C (20-22). DegP provides cell 
envelope quality control, enabling the degradation or refolding of misfolded OMPs, 
preventing their accumulation in the periplasm and the induction of stress responses (21, 22).  
DegP normally exists as a hexamer (DegP6), formed from two trimers, though the functional 
protein is a multimer, DegP12 and DegP24, the formation of which is stimulated by substrate 
interactions (20, 22). Crystal structures of DegP have shown the N-terminal protease contains 
two PDZ domains, possessing  His105, Asp135 and Ser210, which are critical to both functions 
(21). With a molecular mass of 1.13MDa and diameter of 195Å, DegP24 is capable of 
accommodating proteins up to 300 kDa during chaperone or protease activity, eight times 
larger than that observed for the cytoplasmic chaperone, GroEL (20, 22).  
Skp, otherwise known as HlpA, comprises the alterative chaperone pathway, working 
with DegP, to collect OMP precursors that have fallen off the major SurA pathway (2, 19). 
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Characterisation of a skp mutant showed only minor defects in OMP assembly, though these 
mutants are defective for the release of OmpA precursors into the periplasm (1, 2, 23). Similar 
to degP, skp expression is also activated by σE and Skp is believed to be most critical during 
times of elevated cell envelope stress (24). 
 
1.1.3. Inner Membrane Composition 
The inner or cytoplasmic membrane is a phospholipid bilayer, decorated with α-helical 
proteins and protein complexes (25). The bilayer is comprised mainly of phosphatidyl 
ethanolamine and phosphatidylglycerol, with some cardiolipin phosphatidylserine and 
polyisoprenoid carriers for the translocation of sugar intermediates (1). Two main 
translocation systems exist for protein export across the IM: the Sec translocon and the Twin 
Arginine Translocation (TAT) system (1, 2). 
 
1.1.3.1. Inner Membrane Translocation Pathways.  
 The SecYEG translocon is a heterotrimeric protein complex, accepting unfolded 
polypeptides. Proteins are delivered to the SecYEG translocon by two different routes: the 
post-translational chaperone dependent pathway and the co-translational signal recognition 
particle (SRP)-dependent pathway. Once engaged, polypeptide translocation is driven by 
proton motive force and the ATPase activity of SecA, an associated accessory protein. The 
precursors are translocated in an unfolded N- to C- terminal direction.   
The majority of proteins exported by bacteria follow the post-translational chaperone-
dependent pathway with substrates including OMPs and ATs (1-3). These proteins emerge 
from the ribosome and are maintained in a translocation competent conformation by a 
chaperone; in the case of E. coli this function is performed by SecB (1).  Proteins exported in 
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this manner are characterised by the presence of an N-terminal Sec-dependent signal sequence 
that is cleaved by signal peptidase I after translocation through SecYEG.  With the co-
translational pathway, SRP binds the first transmembrane segment of the protein as it emerges 
from the ribosome and arrests translation (1). Subsequently, the ribosome-mRNA-nascent 
polypeptide complex is targeted to the IM by interaction of SRP with the IM receptor FtsY.  
This interaction aids the release of SRP and the transfer of the nascent polypeptide to the Sec 
translocon (26). Once SRP is released translation resumes such that export and translation 
occur contemporaneously. These substrate molecules can be released by the Sec translocon 
into the hydrophobic environment of the IM or into the hydrophilic periplasm (1, 26).  
The Tat complex functions in parallel to the Sec system, transporting folded proteins 
across the IM. Substrates for the Tat system are distinguishable by the presence of two 
arginine residues within the N-terminal signal sequence (27-30). The complex is composed of 
five functional proteins TatA, B, C, D and E. TatA forms the translocator, which exists in two 
states, one as complex of TatABC, approximately 370 kDa in size and the second as a TatA 
homo-oligomeric complex, ranging between 50-500 kDa (31). TatB and C are required for 
substrate targeting and binding and form the basic components of the translocation complex 
with TatA (1, 31, 32). Until recently TatD was thought to be unrelated, though recent 
investigations have shown this soluble component, is required for ‘quality control’ of the 
translocated substrates. Although the protein is not thought to be required for translocation per 
se, once substrates have been targeted to the complex, TatD recognises those which are 
misfolded, targeting these for degradation (33). TatE is a paralogue of TatA, which can also 
form translocation complexes in the absence of TatA, though these are significantly smaller, 
ranging between 50-110 kDa in size. Recent investigations have proposed that TatE may 
interact with the TatABC complex, to form larger translocation complexes of over 400 kDa, 
10 
 
to accommodate substrates >90 kDa (31). Substrates of this complex range in size between 
10-100 kDa and include the peptidoglycan amidases; AmiA and AmiC required for cleavage 
of NAM cross links during cell division and molybdoproteins TorA and DmsD (1, 28, 32, 
33). 
 
1.1.3.2. IM Sensory Pathways.  
 A number of IM associated protein complexes exist, sensing and responding to 
changes in cell envelope homeostasis, including EnvZ-OmpR responding to changes in 
osmotic pressure, σE and Cpx to cell envelope stress. The mechanism by which EnvZ 
(situated at the IM) senses osmotic pressure is largely unknown, though its 
autophosphorylation stimulates phosphorylation of the transcriptional regulator, OmpR, 
regulating the switching of expression between OmpF and OmpC  (34-36).  
The σE system, forms an extracytoplasmic stress response (ECR) system, sensing and 
responding to cell envelope stress in E. coli, through the regulation of 40 genes, including 
periplasmic chaperones, proteases, LPS biosynthesis and transcriptional regulators, including 
fkpA, surA, htrA, rfaCDF and rpoE/D/H  (37, 38). The σE system comprises of the IM proteins 
DegS, RseA and RseP and the periplasmic protein RseB (39). Under non-stressed conditions 
σE is sequestered by the IM spanning RseA, whereby σE is bound to the cytoplasmic N-
terminal of RseA. The interaction of σE and RseA is further stabilised by the binding of RseB 
to the periplasmic C-terminal of RseA, blocking the interaction of σE with RNA polymerase 
(39, 40). Under conditions of cell envelope stress, such as the accumulation of OMPs or high 
temperatures, a catalytic cascade is initiated resulting in the release of σE. The PDZ domains 
of DegS and RseP inhibit their catalytic functions under normal conditions, while the binding 
of unfolded OMPs to DegS results in activation of catalytic activity, promoting degradation of 
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periplasmic domain of RseA, thus releasing RseB into the periplasm. This activity simulates 
the catalytic response of RseP, resulting in the degradation of the transmembrane domain of 
RseA and subsequent release of σE into the cytoplasm, allowing for interactions with RNA 
polymerase, as shown in figure 1.2. (39, 40).   
CpxA, R and P sense and respond to both extracellular and cell envelope stress, in a 
similar manner to the σE pathway (25, 38, 41). Originally described as a two component 
system, comprising of the 52 kDa histidine kinase, CpxA and 26 kDa response element, 
CpxR, the periplasmic sensory component CpxP was only later identified (25, 42). CpxA 
spans the IM with both periplasmic and cytoplasmic exposed domains, whereby binding of 
CpxP to the periplasmic sensory loop maintains the complex in an inactive form, with CpxR 
bound to the cytoplasmic face (25, 41). Under conditions of stress the complex becomes 
activated through a series of degradation and phosphorylation reactions; whereby CpxP is 
degraded by DegP, enabling ATP dependant autophosphorylation of the conserved histidine 
residues on CpxA, which in turn phosphorylates CpxR at a conserved aspartate residue, 
allowing for direct interactions between CpxR and DNA (25, 43).   
The Cpx system responses to numerous cellular stimuli, including altered external pH, 
changes in membrane composition, the accumulation of misfolded pili subunits and the 
activation of NlpE by adhesion to hydrophobic surfaces (25, 42-45). The Cpx system 
functions across 34 operons, regulating and stimulating the expression of 50 genes, including 
periplasmic chaperones and proteases, peptidoglycan associated enzymes, IM associated 
proteins and cell envelope localised components (including ppiA, degP, amiA, amiC, hlpX and 
yccA) (43). 
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Figure 1.2. Membrane stress response pathways 
Mechanisms for responding to extracellular and periplasmic stress in Gram–negative bacteria, 
showing the components of the Sigma (σ) E and Cpx systems under both non-stressed and 
stressed conditions. The σE pathway is comprised of RseA/B/P, DegS and σE. Under normal 
conditions σE is sequestered by RseA, stabilised by the binding of RseB. Under conditions of 
periplasmic stress and accumulation of unfolded OMP precursors, DegS becomes activated 
leading to the degradation of RseA on the periplasmic face, stimulating the release of RseB 
into the periplasm and the catalytic activity of RseP, which degrades RseA at a 
transmembrane site, subsequently releasing σE into the cytoplasm to allow interaction with 
RNA polymerase. The Cxp system comprises the periplasmic CpxP, IM CpxA and 
cytoplasmic CpxR. Under normal conditions CpxP is bound to CpxA, inhibiting histidine 
kinase activity, thus preventing phosphorylation of CpxR. Stimulation of Cpx system by cell 
envelop or extracellular stresses, causes the degradation of CpxP by DegP, allowing for 
autophosphorylation of CpxA, which in turn phosphorylates CpxR, leading to its release 
enabling interactions with DNA to promote transcription of specific genes. Example shown 
for both systems is the activation of degP transcription, though neither system is limited to 
this gene alone.  
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Investigations into cell envelope stress responses mediated by σE and Cpx systems 
indicate significant overlap, with regards to the direct regulation of the same genes (i.e. degP), 
but also regulation of genes encoding functionally redundant proteins (i.e. isomerases such as 
FkpA and PpiA) (46). Though interestingly only components of σE pathway are essential for 
viability (46).  
  
1.1.4. Cell envelope complexes required for the biogenesis of OM components  
As discussed previously several complexes exist for the biogenesis and insertion of 
key OM components, including the Lol pathway for lipoprotein insertion into the OM, the Lpt 
pathway for LPS biogenesis and the BAM complex for the correct assembly of β-barrel 
OMPs (figure 1.3). Whilst no pathway, complex or individual proteins have been identified 
for the insertion of phospholipids into the inner leaflet of the OM, the Maintenance of Lipid 
Asymmetry (Mla) pathway has been shown to regulate OM phospholipid content.  
 
1.1.4.1. Lol Pathway.  
 The Lol pathway distinguishes OM lipoproteins, ensuring correct cellular localisation 
and catalysing their insertion into the membrane (1). Lipoproteins, similar to other cell 
envelope destined proteins contain an N-terminal signal sequence facilitating transport across 
the IM by the Sec translocon. For lipoproteins destined for the OM an additional N-terminal 
consensus sequence, termed a ‘lipobox’, consisting of Leu-(Ala/Ser)-(Gly/Ala)-Cys, targets 
these to the Lol pathway (1, 30). In contrast, IM destined lipoproteins, contain an aspartate at 
position two of the mature protein, functioning as a Lol avoidance signal (30). In 
contradistinction to OMP precursors, lipoproteins are modified by 
phosphatidylglycerol/prolipoprotein diacylglyceryl transferase, Lgt, forming a thioesther  
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Figure 1.3. Cell envelope pathways for OM component transport and insertions 
The components and pathways associated with LPS, OMP and Lipoprotein insertion into the 
OM, by the Lpt pathway, BAM complex and Lol pathway, respectively. All OM components 
are synthesised in the cytoplasm and transported by their dedicated pathways to the correct 
site. The Lpt pathway consists of LptB, C, F and G at the IM, whereby LptB energies the 
complex to allow release of LPS molecules to the periplasmic LptA, forming a bridge across 
the periplasm for the transport of LPS, where its transferred to the lipoprotein LptD and OMP 
LptE. Though the exact mechanism by which LPS becomes localised to the outer leaflet is 
unknown. The BAM complex folds and inserts OMP into the OM, OMP precursors are 
transported across the IM by Sec translocon and collected by periplasmic chaperones 
(including SurA, DegP and Skp) for transport across the periplasm to the BAM complex at 
the OM. SurA has been shown to directly interact with BamA POTRA (P) 1, transferring 
precursors to the complex. Lipoproteins BamB, C, D, E function in conjunction with the 
integral OM protein BamA to fold and insert β barrel OMPs into the membrane. Whereby 
BamB directly interacts with BamA through P2-5, BamD interacts with BamA independently 
of BamB, though P5, providing the means of interaction of BamC and BamE with BamA. The 
Lol pathway accepts OM destined lipoproteins from Sec machinery at the IM, transferring 
these to LolC (in complex with LolD and LolE at the IM), rearrangement of the complex 
allows for transfer of the lipoprotein to periplasmic LolA in an ATP dependant manner. LolA 
transports lipoproteins across the periplasm to LolB where they are transferred in an affinity 
dependant manner. Currently the mechanism by which LolB inserts lipoproteins into the OM 
is unknown.  
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diglyceride at the cysteine residue prior to signal sequence cleavage by signal peptidase II (1, 
30).  The N-terminal cysteine is then further modified by the phospholipid/apolipoprotein 
transacylase (Lnt), which adds a fatty acyl chain enabling the protein to be tethered to the 
membrane (1, 30).  
The IM ABC transporter LolCDE (present in 1:2:1 stoichiometry) facilitates the 
transfer of the OM lipoprotein from the IM to the periplasmic LolA, in an ATP dependant 
manner, during which LolC acts as a scaffold for LolA, LolE reorganises the complex for 
transfer and LolD catalyses the binding and hydrolysis of ATP (30). LolA is responsible for 
the delivery and transfer of lipoproteins to the OM LolB lipoprotein, which is itself anchored 
to the inner leaflet of the OM. The subsequent transfer of lipoproteins from LolA to LolB is 
predicted to occur in a ‘mouth to mouth’ action between the respective hydrophobic cavities 
of each protein. Transfer from LolA to LolB is thought to be mediated simply by LolB having 
a greater affinity for the acylated portion of the molecule. The mechanism of transfer and 
insertion of lipoproteins from LolB to the OM currently remains ambiguous, though both the 
N-terminal LolB membrane anchor and Leu68 are thought to be critical  (30). 
 
1.1.4.2. Lpt Pathway.  
 All components of LPS, including the core polysaccharide and the O-antigen 
polysaccharide (where applicable) are synthesised in the cytoplasm or at the inner leaflet of 
the IM, and require transport across the IM to the periplasm and beyond to the OM (47). The 
biosynthesis of lipid A occurs at the inner leaflet of the IM, with the addition of two Kdo 
molecules, to which four fatty acid chains are attached, prior to the addition of two CMP-Kdo 
residues, via the CMP-Kdo transferase, creating the Kdo2-lipid IVA molecule. This molecule 
undergoes acylation to form the hexaacylated Kdo2-lipid A molecule, before the addition of 
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sugars, via a specific glycosyltransferase to create the oligosaccharide core (47). The core 
lipid A molecule is anchored to the IM, with the hydrophilic moiety exposed to the 
cytoplasm, for flipping by the ABC transporter, MsbA (47, 48). 
O-antigen (where present) is also produced at the IM and attached to the lipid carrier 
undecaprenyl diphosphate. The precise O-antigen structure is highly variable amongst Gram-
negative bacteria and is dependent on the nature, order and linkage of the different sugars 
within the polysaccharide. The core lipid A and O antigen molecules are ligated on the 
periplasmic side of the IM, by the ligase WaaL (47).  
The hydrophobic nature of the LPS molecule presents a significant challenge to Gram-
negative bacteria, since they must transport the molecule through the hydrophilic environment 
of the periplasm. To facilitate this transfer, Gram-negative bacteria have evolved the 
conserved and essential Lpt pathway.  The Lpt pathway is a transenvelope complex formed by 
LptA-G (47, 49). LptB is cytosolic, forming a complex with LptC, F and G at the IM, while 
LptD and E comprise the OM β-barrel protein and lipoprotein, respectively (49). The ABC 
transporter LptB energises the complex, allowing for release of LPS from the IM to LptC. 
LptC mediates transfer of LPS to the periplasmic LptA protein, which forms a continuous 
bridge between the IM complex and the OM components. Transport of LPS across the 
periplasmic space to the OM components LptD and LptE is thought to occur in a continuous 
manner, much like a conveyor belt and although, the mechanism by which LPS is inserted 
into the OM still remains unclear(47, 49) two hypotheses exist: (1)  LPS is inserted into the 
inner leaflet of the OM and flipped to the outer leaflet or (2) LPS is released into the 
membrane through lateral transfer from LptD (47). 
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1.1.4.3. BAM Complex.  
 The BAM complex is required for the correct insertion of folded β-barrel OMPs into 
the OM (50-53). The complex is made up of the essential OMP BamA (previously known as 
YaeT) and four lipoproteins, including BamB (YfgL), BamC (NlpB), BamD (YfiO) and 
BamE (SmpA), of which BamD is essential (50, 52, 54, 55).  
BamA, is an integral OM-spanning β-barrel with an N-terminal extension of five 
polypeptide transport associated (POTRA1-5) domains extending into the periplasm (55, 56). 
The POTRA domains have been shown to mediate the interaction of BamA with BAM 
lipoproteins; BamB via POTRA2-5 and BamD via POTRA5, while POTRA1 interacts with 
the periplasmic chaperone SurA (55, 57). Despite having low sequence homology (<13% 
identity), the POTRA domains have been shown to demonstrate significant structural 
similarity. Each domain is comprised of three β sheets and two antiparallel α helices (55, 56, 
58). However, POTRA3 displays key difference from the other POTRA domains; it possesses 
a longer loop between the two α helices and a β bulge located in β strand two, allowing for the 
binding of additional β strands (58). Subsequent NMR and SAXS analyses revealed each 
POTRA domain exists in a monomeric form, with rigid hydrogen bonding between POTRA1-
2 and POTRA3-4 (58). Interestingly, the structures of POTRA2-3, solved by two separate 
groups, demonstrated significantly different degrees of conformation (30
o
 and 130
o
) in the 
angle connecting these domains, suggesting this connection serves as a flexible hinge, to draw 
substrates closer to the BamA barrel (59, 60).  
While the structures of all POTRA domains were determined some time ago, the 
structure of the BamA barrel was only published in September 2013 (61). The structure of the 
β barrel, indicates BamA contains a large periplasmic domain which is attached to the 16 
stranded β barrel, with extracellular loops and periplasmic loops connecting the individual 
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strands. Loops 4, 6 and 7 have been shown to form a large ‘dome like structure’ across the top 
of the barrel, whereby loop 4 encodes an α helix predicted to be positioned horizontally to the 
membrane, allowing the formation of electrostatic interactions with loops 3 and 6 along the 
surface, sealing the barrel lumen from the extracellular environment (61).  Uniquely the 
structure indicates the interactions between β strands 1 and 16 are sufficiently destabilised to 
promote lateral opening of the barrel into the OM, a mechanism previously thought to be 
biophysically unfavourable. Though consistent with this hypothesis, analyse of the local 
membrane environment surrounding the barrel, suggests the hydrophobic extracellular surface 
results in local destabilisation of membrane lipids, priming the membrane ready for OMP 
insertion (61). In light of this publication, several theories regarding the biogenesis of OM β 
barrel proteins may need to be reinvestigated, to reconcile previous hypotheses with this 
model for lateral transfer.  
As described above the BAM complex includes four lipoproteins. BamB is highly 
conserved and interacts directly with BamA through POTRA2-5 domains mediating the 
transport of OMPs from chaperones (e.g. SurA) to the complex (52, 54, 56, 62, 63). Structural 
investigations have suggested BamB is capable of interacting with both BamA and unfolded 
OMPs simultaneously, by β augmentation, supporting the OMP precursor during folding (64). 
Deletion of bamB causes serve defects in OMP biogenesis, increased permeability and 
sensitivity towards antibiotics including vancomycin (54, 56, 57). However, the underlying 
molecular basis for this defect has yet to be elucidated. 
BamC forms a surface exposed lipoprotein. It is predicted to maintain the stability and 
function of the BAM complex by enhancing the efficiency of interactions with OMPs. 
However, deletion of bamC results in only a slight membrane permeability defect, as 
determined by increased sensitivity to rifampicin (55, 56, 65). 
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BamD is the only other essential component of the BAM complex (52, 55). Interacting 
with BamA via POTRA5, it provides the scaffold connecting BamC and BamE to the 
complex (55). BamD is predicted to act as a substrate recognition protein, binding the C-
terminus of β-barrel precursor molecules, functioning paradoxically with BamE to mediate 
the switching of BamA conformations (55, 58, 63, 66). In this model BamD mediates the 
conformational change of BamA, creating a protease sensitive form, where extracellular loop 
6 becomes surface exposed (67). BamE restores BamA to the protease resistant form, in 
which loop 6 is predicted to reside in the barrel. The function of these morphological changes 
has get to be confirmed, though this change in conformation is proposed to represent the cycle 
of OMP biogenesis, whereby BamA is required to adopted an altered conformation, in order 
to complete the biogenesis, while BamE returns the complex to its native form upon 
completion  (66). 
BamE is also nonessential and was proposed to stabilise the complex through 
interactions with inner leaflet phosphatidylglycerol (68). Similar to that of other nonessential 
BAM components, deletion of bamE does not appreciably affect the biogenesis of ATs, 
although it does result in elevated sensitivity to markers for membrane permeability including 
vancomycin (69). 
 
1.1.4.4. Phospholipid Transport.  
 To date no mechanistic pathway for the means which phospholipids are inserted into 
the inner leaflet of the OM has been identified, despite early investigations having shown the 
rates of phospholipid translocation from the IM to OM are not consistent with that of 
diffusion nor is this process coupled to protein or LPS biosynthesis (70). Though it has 
previously been suggested that lipoproteins may play a partial role, this hypothesis has yet to 
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be confirmed experimentally (30). Identification of the Mla pathway, provides significant 
insight into the means by which bacteria regulate, and prevent phospholipid accumulation in 
the outer leaflet of the OM (71), though this pathway functions solely for recycling and not 
insertion. The Mla pathway is comprised of MlaBDEF complex at the IM, the periplasmic 
component, MlaC and OM lipoprotein, MlaA (71). MlaA is predicted to remove 
phospholipids from the outer leaflet of the OM, transferring these to the soluble MlaC for 
trafficking back to the IM complex MlaBDEF (figure 1.4), after which the fate of the 
phospholipid is currently unknown (71).   
This system differs from the already known mechanisms of PldA and PagP, which 
destroy outer leaflet phospholipids recycling them via the Fatty Acid Degradation (FAD) 
pathway and catalysing the transfer of palmitate from the sn-1 position on phospholipids to 
lipid A, respectively (72, 73). Consistent with these similar functions, over expression of 
pldA, but not pagP, can compensate for the loss of mla (71).  
 
1.2. SECRETION SYSTEMS IN GRAM NEGATIVE BACTERIA 
The ability of bacteria to secrete proteins is an essential facet of survival. Secreted 
proteins provide an array of beneficial functions for bacterial cells including acting as 
mediators of motility and nutrient acquisition, immunomodulators and adhesins.  However, 
the impermeable nature of the OM poses a significant barrier to the secretion of proteins to 
the extracellular milieu since these proteins are larger than the diffusion limit of the OM.  
Gram-negative bacteria have evolved a limited number of specialised proteinaceous 
machineries to overcome this obstacle. To date seven OM secretion systems have been
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Figure 1.4. Mechanisms for maintaining OM asymmetry 
The asymmetric nature of the OM, with LPS on the outer leaflet and phospholipids on the 
inner leaflet is maintained by three methods; the Mla pathway and the OM proteins PagP and 
PldA. The Mla pathway consists of the OM lipoprotein MlaA, which is predicted to remove 
phospholipids from the outer leaflet, transferring these to the periplasmic MlaC for transport 
back to the IM complex MlaB, D, E and F, where the fate of the phospholipids is unknown. 
PagP is localised to the OM with the active site exposed to the extracellular environment. The 
means by which PagP interacts with outer leaflet phospholipids is unknown, though 
predictions suggest the mislocalisation of phospholipids promotes access to PagP, which 
catalyses the transfer of palmitate from the sn-1 position to lipid A. PldA is found in two 
conformations, the inactive monomer or active dimer, binding of calcium promotes 
dimerisation, catalysing the removal of sn-1 and sn-2 fatty acid chains from the phospholipid 
backbone. Currently no pathway or mechanism has been identified for phospholipid transport 
to the OM. 
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identified, as shown in figure 1.5 and 1.6 (74, 75). Most of these utilize a series of protein 
complexes, comprised of numerous accessory proteins functioning in conjunction with 
chaperones and other factors. However, they can be largely subdivided into two categories: 
(1) the one step mechanism whereby substrates and effector molecules are transported directly 
from the cytosol to the either the extracellular environment or eukaryotic host cell or (2) the 
two step mechanism, whereby substrates require transport across the bacterial IM, prior to 
secretion (75). 
 
1.2.1. One-step secretion systems across the OM 
The Type I secretion system (T1SS), is composed of a tripartite system, delivering 
proteins of varying size (82- 8000 amino acids) directly from the bacterial cytosol to the 
extracellular environment. Substrates of the T1SS include toxins, proteases, lipases, S-layer 
proteins, bacteriocins and other proteins with as yet unknown functions. The best studied 
example is that of hemolysin found in UPEC and Enterohemorrhagic E. coli (EHEC) (75, 76). 
The T1SS comprises of the IM traffic-ATPase (ABC) or proton-antiporter, a periplasmic 
adaptor or membrane fusion protein (MFP) and an Outer membrane factor (OMF), which is 
normally TolC or a related protein (75). TolC forms a 12-stranded trimeric OMP with -
helical periplasmic extensions.  The periplasmic domains of TolC interact with the IM ABC 
protein through interactions with the periplasmic MFP creating a continuous channel through 
the bacterial cell envelope (77).  The system utilises ATP binding and hydrolysis to drive the 
transport of substrates (75). 
A system with many analogies to the T1SS is the multidrug efflux pump formed by 
TolC, AcrB (the IM ABC) and AcrA (a periplasmic MFP), which mediates the interaction 
between AcrB and TolC. Together this complex confers resistance to compounds including
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Figure 1.5. Type 1,2,3,4 and 6 secretion systems of Gram negative bacteria 
Simplified schematic of secretion systems found in Gram-negative bacteria for the export of 
proteins and DNA to either the extracellular environment or the cytoplasm of host cells. 
Type1,3,4 and 6 provide one step secretion of their relevant substrates, while Type 2, requires 
the assistance of the Tat or Sec Translocon at the IM for transport of substrates to the 
periplasm in preparation for export. The Type 1 SS, is exemplified by the export of 
Hemolysin. Type 2 SS complex is envelope spanning, utilising ATP to drive secretion of the 
substrates to the extracellular environment. Type 3 secretion, also known as injectosome, 
transports effector molecules directly to the eukaryotic cell cytosol, with some of best studied 
examples being that of SPI1 and SPI2 encoded T3SSs in Salmonella. Type 4 secretion 
promotes conjugative transport of DNA, plasmids and other mobile genetic elements, directly 
to recipient cells. The Type 6 SS, is homologous to the that of bacteriophage secretion 
systems, enabling secretion of effector molecules directly into the host cell cytosol. 
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Figure 1.6. Type V secretion  
The subclasses of the Type V SS, designated a-e. This two step system, uses the Sec 
translocon at the IM to transport AT precursors to the periplasmic space where they are 
collected by periplasmic chaperones (including SurA, DegP, FkpA) for transport to the BAM 
complex at the OM. BamA and BamD have been shown to be critical for the secretion of Va 
proteins, through the requirements for other subclasses have yet to be explored. The BAM 
complex folds and inserts the β-barrel domain into the OM, while the TAM complex is 
predicted to assist in passenger domain folding. Va proteins are encoded as a single 
polypeptide forming a 12 β-barrel in the membrane, with a secreted or surface exposed 
passenger domain, examples include ShdA and MisL from S. Typhimurium. In the case of Vb 
or two partner secretion, the β domain and passenger domain are encoded for by separate 
polypeptides. Where the β domains fold to form a 16 stranded barrel with two N-terminal 
POTRA domains, examples include FHA from B. pertussis and HMW1 from H. influenza.   
Vc comprise the TAAs, whereby three monomers conform to create the 12 β-barrel in the 
membrane with a trimerised passenger domain attached at the surface, including the 
prototypical example YadA from Y. enterocolitica. Vd, the fussed two partner secretion, is 
encoded by a single polypeptide with a POTRA domain encoded between the passenger and 
β-domains, with PlpD from P. aeruginosa being the main example. Ve are inverted ATs 
where the β-domains are encoded N-terminally, with C- terminal passenger domain, separated 
by a LysM domain. The main example is Intimin from E. coli. 
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antibiotics, dyes, organic solvents, detergents (78, 79) and natural metabolites including 
indole and siderophores (51, 77). Other drug efflux systems with differing specificities also 
exist within E. coli (80). 
The Type III secretion system (T3SS), also known as the injectisome, mediates 
transport of effector molecules from the bacterial cytosol directly to the cytosol of eukaryotic 
cells. This system has been extensively studied in Salmonella, Shigella, Yersinia and various 
E. coli types, including Enteropathogenic E. coli (EPEC) and EHEC strains, to name but a 
few. The T3SS is composed of over 20 proteins, including highly conserved membrane 
proteins, cytoplasmic chaperones and several accessory proteins (75). The structure of the 
complex is significantly similar to that of flagella, with their biogenesis tightly controlled in a 
stepwise manner, with the initial formation of the basal body, preceding that of the needle 
(75). While the effector molecules secreted by these complexes have no obvious signal 
sequence, the N-terminal 20-50 residues commonly share an unusual enrichment of serine and 
there is evidence that the 5’ mRNA plays a role in secretion. Suggesting a combination of co-
transcriptional regulation of effectors with T3SS chaperones may aid in their targeting to the 
complex (81).  
The Type IV secretion system (T4SS) is responsible for the conjugative transfer of 
DNA, plasmids and other mobile genetic elements (75). These systems are composed of 12 
individual proteins, named VirB1-11 and VirD4, spanning the cell envelope. VirB4-B11 and 
VirD4 form the IM associated ATPase in conjunction with the IM complex formed by VirB6, 
B8 and B10, VirB7 and B9 comprise the OM complex, while VirB2 and B5 are required for 
surface contact with host cells and VirB1 functions as lytic transglycosylase, breaking down 
peptidoglycan to allow complex assembly. Additionally, VirB3 is IM associated, though its 
function is unknown (75). This secretion system has been extensively investigated in the 
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gastric pathogen Helicobacter pylori where it is encoded by the 40-kb cag pathogenicity 
island (cag PAI). The system translocates the cytotoxin associated gene A (CagA) into host 
epithelial cells, which stimulates the induction of NF-κB and pro-inflammatory immune 
responses (82).  
The recently discovered Type VI secretion system (T6SS) was identified and named in 
2006, after its initial identification in Vibrio cholera and Pseudomonas aeruginosa. Initially 
named as virulence associated secretion (VAS) due to its requirement for contact-dependent 
cytotoxicity in amoebae and macrophages (83). The T6SS is present in a variety of Gram 
negative organisms and its transcription (where examined) is linked to that of other virulence 
associated complexes, including T3SS, though is predicted to be tightly controlled through 
post translational modifications (84). T6SSs are commonly encoded for by 13-25 genes 
dependant of the species, forming a needle like structure similar to that observed with the 
T4SS (85, 86). Components of the T6SS are largely subdivided into three categories; 
membrane proteins (TssL and TssM) or lipoproteins (TssJ) forming a cell envelope complex 
with peptidoglycan, several proteins of unknown function (TssA, TssF, TssG and TssK) and 
bacteriophage tail like proteins (hemolysin coregulated protein [Hcp] and the valine–glycine 
repeat protein G [VgrG], TssB, TssC and TssE) (86). Of this latter group, TssB and TssC 
form sheath like tubular structures, enclosing the Hcp tubular domain, which is thought to 
holding the Hcp/VgrG complex in place at the cell envelope, until activation when release 
from TssB/C shealth provides propulsion to direct Hcp/VgrG through the cell envelope and 
into the membrane of the target cells (86).      
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1.2.2. Two-step secretion across the OM 
The Type II secretion system (T2SS) is a two step secretion mechanism, with 
substrates requiring translocation to the periplasm, prior to secretion across the OM (75). 
Substrates for the T2SS can be translocated across the IM by the Sec or Tat translocons (75).  
The substrates then dock with the T2SS which is an envelope spanning complex comprised of 
12-16 protein components. These are usually transcribed as a single operon and are highly 
conserved across both human and plant pathogens. In E. coli these proteins have been 
designated as GspA to GspO (75, 87). GspA and GspB form part of the IM complex, required 
for energy transduction from ATP hydrolysis, GspC selects the substrate, GspD oligomerizes 
forming the OM channel, GspE functions as cytoplasmic ATPase, GspF forms the inner 
transmembrane protein, while GspG to GspK form the major and minor pseudopilin (75, 87). 
Substrates of this system include a variety of toxins and enzymes, including lipase, elastase, 
alkaline phosphatase and phospholipases (87). 
The chaperone usher (CU) pathway is responsible for the secretion of surface 
associated pili and fimbriae. With a dedicated periplasmic chaperone, and OM pore protein 
termed the usher component, directing assembly (75). The chaperone prevents polymerisation 
in the periplasm, and directs subunits to the usher platform where polymerisation is controlled 
in a sequential manner. (88). P and Type 1 pili are two of the most well studied examples in 
pathogenic E. coli strains, ranging in size between 12 and 20 kDa, dependant the number of 
major subunits. Both P and type 1 pili are relatively similar, though type 1 exhibit a shorter 
fibrillae tip (88). These multi-subunit structures are polymerized from the distal tip with 
PapG/FimH first, followed by an adaptor subunit PapF (P pilus only) and five to 10 subunits 
of PapE or one FimG. The adaptor subunits PapK/FimF connect the tip to the major rod 
PapA/FimA, of which potentially thousands of subunits maybe present, with the terminal 
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subunits PapD/FimC attached at the base, and in the case of P pilus, followed by the 
terminator subunit, PapH (88).  These structures have long been associated with virulence, 
biofilm formation, adhesion and motility (75, 88).  
 
1.2.3. The Type V Family 
The Type V secretion system (T5SS) can be subdivided into classes Va-Ve, based on 
the genetic organisation and protein structure (figure 1.6). This system is the simplest and 
most wide spread protein secretion system in Gram negative bacteria (89). Proteins secreted 
by the T5SS are characterised by the presence of three key domains: (1) an N-terminal signal 
sequence, (2) a secreted or surface exposed passenger and (3) an integral outer membrane -
barrel to mediate translocation of the passenger domain to the cell surface (90-92).  
The signal sequence is required for Sec-dependant targeting and translocation across 
the IM. Analyses of the signal sequences from several proteins secreted by the T5SS reveal 
the presence of two distinct groups: those containing a classical signal sequence of 20-30 
amino acids, and those that encode a signal sequence of 50-60 residues (74, 90). When 
compared to the classical signal sequences, the larger signal sequences possess an N-terminal 
extension sequence of approximately 25 amino acids (74). Previous speculation regarding the 
function of the extended signal sequence, suggested it may be required for SRP targeting or to 
direct the polypeptide to an alternative translocator at the IM, such as the Tat system (93). 
However, more recent investigations have resolved this matter, having shown the extended 
sequence inhibits SRP binding, maintaining the protein in an unfolded manner whilst in the 
cytoplasm (74, 90). Interestingly, these extended signal sequences are confined to proteins 
larger than 100 kDa (90, 93).  The various modes of passenger domain translocation across 
the OM are detailed in the sections below. 
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1.2.3.1.Type Va (Classical ATs). 
  The Type Va are also known as the ‘classical ATs’. In the case of the classical ATs 
the protein is encoded by a single polypeptide containing a signal sequence, a C-terminally 
located translocator or  domain and an autochaperone (AC) domain located between the 
passenger and β domains (92). The translocator domain forms a 12 stranded β barrel in the 
OM, while the majority of the passenger domains (>97%) fold to form a right-handed β 
helical arrangement. In contrast, the remaining passenger domains (<3%) have been shown to 
form a globular structure, rich in α helices (94).  
The term ATs was based on early hypotheses that the AT polypeptide contained all the 
elements required for its own secretion. Since their initial identification, with the isolation and 
characterisation of the IgA protease from Neisseria gonorrhoeae (95), significant amounts of 
research have shown this theory of self export is not strictly true, but requires numerous other 
cellular complexes and proteins to aid in their secretion and folding (90). Once the AT 
polypeptide emerges from the Sec translocon it must be trafficked to the OM, by periplasmic 
chaperones including SurA, DegP, Skp and FkpA which have been shown to be critical for 
translocation of EspP precursors (16, 96). Chaperone AT interactions prevent misfolding and 
the accumulation of aggregated precursors in the periplasm, though binding and degrading, 
respectively while en route (16).   
As SurA is required for efficient AT biogenesis, and is known to dock with POTRA1 
of the BAM complex, it was hypothesised that the BAM complex must be directly involved in 
the assembly of ATs. In support of this hypothesis, Jain et al (97) demonstrated that depletion 
of BamA inhibited the secretion of IcsA and SepA from Shigella flexneri.  Since this 
investigation the involvement of the BAM complex in the assembly and biogenesis of ATs 
into the OM has been identified for several species (98, 99). As described above, chaperones 
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translocate AT precursors across the periplasmic space to the BAM complex, where the 
essential BAM components, BamA and BamD are required for biogenesis (16, 63, 90). 
Interestingly thoughly, the non-essential lipoprotiens BamB, C and E  are not involved in AT 
secretion nor do they contribute to passsenger domain folding, in the case of Antigen 43 
(Ag43) or Pet (100). 
Whilst it is clear that the BAM complex plays a crucial role in the biogenesis of ATs, 
the mechanism by which the passenger domain is secreted to the exterior of the cell remains a 
subject of extensive research. Several models were proposed for the mechanism of passenger 
domain secretion: N-terminal threading, multimer, BamA, and hairpin. However, several 
investigations provided evidence that largely discounted two of these theories, with the most 
viable options remaining being that of the BamA and hairpin models (90). 
The BamA model suggests the AT  barrel is maintained either in the pore of BamA 
or adjacent to BamA, in a semi-folded state, allowing for a larger pore size and thus secretion 
of the passenger domain in a hairpin like manner or alternatively the passenger domain is 
secreted via BamA first with the AT β domain being inserted second (90). Consistent with the 
proposed BamA model, studies in N. gonorrhoeae have shown BamA can form pores up to 
2.5 nm in diameter, sufficient to accommodate a partially folded passenger domain (90). 
Additionally the recently described structural data for BamA does suggest lateral opening into 
the membrane is possible (61), which does give more premise to the theory of BamA 
maintaining the AT  barrel in a partially folded conformation to allow for passenger domain 
secretion in a hairpin like fashion. As investigations with ATs containing engineered 
passenger domains with large periplasmic secondary structures can block secretion when the 
secondary structure is above a certain size (101). Though closer inspection of these stalled 
intermediates indicates the C terminal region of the passenger domain is exposed on the 
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surface while the N terminal region is undetectable, in the barrel lumen and periplasm (101), 
consistent with the hairpin model of secretion. Thus the BamA model, promoting hairpin like 
secretion of the passenger domain, does additionally reconciling previous complications with 
the suggested idea of the AT -barrel promoting hairpin like secretion of the passenger 
domain in the absence of other factors. Particularly regarding the issue that a folded AT -
barrel alone, is too narrow to accommodate anything more than two completely unfolded 
polypeptides (90), though the presence of linker region within the  barrel has been shown to 
be a requisite for passenger domain secretion in EspP (102). Providing further evidence 
towards the theory that BamA maintains the AT -barrel in a semi-folded/incomplete 
conformation which does allow for the formation of linker region structures, to enable hairpin 
secretion and folding of the passenger domain, prior to AT protein release from BamA as a 
completed structure.   
In addition to the above described model, the recently discovered TAM complex has 
been proposed to aid in passenger domain secretion after insertion of the β domain into the 
membrane by BamA (103). The TAM complex is comprised of the 16-stranded OM β barrel 
protein TamA, which contains three N-terminal POTRA domains extending into the 
periplasmic space, predicted to mediate interactions with the IM protein, TamB. Additionally, 
TamA is present across all classes of proteobacteria, and shows significant sequence 
homology to that of other Omp85 proteins, including BamA (103).  
Investigations with C. rodentium tamAB double deletion mutants indicated the 
requirement of these proteins for OM localisation of the AT protein p1121 in this strain. 
While in E. coli K12, tamAB mutants expressing either Ag43 or EhaA are significantly 
reduced in their ability to autoaggregate indicating these proteins were not displayed on the 
bacterial cell surface in a functional manner (103-105). The TAM complex is predicted to 
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work in collaboration with the BAM complex, whereby the BAM inserts the AT β barrel into 
the OM, while TAM aids in the secretion of the AT passenger domain (103). However, this 
hypothesis requires to be reconciled with the recently published structural information for 
BamA and the current published models for AT passenger domain secretion.  
Once secreted to the bacterial cell surface the passenger domain must be folded into its 
mature form.  In the case of passenger domains that adopt a -helix, the AC domain folds on 
extrusion to the bacterial cell surface and templates the folding of the -helix.  Several studies 
have suggested that the AC domain may drive passenger domain secretion with folding 
providing the impetus for movement of the passenger domain through the -barrel lumen. 
However, this is controversial as heterologous constructs lacking the AC domain may be 
translocated to the bacterial cell surface and a small proportion of ATs, with surface exposed 
globular passenger domains, lack AC domains completely.  
Once secreted to the bacterial cell surface the fate of the folded passenger domain can 
vary dramatically depending on the protein. The passenger domain may be cleaved releasing 
the passenger domain from the barrel e.g. the SPATE class of ATs, or it may remain as a 
single uncleaved polypeptide displaying the functional domain on the surface e.g. EstA (106-
108).  In a limited number of cases, the passenger domain may be cleaved but remain 
associated with the bacterial cell surface through a non-covalent interaction with the  domain 
e.g. Ag43. 
 
1.2.3.2. Type Vb (Two Partner Secretion).  
 The Vb or Two-partner secretion (TPS) is similar to the classical ATs, with the 
distinct difference that the α and β domains are transcribed as two separate polypeptides each 
containing an N-terminal Sec dependant signal sequence, termed TpsA and TpsB, 
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respectively, which are commonly (but not always) transcribed from the same operon (109). 
Similar to other AT subclasses, once in the periplasm, the β domain is folded and inserted into 
the OM as a β barrel, allowing for the secretion of the passenger domain (91, 92).  
In contrast to the Type Va subclass, the TSP β domains (TpsB) form a 16-stranded β 
barrel in the OM, containing two POTRA domains, extending into the periplasmic space. 
These -domains belong to the Omp85 family of proteins and displays homology with both 
TamA and BamA.  The POTRA domains are predicted to be involved in the recognition of a 
specific motif (termed the TPS domain) located in the N-terminus of the TpsA passenger 
protein. This recognition event initiates passenger domain secretion through the lumen of 
TpsB, facilitates folding of the passenger domain and is based on recruitment of TpsA β-
strands by means of β-augmentation (110-113).  The passenger domains of these proteins are 
often large, with many TpsA proteins >3000 amino acids. Despite the sequence diversity 
among these proteins, they usually fold into a right-handed β helical conformation similar to 
those observed for the classical ATs (109, 114).  
 
1.2.3.3. Type Vc (Trimeric AT Adhesins). 
 The trimeric AT adhesins (TAA) are unique from the previous two classes. Whilst 
being transcribed as a single polypeptide, the β domains are considerably shorter than that 
observed for other ATs, composed of only 70-100 amino acids, in contrast to the ~300 amino 
acids observed for Va (115, 116).  These shorter β domains contribute four β strands forming 
a homotrimer in the OM, generating the 12 stranded functional β-barrel in the OM (91, 92, 
117, 118). The passenger domains also trimerise to form the functional moeity and normally 
consist of three individual subdomains; head, neck and stalk, as observable as Pfam:Hep_Hag 
(PF05658) motifs (head), a single Pfam:HIM (PF05662) motif (neck) and a series of small 
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unconserved repeats comprising the stalk (118). To date all characterised Vc proteins have 
been shown to function in adhesion, with the prototypical example being that of YadA from 
Yersinia enterocolitica, through several other characterised TAAs include UpaG from UPEC, 
Hia from Haemophilus influenzae and NadA from Neisseria meningitidis, to name but a few 
(75, 119). 
 
1.2.3.4. Type Vd (One Piece TPS).  
 The recently described patatin-like protein, PlpD, identified in an environmental 
Pseudomonas strain lead to the annotation of a fourth type V subclass (120). Similar to the 
classical and trimeric ATs, Type Vd proteins are transcribed as a single polypeptide. 
However, the β domains are not homologus to the β-domains of these sytems but rather 
display homoly with the TpsB proteins of the Type Vb family of proteins. Like the TpsB 
proteins these proteins possess POTRA domains located between the passenger and β 
domains, indicative of a gene fusion event between TpsA and TpsB (92). To date no Vd 
proteins have been identified in E. coli, though further investigation may yield the 
identification of new proteins.  
 
1.2.3.5. Type Ve – Inverted AT.   
 The Type Ve subfamily were only recently categorised as part of the T5SS family. 
These proteins are similar to the Type Va ATs, with the key difference being the inverted 
orientation of the passenger and β domains within the polypeptide (91, 92). Each protein is 
encoded as a single polypeptide, with an N-terminal Sec dependant signal sequence followed 
by the β domain, a LysM domain (associated with peptidoglycan binding) and the C-terminal 
passenger domain (121, 122). In contrast to the classical ATs, this inverted structure results in 
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passenger domain secretion occurring in an N to C terminal direction. However, like the 
classical ATs, this subfamily also produce 12-stranded β domains (91). Furthermore, the 
passenger domains of these proteins adopt an Ig-like fold which often possess significant 
disulphide bonding.  Key examples of this subclass, include Intimin from E. coli and Invasin 
from enteropathogenic Yersinia spp. shown to be critical for adhesion and cell contact with 
host cells (91).   
 
1.2.4. Functions of proteins secreted via the T5SS.  
 ATs characterised to date are associated with numerous pathogenic phenotypes, 
including binding extracellular matrix (ECM) proteins, adhesion and invasion of host cells, 
autoaggregation and biofilm formation, promoting serum resistance and apoptosis of specific 
cell types or functioning as toxins in host cells, to name but a few roles (75, 92). Though 
specific functions are often associated with particular protein subclasses and are commonly 
infection site and species specific, making functional predictions difficult. For example two of 
the three Type Va AT from S. Typhimurium, MisL and ShdA have been previously 
characterised. Consistent with the mode of Salmonella infection, these proteins have been 
shown to promote adhesion to ECM molecules, including fibronectin and collagen I (ShdA 
only), in addition to human epithelial cell lines (123, 124). While EhaB from EHEC, although 
also associated with ECM binding of collagen I, this protein additionally binds laminin and 
has been shown to be associated with phenotypes including biofilm formation and 
autoaggregation (125). While in stark contrast to these, the Type Va protein EstA from 
Pseudomonas aeruginosa encodes a GDSL passenger domain, with catalytic activity, 
preferentially hydrolysing of short chain fatty acids, particularly those ranging between four 
and six carbons (126, 127). All characterised TAAs (to date) have been associated with 
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adhesion to ECM molecules and various cell types. For example the prototypical example 
YadA from Yersinia enterocolitica binds a variety of extracellular matrix proteins, including 
collagen, laminin, and fibronectin (92). In addition to promoting serum resistance (92). By 
contrast the TAAs UpaG and EhaG from UPEC and EHEC, respectively, are more commonly 
associated with promoting biofilm formation and autoaggregation, though have been shown to 
bind bladder cells and colorectal epithelial cells, representative of the differing sites of 
infection associated with these strains (128). As general guide Table 1.1. details the 
phenotypes of a selection of proteins from various subclasses.  
 
1.2.5. Outlook for T5SS research.  
 As ATs represent a family of large OM localised structures, there potential as possible 
vaccine candidates provides real promise as shown with the success of the acellular 
Bordetella pertussis vaccine against whooping cough, which includes purified Pertactin and 
Filamentous Hemagglutinin (FHA), Va and Vb proteins. While the recently developed 
Bexsero vaccine against Serogroup B meningococcal, contains the Vc protein NadA (129). 
Inducing protection without the risks associated with using attenuated bacterial strains, which 
have the capability of reverting to pathogenic forms (130). Investigations using other OM 
structures, including the OM porin OmpD from S. Typhimurium have shown similar promise, 
with the ability to induce T cell independent antibodies, which are protective (131). These 
results highlight the need for further investigation in this field. 
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Table 1.1. Type V Proteins – Classification and Functions 
Name V Organism Description Reference 
Antigen 
43 
a E. coli β helical, cleaved but remains covalently 
attached, autoaggregation and biofilm 
formation 
(132, 
133) 
ApeE a S. Typhimurium Globular α helical structure, Esterase, 
degrading C6-C16 fatty acid chains  
(127) 
EhaB a EHEC β helical, ECM binding and biofilm 
formation  
(125) 
EstA a P. aeruginosa Globular α helical structure, Esterase, 
degrading C4-C8 fatty acid chains, 
additional roles in motility and biofilm 
formation 
(126, 
127) 
MisL a S. Typhimurium β helical, ECM binding, required for 
intestinal colonisation and faecal shedding 
in mice 
(123) 
Pertactin  a B. pertussis β helical, Adhesion and resistance to 
neutrophil mediated clearance. 
Component of B. pertussis acellular 
vaccine 
(92) 
Pet a EAEC β helical, cleaved passenger domain, 
SPATE, cytotoxin  
(134) 
ShdA a S. Typhimurium β helical, ECM binding, required for 
intestinal colonisation and faecal shedding 
in mice 
(124, 
135-137) 
     
FHA b B. pertusis Binds C4 complement, component of the 
B. pertussis acellular vaccine 
(138) 
HMW1/2 b H. influenzae Adhesion to respiratory epithelial cells (139) 
ShlA b S. marcescens Hemolysin (140) 
     
EhaG c EHEC ECM binding and adhesion to colorectal 
epithelial cells 
(128) 
Hia c H. influenzae Adhesion to epithelial cells  
NadA c N. meningitidis Adhesion to epithelial cells, component of 
the Bexsero vaccine 
(141) 
UpaG c UPEC ECM binding and adhesion to bladder 
cells 
(119, 
128) 
YadA c Y. enterocolitica ECM binding, adhesion to epithelial cells, 
serum resistance 
(117, 
142-144) 
     
PlpD d P. aeruginosa Lipase (92) 
     
Intimin e EPEC and some 
STEC 
Adhesion and lesion formation (92) 
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Additionally recent reports have also highlighted the potential of AT proteins as a 
means of recombinant protein production and surface display of antigens, whereby both the 
AT proteins, Pet and Hbp have been shown to tolerate the exchange of their native passenger 
domains, for that of other proteins (106, 145). Further enhancing the possibilities for which 
these proteins can be exploited.  
 
1.3. SALMONELLA 
Salmonella is a Gram-negative organism, which can be divided in two species, 
Salmonella bongori and Salmonella enterica. S. bongori is largely restricted to cold blooded 
animals, while S. enterica can be further subdivided (146). Within S. enterica numerous 
serovars exist, including those limited to human hosts, such as Typhi and Paratyphi or those 
capable of broad host range pathogenicity, including Typhimurium and Enteritidis (147).  
S. enterica serovar Typhimurium demonstrates a broad host range, capable of 
pathogenesis in a number of species including humans, birds, livestock and poultry (148, 
149). S. enterica infection commonly occurs via ingestion of the bacteria from contaminated 
food or water supplies (150). Due to the ability of S. Typhimurium to infect a variety of hosts, 
including those within the food chain, transmission between species can occur readily (123). 
Though in contrast to public perception, recent investigations into the source of numerous 
North American outbreaks have shown an ever increasing association with the consumption 
of contaminated fruit and vegetables. Indeed, consumption of contaminated vegetable produce 
is now the most prevalent source of non typhoidal Salmonella (NTS) infection in developed 
countries, rather than contaminated poultry (151-154). 
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1.3.1. Mode of S. enterica infection 
S. Typhi and S. Typhimurium in humans and mice, respectively, causes systemic 
infection resulting in typhoid fever (147, 150, 155), while S. Typhimurium in humans usually 
results in a self-limiting non-typhoidal gastroenteritis and bacteremia in immunocompromised 
individuals or children (131).  
As mentioned previously infection predominantly results from oral consumption, 
whereby bacteria require transit through the stomach to reach the small intestine. In order to 
survive the harsh environmental pH of the stomach, Salmonella encode acid tolerance 
response genes, including fur and atp, induced in conditions of low pH (156). Once at the 
small intestine, bacteria are capable of binding to epithelial and specialised M cells (localised 
to the Peyers patches, required for antigen uptake and presentation to phagocytes) by means 
of fimbriae and other surface structures, including AT proteins MisL and ShdA (123, 155, 
157).  After initial adherence, Salmonella induce cytoskeletal rearrangements within the host 
cell; these are manifested as membrane ruffling and subsequent engulfment of the bacteria 
into Salmonella containing vacuoles (SCV) (157).  
S. enterica encode a variety of tools, to induce the changes in host cell morphology 
described above. The T3SSs (as discussed in Section 1.2.1), encoded on Salmonella 
Pathogenicity Island 1 (SPI-1), encodes a series of effector molecules required for invasion 
including, SopE and SptP which are associated with cytoskeleton rearrangements. Other 
effector molecules such as SipA, SopC, SopD and SopE induce signal cascades in the host 
cells leading to the recruitment of neutrophils and macrophages to the site of infection, in 
addition to the secretion of pro-inflammatory cytokines (147, 150, 155, 158).  
Once the SCV matures its translocates through the epithelial cell, to the basal 
membrane, where it is able to interact with and enter macrophage and dendritic cells (147). 
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Ingestion by these cell types controls the spread of infection through the induction of reactive 
oxygen species and reactive nitrogen intermediates. However, these cells are often hijacked as 
a means of transport through the host lymphatic system and the blood (155, 159).  
Once the SCV is formed, SPI-1 expression is strongly inhibited through the repression 
of HilA, by the PhoP/Q system. This results in the activation of an alternative T3SS encoded 
by SPI-2. SPI-2 expression promotes intracellular survival (158). The SPI-2 dependent 
secretion of the SpiC effector prevents SCV fusion with late endosomes and lysosomes, 
limiting bacterial killing by reactive oxygen and nitrogen (158). Other SPI-2 T3SS effector 
molecules associate with host cell microtubule bundles aiding the formation of Salmonella-
induced filaments, which protrude from the SCV. These are thought to be required for 
intracellular replication of the bacterial within these vacuoles (147). Such effector molecules 
have long been associated with host cell cytotoxicity, enabling bacterial escape at the relevant 
time (155, 160). For example SpvB has been demonstrated to induce Toll-like receptor 
activation resulting pro-apoptotic responses, while SipB has been shown to induce activation 
of host caspase-1 (158).  Once released from the macrophages, bacteria can survive 
extracellularly in the blood stream or rapidly colonise various sites, including the spleen, 
liver, gall bladder, mesenteric lymph (MEL) nodes and bone marrow, resulting in persistent 
infection and continual faecal shedding, as shown in figure 1.7 (155).  
 
1.3.2. Investigating host responses to Salmonella 
The mouse model provides an effective means of studying S. Typhimurium infections, 
both from the perspective of host pathogen interactions, but also for identifying and testing 
suitable vaccine candidates for efficacy. Investigations have highlighted a number of genetic 
factors affecting murine susceptibility to S. Typhimurium, including; nramp1 which limits the
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Figure 1.7. Salmonella Infection  
The course of Salmonella infection following ingestion of contaminated food or water. Upon 
arrival in the small intestine, bacteria transverse the gut epithelia at the Peyers patches, using 
specialist M cells, associated with antigen presentation. Invasion at these sites stimulates the 
release of pro-inflammatory cytokines, promoting the recruitment of T cells, B cells, 
macrophages and neutrophils to the affected area. Salmonella can invade macrophages, 
residing intracellularly as required, providing a means for transport throughout the host 
lymphatic system, where bacteria can colonise sites including the Mesenteric lymph nodes 
(MEL), spleen, bone marrow, liver and gal bladder, allowing for bacterial reseeding back into 
the intestine and continued faecal shedding.  
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 intracellular replication of bacteria in macrophages, by limiting the availability of divalent 
cations, providing key insight into host defences (155). However, within the same context the 
mouse model does provide a series of limitations, with a key defect being the lack of a 
satisfactory complement system (161). 
Other immune factors including the major histocompatibility complex (MHC) class II 
and class III, CD4
+
 and CD8
+
 T lymphocytes are known to play key roles in bacterial 
clearance, while IFN–γ, IL-12 and IL-23 are hypothesised to control the intracellular 
replication of the bacteria, particularly in persistent infections (131, 155, 162). Importantly, 
resistance to re-infection is dependent on CD4
+
 and CD8
+
 T cells in addition to S. enterica 
specific antibodies  (163). 
Antibody responses are critical for limiting bacteremia, a major cause of mortality in 
infants between six and 24 months (131). The increased risk for S. enterica mediated 
septicaemia strongly correlates with the loss of maternal antibodies and activation of the 
humoral immune system (131). Therefore, the identification of bacterial factors that can 
induce a memory mediated antibody response is critical for the development of an effective 
vaccine.  
 
1.3.3. Salmonella infection and vaccine development 
Due to its prevalence across a broad range of species, S. Typhimurium infections are a 
significant cause for concern and are associated with almost 100 million cases of 
gastroenteritis each year (164). NTS infections are highly prevalent in African countries with 
sub-Saharan regions demonstrating some of the highest numbers where the infection 
predominantly affects children aged six months to five years and immune compromised 
individuals (131). Infection often presents as bacteraemia in the absence of other 
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gastrointestinal symptoms, making diagnosis difficult (131). Furthermore, HIV positive 
individuals demonstrate significantly higher risks of mortality, due to the loss of immune 
features such as Th17 from the gut mucosa, leading to reduced gut barrier and the 
dysregulation of critical cytokines, such as IL-12, which is responsible for the induction of 
IFN-γ (131, 165, 166). 
Effective treatment of NTS infections has become increasingly difficult with the 
emergence of antibiotic resistant strains, including resistance to ampicillin, chloramphenicol, 
streptomycin, sulfonamides and tetracyclines. Requiring more routine use of other antibiotics 
including, cephalosporins and fluoroquinolones in order to treat the infection (167). 
Currently no licensed vaccines exist for the treatment of S. Typhimurium in humans, 
and its significant prevalence in regions with poor healthcare and sanitation, particularly 
among infants and HIV positive individuals, makes this a global concern and therefore 
investigation into potential vaccine candidates should be a priority. To date OmpD from S. 
Typhimurium offers one of the most promising vaccine candidates (131). However, any 
potential vaccine candidates require significant investigation, to ensure bactericidal activity, 
in contrast to anti-LPS antibodies which have been shown to enhance the severity of the 
infection in some individuals by blocking, access to other bactericidal antibodies and 
complement (168). 
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1.4. AIMS  
 This study aims to investigate the mechanisms of membrane homeostasis and how this 
contributes to the virulence of the pathogenic Gram-negative organisms. By investigating the 
roles of non-essential genes, in the laboratory strain E. coli K12 and broad host range 
pathogen S. Typhimurium we aim to identify those required for the maintenance of membrane 
barrier function and normal homeostasis, characterise their specific functions, in the case of 
PlpA and assess their roles in virulence, using the murine model of Salmonella infection. 
Whilst determining the contribution of Type V proteins from S. Typhimurium to virulence, to 
ascertain their functional roles in and investigate their potential as future vaccine candidates.  
 
45 
 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
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2.1. SUPPLIERS 
Unless otherwise indicated all culture reagents were purchased from Oxoid Limited and 
chemicals were purchased from Sigma Aldrich. Thermus aquaticus (Taq) polymerase was 
purchased from Thermo Scientific. Phusion High Fidelity DNA polymerase and alkaline 
phosphatase were purchased from New England Biolabs. T4 DNA Ligase was purchased 
from Invitrogen. Restriction Enzymes were purchased from Fermentus. Oligonucleotides 
were purchased from either Alta Biosciences (University of Birmingham) or Eurogentec 
(Hampshire, UK). Custom primary antibodies were generated by Eurogentec; secondary 
antibodies were purchased from Sigma Aldrich. Animals (C57BL6 mice) were obtained from 
Harlan, or directly from the Biomedical Services Unit (BMSU, University of Birmingham).  
 
2.2. CULTURE MEDIA AND CONDITIONS 
Bacterial strains and plasmids used in this study are detailed in table 2.1. and table 2.2., 
respectively. BW25113 is the parental strain for the KEIO library, therefore all single mutants 
and subsequent double mutants were constructed and assessed in this strain. E. coli BL21 
strains were selected for protein expression studies, while E. coli M15 strains were selected 
for phenotypic assays, due to the levels of aggregation observed in E. coli BL21. S. 
Typhimurium SL1344 and the attenuated derivative SL3261 strains were selected for use in 
Salmonella studies due to the prior characterisation of these strains during both in vitro and in 
vivo experiments since their isolation in 1978 and 1981, respectively, while the availability of 
complete genome sequences provided an additional aid for molecular manipulations. Strains 
were routinely cultured in liquid and solid media, and stored as glycerol stocks at -85
o
C, in 
the presence of 15% glycerol. Strains were cultured on Luria Bertani or M9 medium, as 
previously described (169). Unless otherwise stated, bacterial cultures were grown at 25, 30, 
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Table 2.1 - Bacterial strains used in this study 
Strain Description Reference 
 E. coli Cloning and Expression Strains  
BL21 E. coli DE3 T7 express, protein expression strain  Invitrogen 
HB101 Non aggregating laboratory E. coli strain (170) 
M15 (pREP4) E. coli strain for tightly regulated expression of 
pQE vectors, carrying pREP4 
QIAGEN 
NEB 5’alpha  Highly efficient compotent cells, derived from 
DH5α 
New England 
Biolabs 
Top10 E. coli strain for cloning and protein expression 
from pASK vectors  
Invitrogen 
   
 E. coli Strains  
BW25113 rrnB3 DElacZ4787 DEphoBR580 hsdR514 
DE(araBAD)567 DE(rhaBAD)568 galU95 
DEendA9::FRT DEuidA3::pir(wt) recA1 rph-1 
(171) 
KEIO Library Various gene disruption mutants in BW25113, 
disrupted between the second and seventh from 
last codon by a kanamycin resistance cassette  
(171) 
BW25113ΔplpA BW25113 with plpA gene deleted This Study 
BW25113ΔplpA 
gpmI::aph 
Derviative of BW25113 ΔplpA with the gpmI 
gene disrupted by kanamycin resistance caseette  
This Study 
BW25113ΔplpA 
mlaA::aph 
Derivative of BW25113 ΔplpA with the mlaA 
gene disrupted by kanamycin resistance cassette  
This Study 
BW25113ΔplpA 
mlaC::aph 
Derivative of BW25113 ΔplpA with the mlaC 
gene disrupted by kanamycin resistance caseette  
This Study 
BW25113ΔplpA 
mlaD::aph 
Derviative of BW25113 ΔplpA with the mlaD 
gene disrupted by kanamycin resistance caseette  
This Study 
BW25113ΔplpA 
mlaE::aph 
Derviative of BW25113 ΔplpA with the mlaE 
gene disrupted by kanamycin resistance caseette  
This Study 
BW25113ΔplpA Derviative of BW25113 ΔplpA with the mlaF This Study 
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mlaF::aph gene disrupted by kanamycin resistance caseette  
BW25113ΔplpA 
pldA::aph 
Derviative of BW25113 ΔplpA with the pldA 
gene disrupted by kanamycin resistance caseette  
This Study 
BW25113ΔplpA 
pagP::aph 
Derviative of BW25113 ΔplpA with the pagP 
gene disrupted by kanamycin resistance caseette  
This Study 
   
 Salmonella Typhimurium Strains  
SL1344 Salmonella enterica serovar Typhimurium (172) 
SL3261 Derivative of SL1344 with ΔaroA (173) 
 Single Mutants  
SL1344 
bamB::aph 
SL1344 with the bamB gene disrupted by a 
kanamycin resistance cassette 
This study 
SL3261 
bamB::aph 
SL1344 with the bamB gene disrupted by a 
kanamycin resistance cassette 
This study 
SL1344 
bamC::aph 
SL1344 with the bamC gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
bamC::aph 
SL1344 with the bamC gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
bamE::aph 
SL1344 with the bamE gene disrupted by a 
kanamycin resistance cassette 
This study 
SL3261 
bamE::aph 
SL1344 with the bamE gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
degP::aph 
SL1344 with the degP gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
degP::aph 
SL1344 with the degP gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
fkpA::aph 
SL1344 with the fkpA gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
fkpA::aph 
SL1344 with the fkpA gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
hlpA::aph 
SL1344 with the hlpA gene disrupted by a 
kanamycin resistance cassette 
This study  
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SL3261 
hlpA::aph 
SL1344 with the hlpA gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
plpA::aph 
SL1344 with the plpA gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
plpA::aph 
SL1344 with the plpA gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
surA::aph 
SL1344 with the surA gene disrupted by a 
kanamycin resistance cassette 
This study 
SL3261 
surA::aph 
SL3261 with the surA gene disrupted by a 
kanamycin resistance cassette 
This study 
SL1344 
tamA::aph 
SL1344 with the tamA gene disrupted by a 
kanamycin resistance cassette 
This study 
SL3261 
tamA::aph 
SL3261 with the tamA gene disrupted by a 
kanamycin resistance cassette 
This study 
SL1344 
tamB::aph 
SL1344 with the tamB gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
tamB::aph 
SL3261 with the tamB gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
ytfP::aph 
SL1344 with the ytfP gene disrupted by a 
kanamycin resistance cassette 
This study  
SL3261 
ytfP::aph 
SL3261 with the ytfP gene disrupted by a 
kanamycin resistance cassette 
This study  
 Autotransporter Single Mutants  
SL1344 
apeE::aph 
SL1344 with the apeE gene disrupted by a 
kanamycin resistance cassette 
This study (Dhaarini 
Raghunathan) 
SL1344ΔapeE SL1344 apeE::aph with the kanamycin resistance 
cassette removed 
This study  
SL3261 
apeE::aph 
SL3261 with the apeE gene disrupted by a 
kanamycin resistance cassette 
This study (Dhaarini 
Raghunathan) 
SL1344 
misL::aph 
SL1344 with the misL gene disrupted by a 
kanamycin resistance cassette 
This study (Dhaarini 
Raghunathan) 
SL1344ΔmisL SL1344 misL::aph with the kanamycin resistance This study 
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cassette removed 
SL3261 
misL::aph 
SL3261 with the misL gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
sadA::aph 
SL1344 with the sadA gene disrupted by a 
kanamycin resistance cassette 
(174) 
SL1344ΔsadA SL1344 sadA::aph with the kanamycin resistance 
cassette removed 
(174) 
SL3261 
sadA::aph 
SL3261 with the sadA gene disrupted by a 
kanamycin resistance cassette 
(174) 
SL1344 
sapP::aph 
SL1344 with the sapP gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344ΔsapP SL1344 sapP::aph with the kanamycin resistance 
cassette removed 
This study 
SL3261 
sapP::aph 
SL3261 with the sapP gene disrupted by a 
kanamycin resistance cassette 
This study  
SL1344 
shdA::aph 
SL1344 with the shdA gene disrupted by a 
kanamycin resistance cassette 
(124) 
   
 Autotransporter Multiple Deletion Mutants  
SL1344 ΔmisL 
ΔsapP 
shdA::aph 
SL1344 with misL and sapP genes deleted and 
shdA gene disrupted by a kanamycin resistance 
cassette (3 in 1) 
This study 
SL3261 ΔmisL 
ΔsapP 
shdA::aph 
As described for SL1344 SL1344 ΔmisL ΔsapP 
shdA::aph, in SL3261 background 
This study 
SL1344 ΔmisL 
ΔsapP ΔapeE 
shdA::aph 
SL1344 with misL, sapP and apeE genes deleted 
and shdA gene disrupted by a kanamycin 
resistance cassette (4 in 1 apeE) 
This study 
SL3261 ΔmisL 
ΔsapP ΔapeE 
shdA::aph 
As described for SL1344 ΔmisL ΔsapP ΔapeE  
shdA::aph, in SL3261 background 
This study 
SL1344 ΔmisL SL1344 with misL, sapP and sadA genes deleted This study 
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ΔsapP ΔsadA 
shdA::aph 
and shdA gene disrupted by a kanamycin 
resistance cassette (4 in 1 sadA) 
SL3261 ΔmisL 
ΔsapP ΔsadA 
shdA::aph 
As described for SL1344 SL1344 ΔmisL ΔsapP 
ΔsadA  shdA::aph, in SL3261 background 
This study 
SL1344 ΔmisL 
ΔsapP ΔsadA 
ΔapeE 
shdA::aph 
SL1344 with misL, sapP, sadA and apeE genes 
deleted and shdA gene disrupted by a kanamycin 
resistance cassette (5 in 1) 
This study 
SL3261 ΔmisL 
ΔsapP ΔsadA 
ΔapeE 
shdA::aph 
As described for SL1344 ΔmisL ΔsapP ΔsadA 
ΔapeE shdA::aph, in SL3261 background 
This study 
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Table 2.2. – Plasmids used in this study 
Plasmid Characteristics Reference 
 Gene Disruption and Deletion  
pKD4 Template plasmid for the amplification of the 
Kanamycin resistance cassette, flanked by FLP 
sites, Kan
R
 
(175) 
pKD46 Temperature sensitive, low copy number 
plasmid expressing the Red recombinase genes 
under the control of an arabinose inducible 
promoter, Amp
R
 
(175) 
pCP20 Temperature sensitive plasmid encoding the 
FLP recombinase gene, Amp
R
 
(175) 
   
pDOC-C Medium copy number pre-recombination 
plasmid containing I-SceI sites for cloning 
fragments prior to recombination in vivo, 
Amp
R
 
(176) 
pDOC-K Template plasmid for amplification of the 
kanamycin resistance cassette, flanked by FLP 
recombinase sites, Kan
R
 
(176) 
pACBSCE Recombinase plasmid expressing I-SceI and 
the λ-Red genes, under an arabinose inducible 
promoter, Cat
R
 
(176) 
pDOC-C tamA Derivative of pDOC-C with kanamycin 
resistance cassette, flanked by 40 bases of 
homology to the STm tamA gene cloned 
between the I-SceI sites 
This Study 
   
 Various Expression Vectors  
pET17b Constitively active T7 expression vector, Amp
R
 Novagen 
pET17b plpA As described for pET17b with E. coli plpA (177) 
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cloned between NdeI and EcoRI 
pET17b plpA TM  As described for pET17b with E. coli plpA 
randomly disrupted by Transposon mutations 
throughout the gene, see Table 2.5 for details.  
(177) 
pET17b plpA STm As described for pET17b with S. Typhimurium 
plpA cloned between NdeI and HindIIII 
This Study  
pET17b plpA H.i As described for pET17b expressing codon 
optimised Haemophilus influenza homolog of 
plpA 
Genscript  
pET17b plpA P.m As described for pET17b expressing codon 
optimised Pasteurella multoclda homolog of 
plpA 
Genscript  
pET17b plpA N.m As described for pET17b expressing codon 
optimised Neisseria meningitidis homolog of 
plpA 
Genscript  
pET17b plpA V.c As described for pET17b expressing codon 
optimised Vibrio cholera homolog of plpA 
Genscript  
pET17b osmY As described for pET17b expressing codon 
optomised E. coli K12 osmY  
Genscript  
   
pET20b T7 expression vector, Amp
R
 Novagen 
pET20b plpA As described for pET20b with E. coli plpA 
gene cloned between NdeI and EcoRI 
(177) 
pET20b plpA PM As described for pET20b plpA, with site 
directed point mutations at various sites, see 
Table 2.3 for details 
(177) 
pET20b wbbL As described for pET20b with wbbL gene 
cloned between NdeI and HindIII 
(178) 
   
pET22b  IPTG Inducable expression vector, Amp
R
 Novagen 
pET22b sapP As described for pET22b with sapP gene 
cloned between NdeI and EcoRI sites 
This Study 
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pET22b sadA As described for pET22b with sadA gene 
cloned between NdeI and EcoRI sites 
(174) 
   
pJH10 IncQ based expression vector, Tet
R
 (179) 
pJH10 plpA Derivative of pJH104 with E. coli K12 plpA 
cloned between sites EcoRI and SacI 
This Study  
   
pREP4 Repressor plasmid, for controlled expression of 
pQE vectors, Kan
R
 
QIAGEN 
pQE60 (Modified)  NdeI site at postion removed, NcoI site at 
position removed and replaced with an NdeI 
site, Amp
R
 
(174) 
pQE60 apeE As described for pQE60 with S. Typhimurium 
apeE gene cloned between NdeI and HindIII 
sites 
This Study 
pQE60 apeES10A As described for pQE60 apeE with Serine at 
position 10 mutated to Alanine  
This Study  
pQE60 sapA As described for pQE60 with S. Typhimurium 
sapA gene cloned between NdeI and HindIII 
sites 
This study 
pQE60 sadA As described for pQE60 with S. Typhimurium 
sadA gene cloned between NdeI and HindIII 
sites 
(174) 
pQE60 plpA As described for pQE60 with S. Typhimurium 
plpA gene cloned between NdeI and HindIII 
sites 
This Study  
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37 or 42
o
C with continuous agitation. Growth rates were determined by measuring optical 
density at OD600 using either an Ultraspec 2100 Pro (GE Healthcare Life Sciences, 
Buckinghamshire) or a FLUOstar Optima (BMG Labtech, Offenberg, Germany), as 
previously described (169). Mammalian cells including J774, RAW 264 macrophages, THP1 
human monocytes and Caco-2 colorectal carcinoma cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) or RPMI at 37°C in a 5% CO2 atmosphere (180, 181). 
THP1 cells were differentiated into macrophages 24 h prior to use, by the addition of 5 ng/mL 
of phorbol 12-myristate 13-acetate (PMA).  Where appropriate antibiotics were added to the 
medium as the following concentrations: carbenicillin (100 g/mL); chloramphenicol (30 
g/mL); kanamycin (50 g/mL) and vancomycin (0-512 g/mL). Stock solutions of 
antibiotics were prepared as previously described (169) 
Suppressor mutants were generated by repeated culture on previously inhibitory 
concentrations of either vancomycin (200 μg/mL) or SDS (4.8%), in both liquid media and 
solid agar. In each instance six independent overnight cultures were applied to agar plates 
supplemented with the above and incubated at 37
o
C until the appearance of colonies. 
Resultant colonies were cultured overnight in liquid media supplement as above, before being 
streaked onto agar containing the above compounds, to confirm the resistant phenotype.  
 
2.3. DNA MANIPULATIONS 
2.3.1. Preparation of genomic DNA, RNA and plasmid isolation 
Genomic DNA was prepared from bacterial cultures using QIAGEN QIAamp DNA Mini Kit, 
in accordance with manufactures instructions. Cell lysate samples were prepared by pelleting 
bacterial cultures and resuspending in sterile deionised water (SDW), boiling for 15 min prior 
to pelleting the cell debris. Total RNA was isolated from both bacterial cultures and infected 
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mammalian tissues, using QIAGEN RNAprotect Bacterial Reagent (bacterial cultures) or 
QIAshredder (infected tissues) and QIAGEN RNeasy Mini Kit, in accordance with 
manufacturer’s instructions. On the column DNase I digestion was performed using QIAGEN 
RNase-Free DNase Set. Plasmid isolation was performed using QIAGEN Miniprep Spin Kit. 
Samples were quantified either by Nanodrop or visual comparison with known standards.  
 
2.3.2. PCR 
PCR primers used in this study are described in appendix table 1. These were used at a final 
reaction concentration of 0.5 µM. MyTaq Red Mix 2x was used in accordance with 
manufacturer’s instructions for cell lysate PCR reactions. The amplification of templates for 
cloning or mutation purposes Phusion High Fidelity Polymerase was used in accordance with 
manufacturer’s instructors, using either genomic DNA or plasmid DNA as the template. 
When using Phusion High Fidelity Polymerase, dNTP’s were added at a concentration of 200 
µM (each). Reactions were run on Mastercycler epgradient S (Eppendorf, Stevenage). 
 
2.3.3. Reverse transcription PCR 
DNA free, total RNA was prepared as described previously. cDNA was prepared using 
SuperScript II Reverse Transcriptase and Random Hexamers and RT PCR using Taq 
Polymerase. 
 
2.3.4. Cloning 
DNA for cloning was purified using either a QIAGEN Gel Extraction Kit or QIAGEN PCR 
Purification Kit, in accordance with manufacturer’s instructions. Template DNA and isolated 
plasmids were digested using Fermentus Fast Digest Enzymes, in accordance with 
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instructions. Digested plasmids were treated with alkaline phosphatase, prior to purification 
with the above described kits. Template and plasmid DNA were quantified, by comparison 
with known standards, and ligated using T4 DNA Ligase, prior to overnight incubation at 4
o
C 
before transformation the following day. Resultant colonies were screened using either PCR 
(amplifying for the presence of the insert) or restriction digests (using enzymes specific to the 
insert) and confirmed by sequencing at the Function Genomics facility, University of 
Birmingham. 
 
2.3.5. Preparation and transformation of competent cells 
Competent cells were prepared as follows. Bacterial cultures were grown to an OD600nm of 0.6 
or 0.8 for chemically and electro competent cells, respectively. Chemically competent cells 
were chilled on ice for 30 min, prior to centrifuging (2880 x g, 4
o
C, for 30 min). Cell pellets 
were resuspened in 0.1 M calcium chloride and stored on ice for 30 min, prior to centrifuging 
as above. The cells were washed and pelleted as described above, prior to re-suspending in 
0.1 M calcium chloride and stored on ice for two hs, before centrifuging (as above). Pellets 
were resuspended in LBB containing 30% v/v glycerol and snap frozen, using ethanol and dry 
ice.  Electro competent cells were incubated at 42
o
C for 15 min, followed by 10 min 
incubation at 4
o
C, with continuous agitation. Cultures were centrifuged as described 
previously. Pellets were resuspended in 20% v/v glycerol containing 1 mM MOPS pH7.4 and 
centrifuged. Cultures were washed as described above and resuspended in 20% glycerol 
containing 1 mM MOPS pH7.4, prior to snap freezing. Chemically competent cells were 
transformed by adding 5 μL of plasmid/ligation or exogenous DNA and incubated on ice for 
one h, prior to heat shock at 42
o
C for 90 s followed by ice for 90 s. Electro-competent cells 
were transferred to a chilled electroporation cuvette 1mm prior to electroporation at 1800V 
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before the addition of 1 mL LBB. Transformants were recovered in LBB for approximately 
one h at an appropriate temperature, prior to plating on selective agar.  
 
2.3.6. Construction of deletion mutant bacterial strains 
2.3.6.1. DATSENKO AND WANNER METHOD FOR SINGLE GENE INACTIVATION.  
Gene disruption mutants were generated using two techniques; Datsenko and Warner Method 
for single gene inactivation (175) and gene doctoring (176). Briefly, to generate mutants via 
the Datsenko and Warner method, the kanamycin resistance cassette was amplified from the 
template plasmid pKD4, to generate DNA fragment, containing 5’ and 3’ ends of 20 bases of 
homology to the flanking regions of the gene to be disrupted. The fragment was purified and 
quantified as described previously. The required bacterial strains were made electro-
competent (as described previously) and transformed with pDK46. Resultant colonies were 
again made electro-competent, with minor alterations to the previously described method, 
incubations were performed at 30
o
C, media was supplemented with 20 mM L-arabinose, 
pellets were washed with 10% glycerol and no 42
o
C heat shock was performed. Electro-
component pKD46 containing cells where electroporated with 200-500 ng the linear DNA 
fragments generated above. Cells were recovered at 37
o
C and plated on selective agar, 
selecting for kanamycin resistance only. Resultant colonies were patch plated to confirm the 
loss of carbenicillin resistance (pKD46), prior to confirmation by colony PCR.  
 
2.3.6.2. GENE DOCTORING. 
 Mutants generated via the gene doctoring method, were generated as described by Lee et al 
(176). Similar to the above described method, the kanamycin resistance cassette was 
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amplified from the plasmid pDOC-K, using primers containing 5’ and 3’ 40 bases of 
homology to the genomic DNA flanking the gene to be disrupted and 20 bases of homology 
to the kanamycin cassette, with distal I-SceI restriction sites. The resultant fragments were 
purified, quantified and digested with I-SceI. In parallel pDOC-C was also digested with I-
SceI and treated with alkaline phosphatase (as previously described). The resultant PCR 
fragment was cloned into pDOC-C and the sequence confirmed by plasmid to profile 
sequencing (performed at functional genomics facility), to generate the plasmid pDOC-C 
tamA. The pDOC-C tamA vector and pACBSCE vector were co-transformed into electro-
competent S. Typhimurium, selecting for resistance to chloramphenicol, carbenicillin and 
kanamycin. Resultant colonies were inoculated into LBB containing 0.5% L-arabinose, at 
37
o
C for approximately five hs. Samples were plated on LBA containing kanamycin and 5% 
sucrose and incubated overnight at 30
o
C. Resultant colonies were patch plated onto 
chloramphenicol and carbenicillin, to confirm the loss of both pDOC-C and pACBSCE, prior 
to confirmation of recombination of the resistance cassette by PCR.  
 
2.3.6.3. REMOVAL OF ANTIBIOTIC RESISTANCE CASSETTE.  
All confirmed colonies were phage transduced, prior to use. In some instances, the kanamycin 
resistance cassette was removed, using pCP20 and FLP recombinase system, as described by 
Datsenko and Warner (175). Briefly; cells were made electro-competent (as previously 
described) and pCP20 electroporated, colonies were selected for growth on carbenicillin at 
30
o
C. The following day, six colonies was selected and incubated at 42
o
C for six h, prior to 
plating on LBA. Resultant colonies were then patch plated, onto LBA containing carbenicillin 
60 
 
or kanamycin to confirm loss of pCP20 and the resistance cassette, respectively, prior to PCR 
confirmation. 
 
2.3.6.4. TRANSDUCTION USING P1 OR P22 PHAGE.  
Mutations were transferred to a clean parental background using phage transduction (182). 
Briefly cultures harbouring the mutation to be transferred were incubated in the presence of 
varying concentration of phage stocks (P1 for E. coli strains, P22 for S. Typhimurium strains) 
for three to 20 h, for P1 and P22 respectively. The following day, phage lysates were 
harvested by the addition of chloroform, prior to centrifuging at 3000 x g, 4
o
C for 15 min. 
Recipient bacterial strains, were incubated with varying amounts of phage lysate for 15 and 
30 min, prior to the addition of 1 M sodium citrate and LB broth containing 5 mM calcium 
chloride and 10 mM magnesium sulfate before incubating for a further 45-90 min. Bacteria 
were pelleted and washed with 1x PBS three times, prior to plating on selective agar. All 
resultant colonies were screened by PCR to confirm the mutation.  
 
2.3.7. Directed Mutagenesis strategies. 
Mutations in protein-encoding DNA were introduced using Quikchange Lightning Kit 
(Agilent) and custom oligonucleotides or by random transposon mutagenesis using the 
Mutation Generation System Kit (Thermo) as described in manufacturers’ instructions. All 
resultant colonies were sequenced to confirm the mutation/insertion site prior to use and are 
described in table 2.3. 
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Table 2.3 – Site direct and random sequence insertion mutants in plpA 
Designation Description 
WT As described for pET20b plpA, non mutated version for control and 
starting material 
A88 Random linker sequence insertion after position A88,  
D125 Random linker sequence insertion after position D125 
L50 Random linker sequence insertion after position L50  
D102 Random linker sequence insertion after position D102 
G160 Random linker sequence insertion after position M159 
W127 Random linker sequence insertion after position W127 
V72 Random linker sequence insertion after position V72 
Q113 Random linker sequence insertion after position Q113 
N109 Random linker sequence insertion after position N109 
Q76 Random linker sequence insertion after position Q76 
V54 Random linker sequence insertion after position R53 
V142 Random linker sequence insertion after position V142 
N105 Random linker sequence insertion after position N105 
 
I128A Mutation at position I128 converting Isoleucine to Alanine 
K131A Mutation at position K131 converting Lysine to Alanine 
R133A Mutation at position R133 altering Arginine to Alanine 
Q135A Mutation at position Q135 Glutamine converted to Alanine 
L137A Mutation at position L137, Leucine converted to Alanine 
S144A Mutation at position S144A, altering Serine to Alanine 
G83V Mutation at position G83V, conserved Glycine to Valine 
G160V Mutation at position G160V, conserved Glycine at Valine 
G83VG160V Mutations at positions G83G160, mutating both Glycine residues to Valine 
W127A Mutation at position W127A, altering Tryptophan to Alanine 
Y75A Mutation at position Y75, alteration from Tyrosine to Alanine 
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2.3.8. DNA sequencing. 
Illumina whole genome resequencing was done by Dr. David A. Rasko, University of 
Maryland, Baltimore, USA or Mr. Ashley Robinson, in the Henderson group at the University 
of Birmingham.  Plasmid sequencing was done at the Functional Genomics Unit, University 
of Birmingham. 
 
2.4. PROTEIN PURIFICATION AND ANALYSIS. 
2.4.1. SDS-PAGE and Western immunoblotting 
SDS-PAGE gels were prepared at 12% and 15% dependant on the protein of interest to be 
investigated. Reagents were prepared as previously described and gels were run in 1 x SDS 
Running buffer, between 80-140V for the required duration. Samples for SDS-PAGE analysis 
were prepared by mixing 1:1 protein sample with laemmli buffer (where not already directly 
resuspended) and boiling for 15 min. Western blots were performed as previously described 
(169). SDS-PAGE gels were transferred to Nitrocellulose Membrane (BioRad) using a 
traditional Western Sandwich with 1x Transfer Buffer containing 20% methanol. Membranes 
were blocked using 5% w/v skimmed milk powder prior to incubation with primary antibody 
(diluted 1:1000-1:10,000 dependant on the antibody), followed by secondary anti-rabbit or 
anti-mouse IgG (whole molecule) Alkaline Phosphatase Antibody Produced in Goats, 
1:30,000 dilution. Western blots were exposed using BCIP/NBT Purple Liquid Substrate 
System for Membranes.  
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2.4.2. ELISA 
Antibody (IgA, IgM and total IgG) responses were measured by coating Maxisorp 96 well 
plates (Nunc) with 5 µg/mL of purified protein in carbonate coating buffer. Plates were 
washed and blocked for 1 h at 37
o
C with 1% BSA in PBS (blocking buffer). Test samples 
were added in blocking buffer and serially diluted and incubated for 1 h at 37
o
C. Secondary 
anti-mouse IgA, IgG or IgM conjugated to alkaline-phosphatase (Southern Biotech) were 
diluted in blocking buffer and added for 1 h at 37
o
C. Signal was detected using the 
SIGMAFAST p-Nitrophenyl phosphate system and plates were read at 405 nm. 
2.4.3. Preparation of antibodies 
Antibodies to specified proteins were raised in New Zealand White rabbits by Eurogentec. 
Antibodies were absorbed against the E. coli strain BL21 containing pET26b empty vector. 
Briefly, overnight cultures were pelleted by centrifugation at 2880 x g, 4
o
C, 30 min. Pellets 
were washed using 1 mL PBS (Invitrogen) and freeze thawed three times using dry ice and 
ethanol. A 0.33 mL cell suspension was added to 1 mL of serum and rotated at 37
o
C for 30 
min. A further 0.33 mL of cell suspension was added and rotated as above. The remaining 
volume of cell suspension was added and rotated at 4
o
C overnight. The following day the 
mixture was centrifuged 12000 x g for 35 min and the supernatant diluted 1:5 in PBS, prior to 
filtering using a 0.22 µM pore size filter. Antibodies were aliquoted and stored at -30
o
C until 
required. 
 
2.4.4. Preparation of cellular fractions 
Bacterial cell cultures were fractionated to isolate whole cells, cell envelopes and outer 
membranes, with some minor alterations to the procedures described in Parham, et al (183). 
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Briefly cultures were grown to an OD600nm 1, cells pelleted by centrifuging at 2880 x g, 4
o
C, 
for 30 min. Supernatant fractions were collected (as required) and secreted proteins 
precipitated as described below. Cell pellets were resuspended in 2x Laemmli buffer (Sigma) 
for whole cell samples or were resuspended in 10 mM Tris pH7.4, 2 mM PMSF prior to either 
sonication (5 x 30 s blast with 10 s intervals) or French press at 1500-2000 psi, unbroken cells 
were removed by centrifuging at 2880 x g, 4
o
C, for 30 min, supernatant fractions were 
transferred to clean vials and centrifuged at 50,000 x g, 4
o
C for one h 30 min. Resultant 
pellets were either resuspended in 10 mM Tris pH7.4, providing cell envelope fractions or 
processed further to obtain outer membrane fractions. Outer membranes were isolated from 
cell envelope fractions by resuspending the pellet in 10 mM Tris, 2% v/v Triton X 100 and 
incubated at room temperature for 30 min with gentle agitation, prior to centrifuging at 50,000 
x g, 4
o
C for one h 30 min. Pellets were washed three times with 10 mM Tris pH7.4 and 
isolated by centrifuging as described above. In some instances prepared outer membrane 
fractions were washed with 5 M urea to remove aggregates or covalently attached material 
(184). Briefly the outer membrane fractions were prepared as described previously, the 
fractions resuspended in 1 x PBS with 5 M urea and placed on a rotary shaker for one h at 
4
o
C. The membrane fractions were pelleted by centrifuging at 50,000 x g, 4
o
C for one h 30 
min. Outer membranes were washed once with 1 x PBS prior to resuspending in fresh 1 x 
PBS.  
Extracellular proteins were harvested by precipitation using 10% TCA (final 
concentration). Briefly, supernatant fractions were filtered through a 0.22 µm pore size filter, 
and stored in the presence of TCA at 4
o
C overnight. The following day samples were 
centrifuged at 24,000 x g, 4
o
C for 45 min to pellet precipitated material. Resulting material 
was washed with ice-cold methanol, and incubated at room temperature for 15 min, before 
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pelleting as described above. The resultant pellets were dried and resuspended in 2 x laemmli 
buffer.  
 
2.4.5. Purification of integral membrane proteins  
Proteins were expressed from BL21 DE3 pET22b induced with IPTG. Cultures were 
harvested at OD600nm=1, and resuspended in 50 mM HEPES, 150 mM sodium chloride, 1 mM 
PMSF pH7.4, prior to sonication as described previously. The cell debris and inclusion bodies 
were pelleted by centrifugation at 20,000 × g. The pellet was the resuspended in 50 mM 
HEPES, 150 mM sodium chloride, 8 M urea, 1 mM PMSF pH7.4 and incubated at room 
temperature for 1 h. Insoluble inclusion bodies and cell debris were removed by 
centrifugation at 50,000 × g and the supernatant containing soluble protein was recovered. 
Fractions were run on SDS-PAGE gels, excised and gel slices homogenised in 0.5 ml of 50 
mM HEPES, 0.1% SDS, pH7.4. Protein was electro-eluted in a Novagen elution system as 
per manufacturer’s instructions. The eluted protein was diluted to 10 mL 50 mM HEPES, 
0.1% SDS, pH7.4  and dialysed three times against 5 L of 50 mM HEPES, 150 mM sodium 
chloride, 0.5% Elugent detergent (Calbiochem). Refolding by dialysis was performed over 
three days. The folded state of the protein was assessed using tryptophan fluorescence at 280 
nm excitation, emission scanned over 300 to 450 nm, 0.5 mm slit width, ~ 1 nm bandwidth, 1 
s response time, 1 nm increments using a QuantaMaster instrument (Photon Technologies 
International).  
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2.5. PREPARATION OF LIPOPOLYSACCHARIDE 
The production of long chain LPS was routinely examined in S. Typhimurium and some E. 
coli strains, using the method described by Browning et al (178). Briefly overnight cultures 
were harvested by centrifugation at 14,000 x g for 10 min. Cell pellets were resuspended in 2x 
laemmli loading buffer, before boiling and freezing in quick succession three times. The cell 
suspension was centrifuged at 14,000 x g for two min, before incubating in the presence of 5 
mg/mL proteinase K at 56
o
C for one h, before heat inactivating at 95
o
C for five min. Samples 
were loaded on Invitrogen pre-cast 4-12% Bis-Tris SDS-PAGE gel and run at 200V for 35 
min, before being stained with Invitrogen Silver Staining kit, in accordance with 
manufacturer’s instructions. 
2.6 DETERMINATION OF PROTEIN AND ENDOTOXIN CONCENTRATIONS  
Protein concentrations were determined using either the tannin assay or Nanodrop, with BSA 
in the appropriate buffer, as the standard. Purified proteins were tested for the presence of 
endotoxin contamination, using a Sigma E-Toxate Kit (Sigma Aldrich) in accordance with 
manufacturer’s instructions. 
 
2.7. MICROSCOPY 
2.7.1. Light microscopy.  
Bacterial cultures were grown to an OD600nm 0.6, harvested by centrifuging at 2880 x g, 4
o
C, 
for 20 min, concentrated 20 fold in 1 x PBS, prior to applying to 1 mg/mL poly-L-lysine  
coated 13mm cover slips by centrifuging at 2600 x g, 15 min and mounted onto slides. In 
some cases bacteria were stained with fluorescent BODIPY-vancomycin 20 µg/mL 
(Invitrogen, UK) for 45 min at room temperature (protected from light), washed three times 
with PBS and mounted onto slides using 0.5 µL fluorescent mountant (Citifluor Ltd, UK), 
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prior to visualisation using phase contrast DIC, with an exposure time 0.2 s and green 
fluorescence filter, 1.5 s exposure time, and gain setting of 1, using either a Zeiss or Leica 
Microscope.  Samples were visualised, by examining a minimum of five randomly selected 
fields with phase contrast Zeiss or Leica Microscope at 100 x magnification.  
 
2.7.2. Scanning electron microscopy. 
Bacterial cultures were grown, harvested and concentrated as described above, prior to 
applying to1 mg/mL poly-L-lysine coated 9mm cover slips by centrifuging at 2600 x g, 15 
min and fixed with 2.5% Electron Microscopy (EM) grade glutaraldehyde (Polysciences, 
Northampton, UK) in 0.1 M phosphate buffer at 4˚C overnight. Samples for were serially 
dehydrated with aqueous ethanol (two x 15 min each) followed by 100% dried ethanol and 
dried with a critical point dryer prior to mounting and platinum coated for three min using a 
sputter coater. Five randomly selected fields were visualised, using 5,000 x to 90,000 x 
magnification. 
 
2.8. DETERMINATION OF CELL HOMEOSTASIS  
2.8.1. Chemical screen for OM integrity. 
Bacterial isolates were screened using a 96 well single well inoculator to transfer 1 µL of 
culture, to LBA supplemented with antibiotics or other compounds (e.g.; vancomycin, SDS, 
sodium chloride, etc). Isolates showing a growth defect were rescreened using either streak 
plating or replica plating methods, as previously described (185) with a minimum of three 
biological replicates examined for each isolate. In some instances (i.e. screening of the KEIO 
Library) isolates were checked by PCR to confirm the genotype, prior to transducing into 
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parental strains.  Single colony glycerol stocks were generated for all isolates tested. Figure 
2.1. shows an example work flow of the screening technique. 
 
2.8.2. Fluorescence-activated cell sorting (FACS) screen for cell viability  
Propidium Iodide (PI) and bis-oxanol (BOX) staining was performed on exponential phase 
cultures (OD600nm=0.6); harvested by centrifugation at 2880 x g, 4
o
C, for 20 min, both prior to 
and post treatment with either vancomycin 100 µg/ml or SDS 4.8%. PI, 5 µg/ml and BOX, 10 
µg/ml were prepared in PBS (containing 4 mM EDTA for BOX only) as required. Cell pellets 
were resuspended in PBS, prior to diluting 20 fold in FACSFlow Buffer (BD, UK), 
containing either PI and BOX singly or in combination, with immediate analysis using FACS 
ARIA II (BD, UK).  Cells were illuminated with a 488 nm laser and data from 10,000 
particles were collected.  Forward- and side-scatter data were collected along with PI 
fluorescence (red, collected through an LP 565 mirror and BP 610/20 filter) and BOX 
fluorescence (green, collected through an LP 502 mirror and BP 530/30 filter). Particles 
smaller than bacteria were eliminated by adjusting the threshold values on FSC and SSC 
channels.   
 
2.8.3. Assessment of efflux capability.  
Hoescht accumulation assays were performed as described previously (186). Briefly, cultures 
were adjusted to OD600nm 0.1 and the uptake of Bis-benzimide (Hoescht 33342) was 
determined in the presence and absence of efflux inhibitor, phenyl-arginine-β-naphthylamide, 
100µg/mL (PAβN) using FLUOstar Optima plate reader. Significance was determined using 
Two –tailed student T-Test (p=<0.05). 
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2.9. MURINE MODEL OF SALMONELLA INFECTION  
In-vivo investigations performed during this study were done so under the Personal Licence 
30/9112 (Faye C. Morris), Project Licences 40/2904 and 30/2850 (Prof. A. F. Cunningham) at 
the Biomedical Services Unit, University of Birmingham Institution Licence 40/2404 or in 
collaboration with Prof. D. Maskell, University of Cambridge. All procedures and protocols 
were ethically approved and procedures performed under the appropriate supervision as 
required. Bacterial strains were grown in LBB, without antibiotics to an OD600nm=1. Cultures 
were harvested by centrifuging at 9000 x g, washed twice with 1 x PBS, prior to diluting in 
PBS to density of either 5 x 10
5
 (IP infection) or 1 x 10
9
 (oral gavage). Infection doses were 
serially diluted and plated post infection to confirm the relevant bacterial dose. 
Bacterial burdens were determined across a time course of infection, ranging from 24 h to 35 
days. Animals were humanely sacrificed, blood, spleen, liver, MEL and payers patches 
collected. Organs were weighed and mashed in 1x PBS using 70 µm cell strainer. Samples 
were diluted in 1x PBS prior to plating on selective agar. Bacterial burdens were calculated to 
bacterial burden/g of organ. Remaining spleen samples were snap frozen in liquid nitrogen, 
and stored at -85
o
C. Statistical significance of results was determined using a non-parametric 
Mann Whitney, two tailed test. Significance was determined as p= <0.05.  Serum was isolated 
from blood samples by incubating at 37
o
C for one h post collection and centrifuged at 16000 
x g, 4
o
C for 15 min. Sera was extracted and stored at -30
o
C until required.   
For challenge studies, purified protein samples were diluted in 1 x PBS or bound to Alum; to 
give a final concentration of 10 µg. Mice were immunised with protein and challenged with 
virulent bacteria at appropriate times. 
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2.10. IN VITRO ASSAYS FOR PATHOGENESIS  
2.10.1. Adhesion and invasion assays 
Cell lines were maintained as previously described. Bacterial cultures were washed twice in 1 
x PBS and resuspended in serum-free culture medium (~10
8 
CFU/ml). Tissue culture treated 
24-well plates were seeded with 10
5 
J774, RAW 264 or THP1 cells or 10
6
 Caco-2 cells per 
well. Bacterial strains were added at a multiplicity of infection (MOI) of 1:100 and incubated 
at 37
o
C for two h. Adherence was determined, by washing the infected cells with 1 mL PBS 
three times to remove the non-adherent bacteria prior to disruption with 1 x PBS, 1% (v/v) 
Triton-X 100, serial dilutions of this solution were plated on to LBA to enumerate CFUs. To 
investigate invasion, the cells were infected as described above, prior to incubation with 
DMEM or RPMI containing 100 µg/mL gentamycin for 2 h at 37°C and 5% CO2 to kill the 
extracellular bacteria. Cells were washed three times with 1 x PBS, prior to solubilisation with 
with 1 x PBS, 1% (v/v) Triton-X 100. Solubilised samples were serially diluted and plated to 
calculate CFUs as above.  
 
2.10.2. Binding to extracellular matrix (ECM) molecules.  
ECM binding assays were performed as previously described (125). High capacity 96 well 
plates were coated with 10 µg/mL of the appropriate ECM molecule (Collagen I, III, IV, 
fibronectin, elastin and laminin, Sigma). Bacterial cultures were adjusted to 1x10
8
 CFU/mL 
and 100 µL added per well. Plates were incubated at 37
o
C for four h, prior to washing three 
times with 1x PBS. Samples were treated with 100 µL of 1 x PBS containing 0.05% Triton X 
100, and serially diluted to 10
-4
, prior to plating on LBA to determine CFU determinations. 
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2.10.3. Serum bactericidal assay.  
The serum bactericidal assays were performed as described previously (187). Killing of 
various S. Typhimurium and E. coli strains were investigated using healthy human serum 
obtained from African and European individuals. Bacterial cultures were harvested at an 
OD600nm 1 and resuspended in 1 x PBS, 10 µL of each sample was added to 90 µL of freshly-
thawed, undiluted serum to give a final bacterial concentration of 10
6 
CFU/ml. The mixtures 
were incubated at 37°C with gentle rocking (20 rpm) and 10 µL samples were withdrawn at 
45, 90 and 180 min. Serial dilutions of the samples were plated onto LBA plates to determine 
the viable bacterial counts. 
 
2.11. BIOINFORMATICS ANALYSIS 
2.11.1. Gene Distribution 
Gene distribution across other organisms and identification of homologues was assessed using 
NCBI BLASTP. All available Gram-negative bacterial genomes were probed using the 
genetic sequence of specific genes of interest, to identify species encoding homologs. 
 
2.11.2. Protein domain architecture 
Protein domain structures were analysed using Simple Modular Architecture Research Tool 
(SMART) software, to identify potential conserved domains and secondary structures, 
including the presence of signal sequences (and their respective cleavage site) and 
autotransporter  domains.  
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2.11.3. Protein Interactions  
Potential interactions between different proteins were investigated using STRINGS 9.0 search 
tool database. This program highlights both known and predicted interactions based on 
genomic context, results from high throughput screening assays, co-expression assays and 
published literature. The database correlates information for over 5 million proteins from over 
1100 organisms.  
73 
 
 
 
 
 
 
CHAPTER 3 
THE ROLE OF NONESSENTIAL GENES IN THE 
MAINTENANCE OF THE OUTER MEMBRANE 
BARRIER FUNCTION 
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3.1 INTRODUCTION 
The Gram-negative cell envelope is a dynamic structure consisting of the OM, 
periplasmic space (enclosing the peptidoglycan) and IM (1). The asymmetric OM, with 
phospholipids on the inner leaflet and LPS present on the outer leaflet creates a selectively 
permeable barrier, limiting entry to toxic antibacterial compounds, whilst allowing the 
diffusion of molecules <600 daltons (1, 4). This creates a significant problem for antibacterial 
treatment, as a number of antimicrobial compounds are unable to penetrate this selectively 
permeable barrier. Additionally, these compounds can also be substrates for efflux pumps, 
which are molecular “vacuum cleaners” that span the cell envelope to prevent solute 
accumulation. While research into new antibacterial compounds has significantly decreased 
over recent decades, the emergence of antibiotic resistance has increased alarmingly (188). 
Thus, the drive to identify new targets for drug development against Gram-negative bacterial 
infections is critical to maintaining everyday medical practice. 
The cell envelope is a rich mosaic of components, including LPS, phospholipids, 
peptidoglycan, proteins and lipoproteins, encoded by both essential and non-essential genes 
(1, 2).  Our current inventory of antibiotics includes drugs which target some of these 
components of the cell envelope e.g. the -lactams that target peptidoglycan synthesis.  On 
this basis, it seems logical that chemicals inhibiting the function of other essential pathways 
(OMP, LPS or Lipoprotein biogenesis) would also prove useful as antimicrobial agents. 
However, despite decades of research, which has significantly advanced our understanding of 
the various pathways involved in the biogenesis of key components, no new antimicrobials 
targeting these pathways have emerged (30, 56, 189, 190).   Over the years, several studies 
have focused on the role of nonessential genes in maintaining cell envelope homeostasis, e.g. 
bamB encoding the BAM complex component, ompA encoding a porin, and surA, degP and 
75 
 
skp encoding various periplasmic chaperones.  These mutations have been shown to induce 
elevated cell envelope stress and membrane defects (19, 50, 54, 191). However, the roles of 
nonessential genes, and the mechanisms by which they all converge to form a coherent 
response to support the maintenance of cell envelope function and to counteract different 
stresses, still remain elusive with many genes and pathways still functionally uncharacterised.  
Prior to commencing this project, no single investigation had sought to identify all the 
nonessential genes that contribute to maintaining the barrier function of the OM or sought to 
understand the mechanisms by which this is achieved. We hypothesised that chemicals which 
targeted the pathways encoded by these non-essential genes, whilst perhaps not bactericidal or 
bacteriostatic in nature, could serve to sufficiently weaken the bacterium such that it is 
incapable of living outside the confines of the laboratory test tube.  Furthermore, these 
chemicals (potentiators) could be combined with currently available antibiotics to enhance the 
entry of the antibiotics into the bacterial cell, thereby increasing their effectiveness. This type 
of approach has previously been shown to be effective against methicillin resistant 
Staphylococcus aureus (MRSA), whereby the combination of tannic acid reduces the MIC of 
fusidic acid in this strain (192). While similar capabilities have been noted for the plant 
derived molecules ethyl gallate and epigallocatechin gallate from Caesalpinia spinosa and 
Camellia sinesis, respectively, both of which have been shown to enhance the activity of   -
lactams (193). Although no potentiators are as of yet used in clinical settings, this remains an 
active avenue of research for combating a variety of bacterial infections (193, 194). 
Therefore, the overarching aim of this study was to identify the repertoire of genes required to 
maintain OM integrity.  To achieve this aim we used the E. coli KEIO library.  
The KEIO library is a series of in-frame single gene disruption mutants in all non-
essential genes in the E. coli K12 strain BW25113 (171). The collection contains mutants for 
76 
 
3985 genes, with two independent isolates obtained for each, resulting in 7970 (171). The 
collection was created using the Datsenko and Wanner method for one step inactivation of 
chromosomal genes, replacing the gene of interest with a kanamycin resistance cassette, 
flanked by FLP Recognition Target sites (FRT), through the aid of the phage λ red 
recombinase system, encoded on the temperature sensitive pKD46 (175). This technique 
limits polar effects on other flanking genes by including the native initiation codon and six 
carboxyl terminal codons, the stop codon and 29 downstream bases, maintaining open reading 
frames (ORF), start codons and translation signals for overlapping genes (171). Since its 
creation, the collection has been rechecked whereby 96.1% (7428 isolates) were deemed to be 
correct and 98.3% (3800 ORF) of mutations were correct for at least one copy, with only 58 
mutants incorrect due to a mixture or duplication (195).   
Here we used chemical biology approaches to probe the KEIO library for mutations 
which conferred loss of OM barrier function. Gram-negative bacteria are normally resistant to 
antibiotics such as daptomycin and vancomycin since they are larger than the diffusion limit 
of the OM (191).  Gram-negative bacteria are also normally resistant to many lipophilic 
compounds such as SDS. The influx of lipophilic compounds is limited by the OM barrier 
function and also by efflux pumps such as AcrAB-TolC (3).  Thus, defects in OM integrity 
were determined by increased susceptibility of KEIO library mutants to two separate 
membrane permeability markers: the glycopeptide antibiotic, vancomycin and the anionic 
detergent SDS (196, 197). The genotype and phenotype for each mutant was confirmed and 
the impact of the mutation on growth rate, cellular morphology and efflux was assessed. 
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3.2. RESULTS 
3.2.1. Screening of the KEIO library for loss of OM homeostasis 
In order to select an appropriate screening concentration of vancomycin and SDS, we 
used the BSAC method (198) to determine the MIC for the parental E. coli strain, BW25113 
against vancomycin and a series of concentrations increasing at regular intervals for SDS. 
Consistent with previous reports, we determined the MIC for vancomycin to be 256-512 
μg/mL (199, 200). Unfortunately, due to the nature of SDS, we were unable to test 
concentrations higher than 8% w/v. However, we were able to demonstrate that this is 
insufficient to inhibit the growth of E. coli BW25113, as determined by growth of this strain 
on LBA supplemented with 8% w/v SDS. Therefore, we recorded for SDS an MIC >8%. 
Based on these data, and to limit the potential for false positives, we selected screening 
concentrations of 100 μg/mL vancomycin and 4.8% w/v for SDS, which were significantly 
lower than the recorded MIC values.   
Using a multi-well inoculator, all 7970 isolates were screened for inhibition of growth 
on LB agar supplemented with either vancomycin or SDS at the concentrations described 
above. From this screening, 871 isolates were identified as defective for growth in the 
presence of at least one compound. Due to the variability associated with this technique and 
discrepancies between the duplicate mutations within the library, each of the 871 isolates was 
rescreened. For each isolate six individual colonies were selected from growth on LB agar 
plates and were restreaked onto LB agar supplemented with either vancomycin or SDS. 
Applying the strict criteria that only isolates exhibiting complete inhibition of growth were 
deemed defective, 201 isolates were selected for further investigation.   
Despite the KEIO library being checked by PCR at the time of creation, Baba et al 
(171) only checked the junctions either side of the inserted cassette, but failed to check for 
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gene duplications, subsequently annotating the collection as containing a <1% error rate. 
Reanalysis by Yamamoto et al (195) indicated only 58 mutants contained duplications and 
they recorded 96.1% of the collection as genetically correct. Given the flaws observed by 
Yamamoto et al (195), we chose to confirm the validity of the mutations being investigated in 
this study. The 201 isolates identified  were subjected to three separate PCR analyses, using a 
combination of gene specific flanking primers (positioned approximately 200 bases up and 
downstream of the gene, for which primer sequences are available in Appendix table 1) either 
together or in combination with internal forward and reverse primers designed to the 
kanamycin resistance cassette. In the case of our collection, ca. 30% of the isolates tested did 
not generate amplicons that would be associated with the correct insertion of the kanamycin 
resistance encoding aph gene and consequential ablation of the target gene.  In total 72 genes 
were identified whose loss gave rise to a compromised OM barrier function as assessed by the 
inability to grow on LB agar containing vancomycin or SDS. 
Closer inspection of the 72 genes within this list revealed a number of genes of 
unknown function, but also a number of instances where the known functions could not be 
attributed to membrane biogenesis or barrier function. Therefore, mutations were transferred 
back into E. coli BW25113 parental strain by P1 transduction.  For each transductant the 
genetic lesion was confirmed using the three PCR methods described above.  After 
confirming the genotype of the newly derived mutants, six individual colonies were selected, 
plated on LB agar containing vancomycin or SDS and assessed for loss of viability after 
overnight growth.  Eighteen of the transductants failed to maintain the phenotype initially 
observed with the KEIO library mutant. This methodology (detailed in Fig. 3.1.) yielded a 
group of mutants harbouring mutations in 54 nonessential genes that could be confidently 
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Fig. 3.1. Workflow diagram for screening of the KEIO library 
The process of identifying E. coli BW25113 mutants with defective outer membrane 
homeostasis is depicted, along with the routes to confirmation of genotype and phenotype.  
The flowchart depicts the pathway for screening against vancomycin; the same pathway was 
applied to identify isolates with a loss of growth phenotype on SDS. 
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Figure 3.2. Comparison of datasets from screening the KEIO library for defective 
growth on vancomycin and SDS.   
Panel A depicts the comparison of data from four separate studies that examined defects in the 
growth of KEIO library mutants in the presence of vancomycin. The integers represent the 
number of mutants which could not grow in the presence of vancomycin.  Panel B depicts the 
number of genes found to be required for growth in the presence of SDS.  
81 
 
Table 3.1.  Isolates Demonstrating Barrier Defects 
Gene 
Other 
Names 
Vanc
a
 SDS Function 
Group
b
 
aceE     Pyruvate dehydrogenase 1 
aceF     Pyruvate dehydrogenase 1 
atpA papA   Membrane-bound ATP synthase, α subunit 1 
atpB papD   Membrane-bound ATP synthase, subunit a 1 
atpC papG   Membrane-bound ATP synthase,  subunit 1 
atpD papB   Membrane-bound ATP synthase, β subunit 1 
atpF papF  WeakMembrane-bound ATP synthase, subunit b 1 
atpH papE   Membrane-bound ATP synthase,  subunit 1 
fumA     Fumarate hydratase class I 1 
galU ychD   Glucose-1-phosphate uridylyltransferase 1 
glnA     Glutamine Synthetase 1 
gpmI gpmM   Phosphoglyceromutase 1 
mipA yeaF   MltA-Interacting Protein 1 
rpiA ygfC   Ribose 5-phosphate isomerase 1 
      acrA sipB   Component of AcrAB-TolC efflux system 2 
acrB acrE   Component of AcrAB-TolC efflux system 2 
bamB yfgL   Component of the BAM complex 2 
bamE smpA   Component of the BAM complex 2 
fepB     Iron enterobactin transporter subunit 2 
fepC     Iron enterobactin Transporter Subunit 2 
ompA tolG   Outer membrane Protein A  2 
pal     Component of Tol-Pal complex 2 
tatC mttB Weak  TatABCE protein translocation system subunit 2 
tolA   Weak  Component of Tol-Pal complex 2 
tolB     Component of Tol-Pal complex 2 
tolC     Component of AcrAB-TolC efflux system  2 
tolQ     Component of Tol-Pal complex 2 
tolR   Weak  Component of Tol-Pal complex 2 
      skp hlpA   Periplasmic protein chaperone 3 
surA     Periplasmic protein chaperone 3 
      cysB     Transcriptional regulator for cysteine regulon 4 
envZ tpo   Two component transcriptional regulator with OmpR 4 
fur    
Transcriptional regulator of ferric uptake associated 
genes 4 
hfq     RNA binding protein, stimulating RNA-RNA pairing 4 
ompR    WeakTwo component transcriptional regulator with EnvZ 4 
rfaH sfrB   DNA-binding transcriptional antiterminator 4 
rseA yfiJ   Negative regulator for sigma E 4 
      
fabH     3-oxoacyl-[acyl-carrier-protein] synthase III 5 
htrB lpxL Weak  Lauroyl acyltransferase 5 
lipA    WeakLipoate synthase 5 
lpcA     Sedoheptulose 7-phosphate isomerase 5 
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Table 3.1. Isolates Demonstrating Barrier Defects (continued) 
Gene 
Other 
Names Vanc SDS Function Group 
msbB lpxM   Myristoyl-acyltransferase 5 
rfaC waaC   LPS heptosyl transferase I 5 
rfaD waaD   ADP-L-glycero-D-mannoheptose-6-epimerase, 5 
rfaE waaE  
Heptose 7-phosphate kinase and heptose 1-
phosphate adenyltransferase 5 
  rfaF waaF   LPS heptosyltransferase II 5 
rfaG waaG   LPSe glucosyltransferase I 5 
rfaP waaP   Kinase p-hophorylating core heptose of LPS 5 
gmhB yaeD    Heptose 1,7-bisphosphate phosphatase 5 
      plpA yraP   Predicted protein 6 
ybgT     Predicted small membrane protein 6 
yfgC     Predicted Peptidase 6 
yibP envC   Predicted membrane protein 6 
yciM     Predicted heat shock protein 6 
a
Defects in barrier function determined as the inhibition of growth:  sensitivity observed as 
no growth; Weak, sensitivity observed as weak growth;  growth comparable with that of the 
parental strain E. coli BW25113.  
b
Functional Groups: 1. Metabolism; 2. Membranes and Transport; 3. Chaperones; 4 DNA and 
Transcription/Translation; 5. Fatty Acid/LPS and Macromolecule Biosynthesis; 6  Unknown 
Function and Predicted Proteins 
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considered to be essential for maintaining OM homeostasis under the conditions tested 
(Table 3.1.).  
Since commencing this project, a number of other groups have also utilised the KEIO 
library for similar means. Three separate studies examined the sensitivity of the KEIO library 
mutants to vancomycin or SDS (199-201). Comparison of the published data, with that 
obtained during this study, highlights striking differences; Tamae et al (199), highlighted 32 
genes required for resistance to vancomycin, while Liu et al (200) highlighted 51 and Nichols 
et al (201) identified 87 genes required for resistance to vancomycin, SDS or both reagents 
(Fig. 3.2.). Each mutant identified by the other studies, but which was not found in our 
investigation, was plated out and subjected to the same phenotypic and genotypic scrutiny 
described above. Of the 32 genes highlighted by Tamae et al only 15 were sensitive and 
genetically correct in our hands, of which four lost their phenotype on P1transduction (dksA, 
rimK, ycbR and yhdP), a further seven were incorrect by PCR and 10 were found to be correct 
by PCR but not sensitive, despite using the same concentrations of vancomycin. Similarly, 
Liu et al identified 50 genes critical for vancomycin resistance. However, only 20 of these 
mutants were found to be sensitive and genetically correct in our hands, seven of which were 
only weakly sensitive and were omitted from our list of 72. Two (dnaK and rimK) lost their 
phenotype on P1 transduction. A further four were incorrect by PCR, one was unconfirmed 
and 25 were correct but not sensitive. While Nichols et al (201) examined sensitivity to both 
vancomycin (50 μg/mL) and SDS (4%) these were at different concentrations to that used in 
our study. Of the 13 mutants highlighted as sensitive to both reagents in the Nichols et al 
study, only seven were consistent with our data, while five of these showed sensitivity to only 
one compound and the remaining mutant was not sensitive in our screen. Of the 35 isolates 
sensitive to only vancomycin, 11 were consistent with the current study. Finally, of the 39 
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isolates sensitive only to SDS, which were highlighted by Nichols et al, 15 mutants were 
consistent with our data; six were found to be genetically incorrect. 
 
3.2.2. Characterisation of mutants with defective barrier function 
To confirm the results were not distorted by artificially slow growth rates, we analysed the 
growth kinetics of the 54 isolates under standard conditions in LB broth at 37
o
C (Figure 3.3). 
The majority of mutants showed similar growth kinetics to that observed for the parental 
strain, with a limited number showing reduced growth in the form of either slower growth 
rates, or earlier entry into stationary phase at lower optical densities, as seen for bamB, fabH, 
glnA, surA, tatC and tolQ. While several isolates displayed increased lag phase or slight 
reductions in growth rates, including aceE, aceF, htrB, lipA, msbB and several atp mutants, 
these reductions were not deemed to be sufficiently dramatic as to have affected the results of 
the earlier screening. 
Having performed standard growth kinetics, we set about assessing the mutants using 
flow cytometry with PI and BOX staining, after standard growth conditions. PI and BOX 
staining is commonly used as means of discriminating between live, dead and stressed cells. 
PI stains the DNA of dead cells but is unable to penetrate the membranes of live cells, whilst 
BOX stains cells lacking IM potential (202-204). As shown in figure 3.4., the resultant plots 
for healthy and killed BW25113, demonstrates healthy cells localise predominantly to 
quadrant (Q) 3, due to minimal staining of either compound. In contrast killed cells localise to 
Q2 indicative of staining with both PI and BOX. Highly stress cells can stain for a loss of 
membrane potential (i.e. BOX only) with resultant Q1 localisation, though PI staining is only 
observed in dead cells, (i.e. Q4 localisation should not be possible in the presence of both 
dyes). Thus, screening by this method should reveal if significant portions of the
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Figure 3.3. Growth kinetics for isolates with defective barrier function.  
Growth kinetics for isolates sensitive to either vancomycin, SDS or both, grown under 
standard laboratory conditions in LB broth at 37
o
C. Data represent the average of the three 
biological replicates with two technical replicates for each.  
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Figure 3.4.Flow cytometry Dot Plot and Histograms for PI and BOX staining 
FACs dot plots, histograms and quadrant (Q) percentages for PI and BOX stained (A) healthy  
BW25113 and (B) ethanol killed samples, with combined PI and BOX Staining, showing 
under healthy conditions population localises to Q3, not staining with either compound, 
though when ethanol killed, the population substantially shifts from Q3 to Q2. Histograms 
show staining for BOX is detected by FITC channel, while PI is PE Texas Red. 
A B 
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population were stressed or losing viability during our analyses.  We examined all 
isolates after growth in LB broth under standard conditions. The results are expressed as a 
percentage the population staing with the relevant dye (Table 3.2.). 
For the majority of isolates, >95% of the population is present in Q3, with a few minor 
exceptions including gpmI, skp, ompR, surA, tolR and yibP. In these isolates >90% of the 
population is present in Q3 (with the exception of skp in which 89.9%), with the remaining 
population distributed across the other quadrants. Interestingly, some mutants show a larger 
proportion of the remaining population in Q4 (than in Q1 or 2), suggesting the resultant 
membrane defect may allow for PI penetration while the membrane remains largely intact 
Interestingly, the skp and surA mutants (both periplasmic chaperones) demonstrated the 
highest remaining proportion present in Q4. 
 
3.2.3. Examination of cellular morphology 
Changes in cell shape can significantly alter optical density readings obscuring 
changes that might occur in the number of viable cells.  To complement the above studies, 
and to rule out the possibility that changes in cell size might be confounding our results, we 
chose to examine the cell morphology using SEM (Fig. 3.3.).  SEM analysis was performed 
for the majority of mutants (48/54); we were unable to gain access to the SEM facility to 
complete the analysis.  In many instances the mutants displayed normal morphology, with 
regards to cell size and shape. Two notable exceptions were strains harbouring mutations in 
tatC and msbA, which displayed an elongated rod shaped morphology. Furthermore, the tatC 
mutant showed a cell divison defect since individual rods did not appear to dissociate but 
rather formed chains. Interestingly, in many cases there appears to be a high level of vesicles 
present, including in the case of the fabH, fumA, galU, hfq, lipA, ompA and pal mutants. 
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Table 3.2. Population Statistics for Flow cytometric analyses of mutants 
 
PI and BOX Standard    PI and BOX Standard  
Gene Q1 Q2 Q3 Q4  Gene Q1 Q2 Q3 Q4 
BW25113 0.1 0.2 99.4 0.3  msbB 0.1 0.1 99.7 0.1 
aceE 0 0 99.9 0.1  ompA 0 0 99.6 0.3 
aceF 0 0 99.2 0.8  ompR 0.9 1.9 92.5 4.7 
acrA 0 0 99.8 0.2  pal 0.4 0.2 98.5 0.9 
acrB 0 0 99.6 0.4  plpA 0.3 0.1 97.9 1.7 
atpA 0 0.1 99.7 0.2  rfaC 0.1 0.3 99.5 0.1 
atpB 0.1 0.3 99.1 0.5  rfaD 0.3 0.5 97.5 1.7 
atpC 0 0 100 0  rfaE 0.1 0.2 97.4 2.3 
atpD 0 0 100 0  rfaF 0.2 0.3 98.1 1.4 
atpF 0 0.1 99.8 0.1  rfaG 0.2 0.1 98.4 1.2 
atpH 0 0.2 99.2 0.6  rfaH 0.2 0.2 99.5 0.2 
bamB 0 0 99.7 0.3  rfaP 0.1 0.1 99.6 0.2 
bamE 0 0 99.9 0.1  rpiA 0.3 0.1 99.5 0.2  
cysB 0 0 99.8 0.2  rseA 1 0.2 97.6 1.3 
envZ 0.3 0.5 98.5 0.7  skp 1.7 0.7 89.9 7.6 
fabH 0.2 0.2 99.3 0.4  surA 0.9 1.7 90.6 6.8 
fepB 0.1 0 99.8 0.1  tatC 1.2 0.4 97.7 0.7 
fepC 0 0 99.8 0.2  tolA 0.2 0.1 99.4 0.3 
fumA 0.1 0 99.8 0.1  tolB 0.4 0.5 95.8 3.3 
fur 0.1 0 99.6 0.2  tolC 0 0 99.9 0.1 
galU 0 0 99.8 0.2  tolQ 0.3 0.2 98.7 0.9 
glnA 0 0 99.9 0  tolR 1.7 1.3 94.9 2.1 
gpmI 1.5 2.8 93.7 2  yaeD 0.1 0 98.5 1.4 
hfq 0.1 0 99.9 0  ybgT 0.2 0 98.4 1.4 
htrB 0 0 99.8 0.2  yciM 0.2 0.1 99.1 0.6 
lipA 0 0 99.9 0  yfgC 0 0 99.9 0.1 
lpcA 0.1 0 99.5 0.5  yibP 0.9 0.9 94.2 3.9 
mipA 0.1 0 99.8 0.1       
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Figure 3.3. SEM for isolates with defects in OM homeostasis. 
E. coli BW25113 mutants were imaged at different magnifications.  The identity of each 
mutant is shown. 
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3.2.4. Investigation of the molecular basis for loss of OM homeostasis 
As mentioned previously, defects in outer membrane homeostasis confer upon Gram-negative 
bacteria susceptibility to a variety of compounds.  The molecular basis for loss of the barrier 
function is incompletely understood, however there are currently two major schools of 
thought.  The first hypothesis suggests loss of the barrier function is related to structural 
instability in the OM resulting from uncoordinated assembly of OM components.  The second 
school of thought suggests that defects in efflux activity leads to the accumulation of toxic 
compounds in the cell leading to cell death. Associated with this is the hypothesis that 
decreases in barrier function allow the ingress of toxic molecules to an extent that the efflux 
systems are overwhelmed, leading to accumulation of toxic substances and cell death.  We 
hypothesised, if mutations led to significant structural instability then the periplasmic contents 
of the cells would leak out of the bacterial cell and if the mutation gave rise to defects in 
efflux on the ingress of toxic substance then this would manifest as accumulation of the 
substances within the cell. 
To test the first hypothesis, we examined the culture supernatant fractions of each 
mutant after overnight growth in LB broth using standard conditions. The supernatant fraction 
was separated from cells and precipitated using TCA. Resultant fractions were compared by 
SDS-PAGE to supernatant fractions of chemically lysed and untreated E. coli BW25113 
cultures. Similar to other E. coli K12 strains, BW25113 does not naturally secrete proteins 
into the supernatant fraction (106). A number of isolates (21 of 54) accumulated proteins in 
the supernatant fraction, including aceE, aceF (weakly), gpmI, hfq, mipA, msbB, ompA, 
ompR, pal, rfaD rfaF, rfaG, rfaH, rfaP, surA, tatC, tolA, tolB, tolQ, tolR and yibP (Fig. 3.4.).  
Interestingly, this correlated with production of vesicles observed by SEM (Fig. 3.3.) These 
fractions were subjected to immunoblotting using antibodies raised against the periplasmic 
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chaperone DegP, confirming the proteins observed were of periplasmic origin (data not 
shown).  In parallel to examining the supernatant fractions the cell envelope fractions of each 
mutant was harvested and analysed by SDS-PAGE (Fig. 3.5). With the exception of ompA 
and ompR mutants, where the absence of OmpA and OmpF/C are observed, respectively, no 
major differences were noted between the parent and mutants.  
To determine whether the elevated sensitivity was due to defective efflux, we investigated the 
efflux activity of all 54 isolates, using the Hoescht accumulation assay as described by 
Coldham et al. (186).  The substrate, Bis-benzimide (Hoescht 33342), naturally diffuses into 
the cell and emits a fluorescent signal upon binding to the DNA. This compound is a substrate 
for the RND efflux pumps, which in healthy cells results in a standard base line of 
fluorescence (based on the balance between diffusion into the cell and efflux out). Inhibition 
of efflux activity in these cells, through the addition of the broad spectrum efflux pump 
inhibitor, phenyl-arginine-β-naphthylamide (PAβN), functioning through competitive 
inhibition of RND pumps (205, 206), provides a suitable control for comparison with 
potential efflux mutants; these mutants display significantly increased fluorescence due to 
increasing intracellular concentrations of Hoescht 33342. The majority of the isolates 
demonstrated comparable efflux activities when compared to the wild-type E. coli BW25113 
(Fig. 3.6.). Notable exceptions were the isolates harbouring mutations in the genes encoding 
the known efflux system AcrAB-TolC. In addition, the hfq, envZ, skp, yciM, yibP and the rfa 
mutants showed increased accumulation of Hoescht 33342 (Fig. 3.6.). To investigate whether 
the increase in fluorescence was due to impaired efflux we added PAβN to the assay.  Only in 
the case of the rfa mutants did PAβN addition fail to increase Hoescht 33342 accumulation.  
Surprisingly, a number of isolates demonstrated a significant increase in efflux activity  
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Figure 3.4.  SDS-PAGE analysis of culture supernatant fractions  
TCA precipitated supernatant fractions from isolates with membrane barrier defects were 
analysed by SDS-PAGE. The size of the molecular weight markers (MWM) are depicted to 
the right of each gel.   
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Figure 3.5.  Cell envelope preparations  
Cell envelope preparations from isolates with membrane barrier defects were analysed by 
SDS-PAGE. The size of the molecular weight markers (MWM) are depicted to the right of 
each gel.  
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Figure 3.6. Efflux activity of all isolates   
The efflux activity of all isolates with compromised OM homeostasis was determined using 
the Hoescht 33342 accumulation assay. Fluorescence levels set to 100% for BW25113 
without an inhibitor. All mutants were compared against BW25113 to generate of a 
percentage of fluorescence by comparison both in the presence and absence of the broad 
range efflux inhibitor, PAβN. Significance was determined using a student T test and P-values 
were scored <0.05 (*), <0.009 (**) or <0.0009 (***). 
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compared to that of the parental strain e.g. atpB, atpC, atpF, fumA, mipA, tatC, tolB, fur and 
ybgT.   
 
3.2.5. Can Flow cytometry distinguish cells with compromised barrier function? 
As we had established that flow cytometry could distinguish between healthy, dead 
and stressed cells we hypothesised that this assay might yield a high-throughput assay to 
distinguish mutants which would succumb to the presence of vancomycin, SDS or other toxic 
compounds to which wild-type E. coli are normally resistant.  To test this hypothesis, we 
chose a selection of isolates we had previously shown to be either sensitive or resistant to 
either vancomycin or SDS. As all mutants displayed normal viability when analysed by flow 
cytometry with PI and BOX staining. Cultures were grown to mid-log phase (OD600=0.6) in 
LB broth at 37
o
C under standard conditions, after which either vancomycin or SDS was added 
to the culture at final concentrations of 100 g/mL or 4.8% w/v, respectively.  Incubation was 
continued for two hours before the addition of PI and BOX, and fluorescence measurements 
were taken as normal. A large portion of the population of the E. coli BW25113 parent strain 
remained viable after treatment with both compounds (Table 3.3.).  Most mutants behaved in 
a manner that might be expected.  Those that demonstrated susceptibility to vancomycin, SDS 
or both compounds in the plate assay also demonstrated a shift from live (Q3) to dead (Q2) or 
stressed (Q1) cells in the flow cytometry assays. However, several of the mutants gave 
contradictory results. For example, aceF, fepB and glnA, incubated with vancomycin continue 
to show >90% residing in Q3, despite previous sensitivity to this compound in the plate 
screening assay. All isolates incubated with SDS (except yciM, which displays 85.7%) show 
<80% of the population residing in Q3. In some instances, this is more significant, with 
mutants such as rfaF and rseA displaying <2% of the population in this quadrant. 
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Table 3.3. PI and BOX staining of isolates with defective barrier function 
 
PI and BOX Post 
Vancomycin 
PI and BOX Post SDS 
Phenotype in Agar 
(Sensitivity)
a
 
Gene Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Vanc  SDS 
BW25113 0.3 0 98.5 1.2 3.7 1.6 92.3 2.4   
aceF 1.9 0.7 93.1 4.3 
  
 
 
  
bamB 3.4 14.3 13.9 68.5 1.2 1 12.6 85.3   
fabH 8.8 18.4 30.5 42.3 
  
 
 
  
fepB 0.6 0.4 96.9 2.2 3.3 31.8 61.6 3.3   
glnA 2.4 1.9 91.3 4.4 
  
 
 
  
gpmI     1.4 40.9 44.9 12.8   
mipA     0.1 0.3 78.6 21.0   
ompR 7.6 24.9 23.6 43.9 
  
 
 
 Weak 
pal 4.4 4.6 66.7 24.4 6.6 55.2 27.8 10.5   
plpA 29.3 15.2 50.2 5.3 0.4 1.0 32.3 66.3  
rfaF     0.5 1.2 1.2 97.1   
rpiA 12 0.8 85 2.2 
  
 
 
  
rseA     0.1 1.8 1.3 96.8   
surA 18.3 54.4 10.5 16.9 8.1 9.8 51.1 31   
tolC     4.3 4.7 44.1 46.9   
yciM 7 8.2 67.2 17.7 0.8 0.5 85.7 13   
 
a 
Phenotype as determined previously in solid agar supplemented with either compound, 
sensitivity as observed as no growth;  Weak, sensitivity observed as weak growth, 
growth comparable with that of the parental strain E. coli BW25113. 
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Interestingly, of the 11 isolates tested in the presence of SDS, eight demonstrate higher Q4 
than Q2 percentages and of these five displayed higher Q4 than any other quadrant.  Despite 
the few exceptions described above, the results obtained from this analysis are consistent with 
those described previously, indicating the method may be useful for large scale screening in 
the future.   
 
3.3. DISCUSSION 
This study has identified 54 nonessential genes which encode products critical for the 
formation and maintenance of the cell envelope barrier function. This is by no means a 
definitive list, in some instances the inability to identify genetically correct mutants from the 
library, may have limited the number of genes identified. For example, mutations in lamB and 
lpp, were predicted to have shown some degree of membrane defect under the conditions 
tested, based on their known functions and defects previously reported in the literature. 
However, we were unable to isolate genetically correct isolates for either of these mutants, in 
addition to numerous others, as shown by the significantly high error rates observed from this 
study (>30%). Additionally, by only selecting two markers of membrane permeability this 
may have further restricted the numbers of genes highlighted during this study. Studies by 
Tamae et al (199)  and Liu et al (200), have shown that sensitivity to different antibiotic 
classes highlights different subsets of genes. Thus, by expanding our initial screens to include 
other non-bactericidal compounds of different functional classes we may have further 
identified other genes and pathways.   
Closer examination of the published literature shows both the Tamae et al and Liu et 
al papers originated from the same research group, though only 22 genes are consistently 
between both articles, of which only 10 were found to be sensitive and PCR correct in this 
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study, of which one lost its phenotype after P1 transduction (rimK). In contrast to this study, 
Tamae et al failed to check the veracity of any of the mutants used during their study, while 
Liu et al, performed only minimal checks, selecting just one mutant from those shown to be 
sensitive to a particular class of antibiotics for PCR checking. Furthermore, in both articles 
only one copy of each mutant was examined for sensitivity, in contrast to this study where 
both copies of each mutant were screened, to account for potential genetic variations between 
the isolates. Additionally, by P1 transducing mutations of interest into the parental strain and 
testing the new mutant, we have further reduced the potential for other secondary site 
mutations, capable of obscuring the true phenotype. 
In contrast to the above articles, Nichols et al performed stringent PCR analysis of the 
mutants used in their study, and although no error rates are quoted in the article, a number of 
mutants are excluded, due to the authors being unable to confirm the veracity of the mutation. 
However, Nichols et al, used a measure of colony size to determine fitness, and thus 
distinguish sensitive mutants, while this study focused on complete inhibition of growth. 
Despite using higher concentrations of both reagents in this study, the criteria of complete 
growth inhibition may account for the significant differences in the numbers of isolates 
perceived as sensitive.  Interestingly, comparison of the vancomycin sensitivity results from 
all data sets (Tamae et al, Liu et al, Nichols et al and this study), indicates only six mutants 
are in total agreement, highlighting the variability associated with both the KEIO library and 
different screening methods. Though despite these inconsistencies the sensitivity observed 
during this study has been reconfirmed by multiple techniques, including PI and BOX 
viability analysis, confirming the results observed here were not an artefact of the screening 
method employed.    
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The significantly high error rates in the KEIO library, reported as part of this study, 
contrast with that previously reported by Baba et al (171) and Yamamoto et al (195), whom 
reported the collection contained <1% and 1.6% incorrect mutants, respectively. These 
inconsistencies are potentially an artefact of the methods employed in the other reports. Here 
we have performed three independent PCR reactions to validate each mutant, using a 
combination of gene specific flanking primers, together or in combination with internal 
kanamycin cassette primers, to check for both gene duplications, and confirm the junctions 
either side of the inserted cassette. We again applied the strict criteria that all three PCR 
reactions, must generate products of the correct size, to be deemed correct. In contrast, when 
the collection was constructed only the junctions either side of the inserted cassette were 
assessed, which failed to check for gene duplications. Further to this, when the collection was 
rechecked, internal primers to the disrupted genes were used to perform ‘negative PCR’ 
whereby the absence of a PCR fragment in the mutant but present in the parental strain, was 
deemed sufficient to annotate the mutation as correct; in other words they used absence of 
evidence as evidence of gene absence. Thus, although the error rate observed in our collection 
maybe an artefact of only having screened 457 isolates (potentially extending our 
investigations may reduce this value) we have shown that the identification of 
correct/incorrect mutants appears to in some instances be collection specific. Comparing our 
PCR data with that reported by Yamamoto et al, highlighted mutants which they have 
annotated as incorrect or a mixture, we have been able to isolate genetically correct colonies 
(i.e. nohA and mdh). However, in other instances the reverse is true; isolates found to be 
incorrect in our collection were annotated as correct in their study (i.e. lamB, lpp and oxyR). 
Nevertheless, while we may not have identified every gene in E. coli that is required for the 
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maintenance of outer membrane homeostasis we are confident that we genes identified in this 
study are absolutely required.  
Of the genes identified, many of the phenotypes observed are easily explainable based 
upon previously investigation and known function. For example many of the mutants 
displaying reduced growth kinetics, increased durations of lag phase or early plateau into 
stationary phase are associated with cellular metabolism or the biogenesis of key cellular 
components. Such as fabH and glnA which encodes a β-ketoacyl-acyl carrier protein (ACP) 
synthase III, responsible for catalysing the first elongation reaction of type II fatty acid 
biosynthesis (207, 208) and glutamine synthase, catalysing the only enzymatic reaction in 
glutamine biosynthesis (209), respectively. The major peptidyl-prolyl isomerase (PPIase) 
periplasmic chaperone, SurA is involved in the transit of OMP precursors (including OmpA, 
OmpF and LamB) across the periplasmic space from the SEC transport machinery (IM) to 
BAM complex (OM) (14, 15). Additionally, tatC encodes a subunit of the IM Tat complex, 
required for the export of folded proteins to the periplasm (27, 29), including the amidases, 
AmiA and AmiC, required for peptidoglycan NAM cleavage during cell division (28, 32), 
respectively.  
In contrast to other studies of a similar nature, we have characterised the membrane 
defect further by examining cell leakage and efflux activity in all mutants. Interestingly, there 
is a correlation between those mutants with ‘leaky’ phenotypes and those that produce 
significant vesicles as assessed by SEM analysis. This correlation has been reported 
previously for some of the mutants, such as for tolA, tolQ, pal, rfaG, ompA, ompR and tatC 
(8, 210-213) suggesting that the resultant proteins observed are most likely due to the 
production of vesicles and not as a direct result of periplasmic leakage.  Interestingly, in a 
number of instances, mutants were identified where proteins were not identified in the culture 
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supernatant fractions but where vesicles were observed by SEM. This may be due to their size 
as it has been shown previously that these vesicles can range in size from 10 - 300nm in 
diameter (214) and larger vesicles may have been excluded during the supernatant filtering 
step prior to TCA precipitation (214). Alternatively, the vesicles may be present at lower 
frequencies and fail to contain sufficient protein concentrations to be detected using this 
technique. Thus, analysis via alternative techniques (including Bradford protein concentration 
assay) may be more suitable. 
The SEM analysis performed to date, both confirm previous literature reports and 
advances our understanding of the similarities between different species, i.e. in the case of 
tatC and msbB mutants have elongated cells, with a clear division defect. This phenotype has 
been previously described for E. coli tatC (27) and similar replication defects have been 
described for msbB mutants in both S. Typhimurium and Shigella flexneri (215, 216).  
Despite not offering a definitive list, this study has provided significant insight into the 
role of nonessential genes in maintaining the cell envelope barrier function, providing new 
insights as to the possible function of predicted gene products e.g. yibP, yciM and plpA. YibP 
is a predicted peptidoglycan hydrolase that maybe associated with cell division (217), 
however, it also has significant homology to the periplasmic RND component, AcrA (65% 
amino acid) (218). Given our results demonstrate that a yibP mutant has a significant defect in 
efflux it is tempting to speculate the protein encoded by this gene may be associated with 
efflux. YciM is a predicted heat shock protein, forming part of the σ32 regulon (219). It too 
had significantly reduced efflux however we do not have a plausible hypothesis to explain the 
defect.  Notably, this gene is essential in S. Typhimurium (220). Our analysis failed to clarify 
the mechanism by plpA (yraP) contributes to membrane barrier function. Therefore, this gene 
is the focus of investigation in chapter 4.  
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A real benefit to this investigation was the development of the PI and Box staining 
assay.  In most instances, the results were consistent with those obtained from growth on agar 
plates although puzzlingly when incubated with SDS a considerable proportion of the 
population localised to Q4. As described previously, Q4 staining should not be possible and 
thus poses an interesting question. SDS has been shown to solubilise cytoplasmic membranes 
(221). It is therefore tempting to speculate that the observed Q4 staining is as a result of ‘dead 
cells’ with a solubilised IM, thus removing the binding site for BOX. However, this requires 
further investigation to confirm this hypothesis, which is not within the scope of this study. 
Nevertheless, it seems this study could be expanded as a rapid high through-put assay for 
compounds which inhibit cell viability and membrane stability. 
This study aimed to identify nonessential genes, which may form suitable (secondary) 
drug targets, for potential co-administration with previously ineffective antibiotics. The 
mutants require significant further investigation, regarding the impact of the gene deletion on 
pathogenic bacterial strains; do the mutations attenuate virulence, or increase susceptibility to 
the host immune system? This will be investigated further in chapter 5, by transferring a 
selection of these mutants to the broad host range pathogen S. Typhimurium for assessment in 
a murine model of infection. 
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CHAPTER 4 
 
IDENTIFICATION OF A PATHWAY FOR THE TRANSPORT OF 
PHOSPHATIDYLGLYCEROL OF THE OUTER MEMBRANE 
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4.1. INTRODUCTION 
The OM of Gram negative bacteria is composed of OMPs, LPS, lipoproteins and 
phospholipids, the first three components are trafficked and inserted into the membrane by 
means of the BAM complex, Lpt and Lol pathways, respectively (1). However, the 
mechanisms by which phospholipids are trafficked and inserted into the inner leaflet of the 
OM remains elusive. The inner leaflet, comprises 70-80% phosphatidylethanolamine (PE), 
20-25% phosphatidylglycerol (PG) and 5% cardiolipin (CL) (222).  
Biogenesis of phospholipids in E. coli occurs via a multi-step process, with the initial 
conversion of dihydroxyacetone phosphate to sn-glycerol-3-phosphate (G3P) via the G3P 
dehydrogenase, GpsA (223). This initial reaction creates the phospholipid backbone and is 
highly conserved in numerous bacterial species. The attachment of the first and second fatty 
acids generating monacyl-G3P and phosphatidic acid, is performed by PlsB and PlsC, 
respectively (223). While the CDP-diglyceride synthase (encoded from cdsA) converts 
phosphatidic acid to its activated intermediate CDP-diglyceride (CDP-diacylglycerol), which 
forms the basis for either PE or PG and CL (223). In the case of PE, phosphatidylserine 
synthase (CDP-diacylglycerol-L-serine phosphatidyltransferase) PssA and phosphatidylserine 
decarboxylase (Psd) catalyse the next two reactions. For PG and CL synthesis the pgsA-
encoded CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase catalyses 
removal of the phosphate moiety from PG phosphate; CL synthase (cls) can then catalyze  the 
condensation of PG to CL and glycerol (223).  
The enzymes associated with phospholipid biogenesis are predominantly IM bound 
or associate with the IM giving rise to the hypothesis that phospholipids are flipped across the 
IM in a manner analogous to LPS. However, the mechanism by which they’re trafficked 
across the periplasm and inserted into the inner leaflet of the OM is completely unknown. In 
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contrast, the pathways and proteins associated with maintaining phospholipid asymmetry at 
the OM are known. Although the biochemical mechanisms by which they function have not 
been completely resolved, their identification has enhanced our understanding of the 
maintenance of lipid asymmetry. Cell envelope stress is a common cause of migration of 
phospholipids into the outer leaflet of the OM. Indeed, exposure to chemicals such as EDTA 
strips 30-50% of LPS molecules from the surface and chelates magnesium ions creating 
destabilised regions, which are predicted to allow phospholipid localisation on the outer 
leaflet (71, 73, 224). In addition, antimicrobial cationic peptides produced by host cells during 
infection, have been shown to induce a flip-flop movement of phospholipids across the OM, 
enhancing permeability to these molecules (224). The Mla Pathway, PldA and PagP proteins 
counteract the accumulation of phospholipids in the outer leaflet but by different mechanisms.  
The Mla pathway contains components localised to the OM, periplasm and IM, for the 
extraction and recycling of phospholipids from the OM to the IM. However, it is currently 
unknown whether this complex is specific for PE or whether it can recognise PG and CL too 
as the MlaC crystal structure was determined whilst bound to PE (71). The OM localised 
MlaA removes mislocalized phospholipids transferring them to the periplasmic MlaC, which 
in turn delivers the phospholipid to the MlaBDEF complex at the IM, where the fate of the 
phospholipid is unknown (71). PldA functions in an alternative manner, normally existing as 
an inactive monomer in the OM. The binding of calcium stimulates dimerisation, enabling 
PldA to sequester and degrade phospholipids, by catalysing the removal of sn-1 and sn-2 fatty 
acid chains from the backbone (72). In contrast PagP catalyses the transfer of palmitate from 
the sn-1 position to lipid A (73). The PagP active site is located on the outer leaflet of the OM 
for association with lipid A. Though the means by which PagP interacts with phospholipids is 
unknown, current hypotheses suggest localisation of phospholipids to the outer leaflet of the 
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OM allows PagP access to its’ substrate (224). Interestingly, despite both these proteins 
functioning to maintain OM lipid asymmetry, only over expression of PldA (and not PagP) 
can compensate for the loss of the Mla pathway (71). 
During this investigation sought to characterise plpA, a gene identified during our 
screen for mutations resulting in membrane defects (Chapter 3). Using a combination of 
bioinformatics analysis, in vivo and in vitro assays, we characterised the function of plpA and 
provide a context to its role in maintaining membrane barrier function.  Here we provide 
evidence that PlpA functions as a PG transporter, moving PG across the periplasm to the OM. 
 
4.2. RESULTS 
4.2.1. plpA encodes a predicted OM lipoprotein with two BON domains 
Having previously shown that plpA mutants result in membrane barrier defects, we 
initially set out to determine the type of product encoded by plpA and its cellular localisation. 
Bioinformatic analyses of the sequence indicated plpA was under the control of σE promoters 
(Fig. 4.1) and encoded a predicted OM lipoprotein as determined by the presence of a Lol-
dependent targeting sequence, lipobox, and an N-terminal cysteine residue at position 19. This 
allows for attachment to the inner leaflet of the OM when acylated, consistent with other OM 
lipoproteins (30). The protein contains two separate Bacterial and OsmY Nodulation (BON) 
domains (Fig. 4.1), predicted to be associated with phospholipid binding, though this function 
has yet to be confirmed experimentally (225). 
 
4.2.2. PlpA is OM localised, but not surface exposed 
As plpA is predicted to encode an OM lipoprotein, we sought to confirm its cellular 
localisation. By immunoblotting cellular fractions using anti-PlpA ABs, PlpA was shown to 
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Figure 4.1. Gene location and protein structure of PlpA 
A. The genetic organisation of plpA, with two upstream promoters under the control of σE. B. 
The domain architecture of PlpA, containing Lol dependant signal sequence, N-terminal 
cysteine residue at position 19 which is acetylated to allow anchoring into the inner leaflet of 
the OM and two BON domains.   
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be localised to the OM fraction of the parental E. coli K12 strain BW25113 and 
complemented mutant, but not the plpA mutant (Fig. 4.2). Recent investigations have revealed 
that certain OM localised lipoproteins have the capacity to be surface localised. Therefore, to 
determine whether PlpA was periplasmically located or surface localised we performed 
immunofluorescence using the same strain set. PlpA was only detected in the permeabilised 
parental strain E. coli BW25113 or the complemented mutant and not in the permeabilised 
plpA mutant or any of the non-permeabilised samples. These data indicate PlpA is localised in 
the periplasm.  As expected, SurA is detectable in all the permeabilised samples due to its 
periplasmic localisation. 
Furthermore, PlpA should be anchored to the inner leaflet of the OM by the N-
terminal acylated cysteine. Therefore, mutation of the cysteine residue to alanine should 
prevent acylation and recognition by the Lol pathway. Immunoblotting the OM fraction from 
this strain in parallel to the parent, plpA mutant and complemented mutant, indicated the 
cysteine mutant failed to localise to the OM confirming the role of this N-terminal cysteine in 
targeting PlpA to the OM.  
 
4.2.3. plpA is distributed throughout proteobacteria   
Further bioinformatic investigations revealed three BON-domain proteins were 
encoded on the E. coli genome: PlpA, OsmY and YgaU (Fig. 4.3). PlpA and OsmY share a 
dual BON-domain architecture and sequence similarity (29.5% identity) but OsmY possesses 
a typical Sec-dependent signal sequence. YgaU is more distinct consisting of one BON and 
one LysM domain. Clustering analyses of sequences (CLANS) obtained by HMMER 
searches were used to determine their taxonomic distribution: PlpA and YgaU are distributed 
throughout the -, - and proteobacteria whereas OsmY is more widely distributed (Fig. 
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Figure 4.2. PlpA is localised to the inner leaflet of the OM  
A. Western blot of OM fractions for parental strain E. coli BW25113, BW25113ΔplpA 
complemented with pET20bplpA, BW25113ΔplpA and BW25113plpAC19A, probed with α 
PlpA primary AB and secondary anti-rabbit AB. Indicating PlpA can only be detected in 
either the parental strain or complement, though is absent in the mutant and not detectable in 
mutated cysteine version, due to the inability of the protein to anchor to the inner leaflet of the 
OM. B. Immunofluorescence of whole cells and permeabilised cells, stained with either α 
PlpA (top panel) or α SurA  (bottom panel) primary AB, and secondary GAR alexa fluor488 
AB. Indicating PlpA is only detectable in permeabilised parental strain, E. coli BW25113 and 
complemented mutant, but not plpA mutant. SurA is detectable in all permeabilised samples, 
but also non permeabilised plpA mutant, indicating the membrane defect allows 
immunoglobulin’s access to the periplasmic space.  
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Figure 4.3. BON Domain containing proteins 
A. Domain architecture of PlpA, OsmY and YgaU proteins. Highlighting PlpA and OsmY 
share the most similar protein domain structure, with each protein containing two BON 
domains, while YgaU is more distinct with one BON domain and C-terminal LysM domain. 
B. Architecture and distribution of BON domain containing proteins, across several bacterial 
phyla. Indicates BON domains are most commonly observed in seven formats, as depicted by 
the number of species for which they are observed in, shown in brackets next to each domain 
type. 
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Figure 4.4. Clustering analyses of sequences (CLANS)  
CLANS analysis for PlpA, OsmY and YgaU. Indicating all three proteins are evolutionary 
connected. PlpA and YgaU are distributed throughout the -, - and proteobacteria 
whereas OsmY is more widely distributed.  
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4.4). The BON domain can be found in several different domain architectures, and our 
comprehensive analysis recovered seven predominant domains co-occurring with BON in 
major groups across different bacterial phyla (Fig. 4.3). 
 
4.2.4. PlpA is not required for resistance to changes in osmolarity  
Although the precise functions of YgaU and OsmY are unknown, both the respective 
genes have shown to be induced during hyperosmolarity (226, 227). As OsmY has been 
predicted to be required for resistance to changes in osmolarity and turgor pressure, and due 
to the structurally similarity of these proteins to PlpA, we next set to examine whether plpA, 
osmY or ygaU mutants were susceptible to elevated salt concentrations (Fig. 4.5). In all 
instances the survival of the mutants was comparable with that of the parental strain, when 
plated on LBA with increasing concentrations of sodium chloride. Indicating that if these 
proteins are required for survival during conditions of increased osmolarity, they maybe 
functionally redundant.  
 
4.2.5. Some PlpA homologues can complement a plpA mutant 
As plpA was shown to be widely distributed across a range of proteobacterial species, 
we next sought to determine whether these homologues performed similar functions, to plpA 
from E. coli. A selection of homologues were either cloned or de novo synthesised into the 
constitutive expression vector, pET17b. These constructs were transformed into the E. coli 
BW25113ΔplpA, and resistance to vancomycin (100 or 200 μg/mL) or SDS (4.8%) used as a 
measure for functional complementation. By initially testing the E. coli BW25113 pET17b 
(empty vector) or BW25113ΔplpA pET17b (empty vector) strains we were able to confirm 
that the presence of the plasmid did not affect the resistance of the parental strain BW25113 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Single plpA, osmY and ygaU mutants are not susceptible to elevated sodium 
chloride concentrations 
Comparison of growth on LBA supplemented with varying concentrations of sodium 
chloride, comparing the parental strain, E. coli BW25113, plpA mutant, osmY mutant and 
ygaU mutant, indicating no single mutant shows elevated sensitivity to NaCl compared to the 
parental strain, though growth of all strains is inhibited in the presence of 1 M NaCl. 
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or the susceptibility of the plpA mutant to either compound. By comparing the growth of the 
various strains (when sampled from a consistent inoculum) on LBA supplemented with 
vancomycin or SDS at the concentrations described above, we were able to show the 
homologues from H. influenza, N. meningitidis, P. multocida and S. Typhimurium 
complemented the phenotype of a plpA mutant completely, restoring resistance to both 
concentrations of vancomycin and SDS (Fig. 4.6). The V. cholera homologue was only 
capable of partial complementation, restoring resistance to 100 μg/mL vancomycin, but not 
200 μg/mL or SDS. While OsmY was unable to complement, as judged by sensitivity to both 
compounds at all the concentrations tested. Indicating that despite the similar domain 
architecture of OsmY and PlpA, they’re not paralogous.   
 
4.2.6. S. Typhimurium plpA mutants have elevated sensitivity to vancomycin and SDS 
As E. coli K12 is an evolved laboratory strain devoid of OM features including O-
antigen, we next sought to examine whether a plpA mutant demonstrated similar phenotypes 
in a pathogenically relevant strain. We therefore constructed a plpA mutant in the broad host 
range pathogen S. Typhimurium, in both the virulent and attenuated S. Typhimurium strains 
SL1344 and SL3261, respectively. Screening the plpA mutants against their respective 
parental strains, indicated that S. Typhimurium plpA mutants were also susceptible to 
vancomycin and SDS as observed previously in E. coli (Fig. 4.7) 
 
4.2.7. S. Typhimurium plpA mutants are mildly attenuated in vivo 
As OM associated lipoproteins have been shown to be important for bacterial 
virulence (i.e. deletion of Lpp in S. Typhimurium results in attenuated virulence (228)), we 
choose to investigate whether PlpA contributes to virulence of S. Typhimurium. As infection 
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Figure 4.6. Complementation plpA mutant with various homologues  
Examining sensitivity of plpA mutant complemented with plpA homologues from various 
species, STm; S. Typhimurium, V.c; Vibro cholera, N.m; Neisseria meningitidis H.i; 
Haemophilus influenzae P.m; Pasteurella multocida in the presence of A. vancomycin 100 
μg/mL or B. SDS 4.8%, indicating the plpA mutant with empty vector (pET17b) is unable to 
grow in the presence of either compound, while other homologues complement, with the 
exception of Vibro cholera on SDS. While osmY is unable to complement in the presence of 
either compound. 
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Figure 4.7. Sensitivity of plpA mutants in E. coli K12 and S. Typhimurium 
Sensitivity of plpA mutants in E. coli K12, and S. Typhimurium, comparing the parental 
strains; BW25113 and SL1344, respectively, plpA mutants, and complemented mutants, 
expressing the respective plpA gene from pET20b or pQE60, respectively. Grown in the 
presence of either vancomycin 100 μg/mL or SDS 4.8%. In all instances the plpA mutants 
were shown to be susceptible, but resistance was restored by complementation. 
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most commonly occurs due to the consumption of contaminated food and water, we therefore 
choose to examine the effects of plpA mutation on the ability to colonise, cause systemic 
infection when administered via the most physiologically relevant route, oral gavage. Using 
virulent S. Typhimurium strain SL1344 and SL1344 plpA::aph, we assessed the ability of the 
mutant to colonise and infect C57BL6 mice, as determined by bacterial burdens four days 
post infection, in the spleen, liver, mesenteric lymph nodes (MEL) and Peyers patches (Fig. 
4.8). The plpA mutant was shown to be mildly attenuated in its ability to colonise sites 
including the Peyers patches and MEL, though bacterial burdens were more comparable with 
the parental strain at systemic sites, including the liver and spleen.  
 
4.2.8. plpA mutants are susceptible to innate immunity 
As the oral infection suggested plpA mutants were mildly attenuated at gastrointestinal 
sites, but not at systemic sites, we questioned whether the observed attenuation was due to the 
environmental conditions of the gastrointestinal regions (i.e. presence of bile salts) and plpA 
mutants being more susceptible due to the membrane defect. We therefore choose to examine 
the ability of the plpA mutants to cause systemic infection, when administered via the IP 
route. Using the attenuated S. Typhimurium strain SL3261 we evaluated bacteria burdens 
over time, to investigate whether the slight reductions observed previously (in the spleen and 
liver) were an artefact of the reduced numbers of bacteria surviving the gastric transit during 
oral infection. The bacterial burdens were determined at days seven, 18 and 28 (Fig. 4.9). The 
bacterial counts at day seven indicated a significant attenuation in the recovered numbers of 
plpA mutants in the spleen (p= 0.004). However the bacterial burdens obtained at day 18, 
although still slightly reduced were more comparable with that observed for parental strain, 
and directly comparable by day 28. 
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Figure 4.8. Oral Infection with plpA mutants  
Bacterial burdens four days post oral infection, with virulent S. Typhimurium, SL1344 and 
SL1344 plpA::aph. MEL refers to mesenteric lymph nodes. Despite reduced bacterial burdens 
of plpA mutants in the Peyers patches and MEL, no statically significant differences were 
observed, between the mutant and the parental strain.   
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Figure 4.9. IP infection over a time course  
IP infection of C57BL6 mice with attenuated S. Typhimurium strain SL3261 comparing the 
parent against the plpA mutant, over a time course, examining bacterial burdens in A. Spleen, 
B. Liver and C. Mesenteric Lymph nodes (MEL) at days seven, 18 and 28. The plpA mutants 
were significantly attenuated in the spleen at day seven, as determined using Mann-Whitney 
test, where * <0.05, **<0.009 
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As all groups were administered the same inoculum, we wanted to investigate the 
cause of this early attenuation. We therefore set to investigate whether this initial attenuation 
was due to susceptibility to innate immune responses, and not necessarily a defect in the 
ability of plpA mutants to cause infection. To investigate this possibility we performed a 24 h 
IP infection study using two separate mouse strains lacking the ability to produce specific 
adaptive immune responses (Fig. 4.10). RagB6 mice do not produce mature T or B cells, 
while CD30 OX40 mice fail to produce memory mediated AB responses due to the deficiency 
of CD
4+
 T cells (229, 230). The recovered bacterial burdens from the spleen of RagB6 mice 
infected with plpA mutants indicated a significant reduction (p= 0.05). While only a mild 
reduction is observed in CD30 OX40 mice, suggestive that plpA mutants maybe more 
susceptible to innate immune responses.   
 
4.2.9. plpA mutants are slightly more susceptible to complement-mediated killing 
To enhance the data obtained from the in-vivo studies, we next sought to investigate 
whether the plpA mutation affected recognition and activation of complement-mediated 
killing. Using healthy human serum we examined resistance of both S. Typhimurium SL1344 
and SL3261 strain sets (Fig. 4.11). In both instances the plpA mutants were slightly more 
susceptible to complement-mediated killing, compared to their applicable parental strains.  
 
4.2.10. PlpA is not involved in LPS biogenesis 
As plpA mutants had a heightened sensitivity to innate immune responses in vivo and 
complement-mediated killing in healthy human serum, we next sought to investigate whether 
PlpA may be involved in LPS biogenesis and thus plpA mutants had an altered profile which 
would have affected resistance in both of these instances. To investigate this hypothesis we 
122 
 
 
 
 
Figure 4.10. IP infection over 24h  
IP infection of A. RagB6 or B. CD30 OX40 mice with attenuated S. Typhimurium strain 
SL3261 comparing the parent against the plpA mutant, over a 24 h period, examining 
bacterial burdens in the spleen and liver. The plpA mutants were significantly attenuated in 
the spleen of RagB6 mice, as determined using Mann-Whitney test, where * <0.05 
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Figure 4.11. Serum resistance of S. Typhimurium strains in healthy human serum 
Serum resistance of S. Typhimurium, virulent SL1344 and attenuated SL3261 strains, 
comparing survival of the respective parental strain against that of the plpA mutant. As 
expected S. Typhimurium, SL3261 is significantly more susceptible to complement-mediated 
killing, compared to the virulent SL1344. Though both strains demonstrate plpA mutants are 
slightly more susceptible than their respective parental strain 
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utilised two strain sets, the S. Typhimurium parent, plpA mutant and complement as described 
above and E. coli K12 strain BW25113 containing wbbL on the vector pET20b (as this gene 
is disrupted by an insertion element, preventing the production of long chain LPS). 
Examining the LPS profiles for both strain sets showed no differences between the parental 
strains and plpA mutants (Fig. 4.12). Confirming that PlpA is not required for the biogenesis 
of long chain LPS. 
 
4.2.11. PlpA does not affect the biogenesis of OMP or BAM complex lipoproteins  
As PlpA is an OM lipoprotein, we next sought to investigate whether it was required 
for OMP or lipoprotein biogenesis. As several components of the BAM complex and Lol 
pathway are OM localised lipoproteins, we initially examined whether disruption of plpA 
resulted in a defect in OMP biosynthesis. We prepared OM fractions and examined these by 
SDS-PAGE electrophoresis, showing there were no obvious differences in the OM profiles 
and the presence of key OMPs such as OmpA and OmpF/C (Fig. 4.13). To determine whether 
plpA maybe required for the function of the Lol pathway, we immunoblotted OM fractions for 
the BAM complex lipoproteins, BamC and BamE. Although a crude method, by comparing 
the levels of BamC and BamE between the parental strain, plpA mutant or complemented 
mutant, no differences were observed in the levels of any of these proteins suggesting PlpA 
does not play a role in trafficking of OM lipoproteins.  Although an obviously visible defect 
would be expected if PlpA was involved in OMP or OM lipoprotein biogenesis, as a means to 
confirm this result further, we performed proteomics assessment of the purified OM fractions, 
indicating there were no differences in the ratios of various integral OMPs and lipoproteins 
between the parental strain and plpA mutant (Figure 4.2.11.B).  
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Figure 4.12. LPS profiles S. Typhimurium and E. coli K12 strains 
LPS profiles for S. Typhimurium strain SL1344, E. coli K12 strain BW25113 expressing 
wbbL from pET20b and E. coli K12 BW25113 with no plasmid, for the respective parental 
strains, plpA mutant and complemented mutant (pQE60 for S. Typhimurium and pET17b E. 
coli). Indicating plpA is not required for long chain LPS and O-antigen production in either S. 
Typhimurium or E. coli. 
 
 
 
 
 
 
 
 
 
 
 
126 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. PlpA does not affect BAM complex lipoproteins or OMP biogenesis  
A. SDS-PAGE gel of E. coli K12 BW25113, plpA mutant and complemented mutant. B. 
Proteomic analysis of OMPs from BW25113 and plpA mutant, indicating deletion of plpA 
does not affect OMP biogenesis. C. Western blots using α-PlpA, α-BamC and α-BamE 
primary ABs, samples ordered as described for A indicating no differences are observed in the 
biogenesis of BAM complex lipoproteins in a plpA mutant. 
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4.2.12. PlpA suppressor mutants against vancomycin have null mutations in mlaA 
As we had performed several assays attempting to define the role of PlpA with no 
avail, we decided to utilise a different approach. As plpA mutants were susceptible to both 
vancomycin and SDS, we selected six independent E. coli BW25113 plpA::aph colonies, and 
plated these on LBA containing either 4.8% SDS or 200 μg/mL vancomycin. The plates were 
incubated at 37
o
C until the appearance of suppressor mutants, which were passaged through 
liquid media (containing the supplement at the above concentration) and restreaked onto LBA 
containing the above, to confirm the resultant colonies were truly resistant, prior to stocking. 
The vancomycin suppressor mutants were resequenced and of the six independent suppressors 
the results highlighted an array of mutations. However two independent mutants, contained 
separate frame shifts mutants resulting in the introduction of stop codons in mlaA. To confirm 
this result, we therefore created the double mutant E. coli BW25113ΔplpA, mlaA::aph and re-
examined the sensitivity to vancomycin. The double mutant was shown to restore resistance 
to vancomycin 200 μg/mL (Fig. 4.14).  
As MlaA is known to work in conjunction with MlaB-F, functioning to recycle 
phospholipids from the OM, we predicted that if the mlaA null mutation was disrupting this 
pathway in order to counteract the plpA mutation, thus disruption of any gene associated with 
Mla pathway should provide the same result. We therefore constructed double mutants of E. 
coli BW25113ΔplpA with mlaC/mlaD/mlaE/mlaF and examined the sensitivity of these 
strains to vancomycin as described above. In all instances the combination of mla mutations 
with a plpA deletion was able to restore resistance to vancomycin, but interestingly not SDS. 
As PldA and PagP have also been shown function as an OM phospholipase and palmitoyl 
transferase, respectively (71), we also investigated whether disruption of these genes could 
compensate for the deletion of plpA, neither double mutant could restore resistance to SDS, 
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Figure 4.14. Double mutants of plpA and mla, pagP or pldA suppress sensitivity to 
vancomycin but not SDS 
Sensitivity to vancomycin 200 μg/mL (top panel) or SDS 4.8% (bottom panel) of single or 
double mutants of plpA with, mlaA/C/D/E/F, gpmI, pagP or pldA. Indicating double mutants 
of mlaA/C/D/E/F, pagP or pldA can restore resistance to vancomycin, but not SDS, while 
double mutants with gpmI cannot restore resistance to either compound.  
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however both mutants could restore resistance to vancomycin. We additionally investigated 
the phosphoglycerate mutase, gpmI (231), though in contrast to the other double 
mutantstested, gpmI was unable to complement the phenotype in the presence of either 
compound. Unfortunately the data for the SDS suppressor mutants was not available at this 
time. 
 
4.2.13. PlpA is associated with Phosphatidylglycerol insertion into the OM 
The suppressor mutants highlighted that by creating null mutations in pathways and 
genes responsible for recycling or degrading OM phospholipids resistance to vancomycin 
could be restored. This raised the hypothesis that PlpA was responsible for inserting 
phospholipids into the membrane to balance the rates of recycling and removal. Thus in the 
absence of PlpA, the Mla pathway may not be counter balanced, resulting in the removal of 
excessive phospholipids. Therefore to investigate this hypothesis we performed lipidomics 
assessments of the OM of the parental strain, E. coli BW25113 and the plpA mutant. In 
collaboration with Jennifer Kirwan, we were able to determine the relative composition of 
various phospholipids in the OM of both strains (Fig. 4.15), indicating the plpA mutants lack 
PG and CL from the OM, but PE is still present, suggestive that PlpA is associated with OM 
trafficking of the phospholipids PG and CL. 
 
4.2.14. Residues critical for PlpA function 
In parallel to our investigations characterising the function of PlpA, our collaborators 
Prof. M. Overduin, Dr. T.J. Knowles and Dr. R. Maderbocus determined the NMR structure 
for PlpA (Fig. 4.16). The structural assessments were complemented by HSQC analysis using 
PG, indicating phospholipid binding was localised to residues on one face of the third α-helix.   
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Figure 4.15. PlpA mutants lack PG in the OM, but have increased levels of PE 
A. Principle component analysis of PG and PE as determined by lipidomics analysis of the 
OM of E. coli K12 parental strain BW25113 and plpA mutant, from two separate 
experiments. Indicating plpA mutants contain an OM with significantly altered lipid content, 
compared to that of the parental strain.  B. Fold change of various lipid species in the OM, of 
the parental strain and plpA mutant, calculated from the principle component analysis shown 
in A. Indicating plpA mutants have significantly reduced quantities of PG, and elevated levels 
of PE, compared to the parental strain BW25113. 
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Figure 4.16. NMR structure of PlpA and residues critical to protein stability and 
function 
A. NMR structure of PlpA, as determined by Dr. T.J. Knowles and Dr. R. Maderbocus, 
indicating PlpA is composed of two BON domains, each containing two α helices and three β 
sheets. B. Site directed mutagenesis and random linker insertion screen (affected residues 
listed above the relevant lane), examining the requirement for various residues to maintain 
protein stability, as determined by western blot of whole cell using α-PlpA ABs, and the 
ability of mutated proteins to complement the ΔplpA phenotype, in by examining growth in 
the presence of vancomycin 100 μg/mL. Below each plate structural representations of the 
positions of affected residues. Panel 1 refers to site directed mutants of the linker region 
connecting BON1 and BON2, panel 2 refers to site direct mutagenesis of the residues located 
within α3 (binding site for PG) and panel 3 refers to random linker insertion mutants 
distributed across both BON1 and BON2 domains.   
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To further confirm this analysis and determine which of the residues highlighted were critical 
for protein stability and function, we utilised two separate techniques, generating a series of 
site direct mutations and a random linker insertion screen, generating mutations described in 
table 2.4, in an effort to both confirm the earlier HSQC analysis, but also investigate whether 
any additional residues were of critical for stability and function. The presence of stable 
protein was assessed by immunoblotting whole cell lysate of each mutated versions, 
expressed in a plpA deletion background. Secondly we examined the ability of each mutant to 
grow in the presence of vancomycin or SDS, as a means of determining functionality. The 
NMR structure indicated that residues located at Y75 and V82 in BON1 and T150, G160, 
L161 and T188 in BON2 were required for the interaction between the two BON domains. 
Site directed mutagenesis, of Y75 highlighted the importance of this residue, whereby stable 
protein can be detected, though this mutation is unable to complement (Fig. 4.16). 
Additionally mutation of either conserved glycine residue (G83V or G160V, which are 
positioned at the terminus of the central β-strand in each BON domain) did not abolish 
function; however combination of these mutations, resulted in a loss of protein, suggesting 
these alterations resulted in a structurally unstable protein, that’s rapidly degraded.  
A series of random linker insertions were isolated with eight insertions in BON1 and 
six in BON2. Of the two BON1 insertions, L50 and V72 failed to complement the ΔplpA 
defect, though the remainder were well tolerated. Of the five insertions in BON2, three were 
well tolerated (positions L142, G160 and A170). While the remaining insertions (positions 
D125 and W127), failed to complement despite producing a stable protein. With both of these 
insertions localised to α3, reaffirming the importance of α3 in PlpA function.  
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4.3. DISCUSSION 
During this study we have characterised the function of PlpA from E. coli K12 and S. 
Typhimurium. Based on the evidence presented as part of this study we hypothesis PlpA is a 
required for the trafficking and insertion of PG and CL molecules into the inner leaflet of the 
OM, as shown by the model in Fig. 4.17. In brief, PlpA binds PG and CL molecules by α3 of 
BON2. Consistent with other OM lipoproteins; PlpA (with bound PG or CL) is collected by 
the IM LolCDE complex – 1, which becomes rearranged for the transfer of PlpA to LolA – 2, 
which delivers PlpA and its cargo to the OM by LolB - 3, PlpA is inserted into the leaflet of 
the OM by LolB – 4, whereby PlpA delivers its phospholipid cargo by an unknown 
mechanism. This pathway works in synergy with the Mla pathway whereby when MlaA 
detects the presence of phospholipids in the outer leaflet - 5, these are removed and 
transferred to MlaC – 6, for traffic back through the periplasm, before being returned to the 
IM MlaBDEF complex – 7, to maintain the asymmetric structure.  
Consistent with this hypothesis, PlpA is not surface exposed and instead anchored to 
the inner leaflet of the OM by N-terminal acetylated cysteine residue, as observed for several 
other OM lipoproteins, but in contrast to that of OM BamC and Lpp lipoproteins (7, 30, 65). 
Thus PlpA is optimally positioned for insertion of phospholipids into the inner leaflet.  
Additionally the indication that both mla pathway mutants, pagP and pldA mutants 
can counteract the phenotype of a plpA mutant, further support the theory that PlpA adds 
phospholipids to the OM, to balance the rate of phospholipid recycling by Mla, PagP and 
PldA. We therefore suggest in the absence of plpA, unregulated recycling of phospholipids 
leads to excessive quantities being removed from the OM, creating ‘gaps’ or highly unstable 
regions, resulting in the serve membrane defect observed.  
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Figure 4.17. Predicted model of PlpA function 
Predicted model of PlpA transport of PG and CL to the OM in a multistep process. PlpA is 
trafficked to the OM via the Lol pathway, with potentially bound phospholipid. 1. PlpA is 
collected by the IM LolCDE complex, which becomes rearranged, 2. PlpA is transferred to 
LolA, transporting PlpA and it cargo to the OM, 3. PlpA is transferred from LolA to LolB, 4. 
PlpA is inserted into the leaflet of the OM by LolB, whereby PlpA delivers its phospholipid 
cargo by an unknown mechanism. This pathway works in synergy with the Mla pathway 
whereby, 5. MlaA detects the presence of phospholipids in the outer leaflet, which are 
removed and transferred to MlaC, 6. MlaC traffics phospholipids back through the periplasm, 
7. To the IM MlaBDEF complex, where the phospholipid is recycled, to an unknown fate, 
ensuring membrane asymmetry is maintained at all times.  
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PagP and PldA are known to be regulated by PhoP/Q and the presence of calcium, 
respectively (71). Though the means by which the Mla pathway is regulated has yet to be 
determined. Answers to these questions may further elucidate the synergy the between PlpA 
and Mla functions. While the crystal structure of MlaC was solved bound to PE, the substrate 
specificity of Mla pathway (to our knowledge) has not been investigated and determined 
exclusively. Raising the question of the phospholipid composition of the membrane of a plpA 
double mutant with mlaA/C/D/E/F, pagP or pldA, which is capable of restoring resistance to 
vancomycin. For example if the PlpA and Mla pathways are shown to share similar substrate 
specificity, is the emphasis on the maintaining specific quantities of phospholipids in the 
membrane or maintaining the balance of phospholipid insertion/recycling from the membrane. 
In order to investigate hypothesis further we are planning lipidomics analysis examining the 
lipid content of plpA, mlaA double mutants to compare with the parental strain, E. coli 
BW25113, in order to determine how the double mutation affects the relative concentrations 
of various phospholipid types.     
We have conclusively shown PlpA only binds PG and CL via α3 on BON2, and 
although we failed to show a role for BON1 in phospholipid binding, we have confirmed the 
importance of residues within this domain and the connecting β strands required for the 
interaction of BON1 and BON2. Mutation of residues outside of BON2 (Y75 or both 
conserved glycine residues simultaneously), significantly abrogates the function and stability 
of the proteins, respectively.  Furthermore using a random linker insertion screen, we 
highlighted other residues also critical for function (i.e. positions L50 and V72 in BON1) in 
addition to confirming the role residues D125 and W127 (located in the helix of BON2 
associated with phospholipid binding) in plpA function.  
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Despite significantly enhancing our understating of phospholipid transport plpA has 
highlighted the continuing dilemma that an alternative pathway for the transport of PE to the 
OM must also exist, as PlpA is only capable of interactions with PG and CL, as shown by 
HSQC analysis. Previously BON domains have been hypothesised to bind phospholipids 
(225), however this is the first reported experimental evidence confirming this role. This may 
suggest potential roles for other BON domain containing proteins, such as OsmY and YgaU, 
which require extensive further investigation. As although both OsmY and YgaU have been 
previously associated with hyperosmolarity, consistent with data reported by others (201), we 
were unable to identify a defect for either single mutant, in the presence of increasing 
concentrations of sodium chloride. While we observed no difference in their growth compared 
to that of the parental strain, E. coli BW25113, Nichols et al reported that ygaU mutants were 
fitter than the parental strain when grown in the presence of increasing concentrations of 
sodium chloride (201).  
Although we have confirmed that PlpA is not a paralogue of OsmY, this does not 
eliminate the possibility that OsmY may be associated with other forms of phospholipid 
transport, such as that for PE. As the data presented as part of this study indicates that cells 
lacking plpA contain a membrane composed of PE only, therefore it’s possible that OsmY 
may at least have a minor role in PE transport. 
However, we have shown plpA is conserved across a number of species and clearly 
performs a similar function, due to the ability of homologues to complement a plpA deletion. 
Though further investigation into the substrate specificity of other plpA homologues will 
provide a more in-depth view of phospholipid transport, i.e. are these homologues restricted 
to PG and CL binding or are they also capable of PE transport, particularly in the case of the 
V. cholera homologue, which was only able to partially compensate a plpA deletion.  
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Consistent with the idea that plpA homologues present in other species performs 
similar roles, we were able to demonstrate that S. Typhimurium plpA mutants demonstrated a 
similar phenotype to that observed in E. coli K12. Further to this we have shown that loss of 
plpA results in mild attenuation of S. Typhimurium due to elevated sensitivity to innate 
immune mechanisms. Although our investigations to date have not confirmed the exact 
mechanism responsible, we have shown that this sensitivity is independent of T cell and B 
cells, through the use of RagB6 and CD30 OX40 mice, which are deficient for the production 
of mature T and B cells, and memory AB responses due to the deficiency of CD
4+
 T cell 
responses, respectively (229, 230), while plpA mutants are increasingly attenuated in 
colonisation of gastrointestinal sites after oral infection and significantly more susceptible to 
innate immunity when administered systemically. It is therefore tempting to speculate this 
sensitivity maybe due to antimicrobial peptides released during the onset of infection. Further 
to this we have shown these innate immune responses would likely be enhanced by 
complement-mediated killing in serum. As mice do not have an effective complement system 
(161), it’s likely that the effect observed during the animal studies was as a result of other 
means. Though if PlpA were to be pursued as a potential drug target, additional investigations 
regarding the impact of the deletion on adaptive immune responses would be required to 
confirm, that the mutation does not alter AB responses against the bacteria and that later stage 
bacterial burdens, beyond day 28 were not more persistent than that of the parent.  
Our investigations have confirmed that plpA is not required for the biogenesis of other 
OM components, such as LPS, OMP or lipoprotein, all of which are associated with aspects 
of bacterial virulence. Mutations resulting in rough LPS structure have been previously 
associated with increased bacterial susceptibility during murine infection, while over 
production of long chain LPS and O-antigen has been linked to increased resistance to 
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complement-mediated killing (168, 216). Incontrast, mutant strains defective for the 
production of particular OMPs and lipoproteins, such as OmpA and Lpp, have been shown to 
be attenuated in pathogenic E. coli and S. Typhimurium, respectively (228, 232, 233) further 
confirming that the attenuation observed is not as a result of defects in the biosynthesis of 
other cellular components.  
This study is the first reported pathway for the transport and insertion of PG and CL 
phospholipids into the inner leaflet of the bacterial OM. We have additionally presented the 
first experimental evidence for the phospholipid binding by BON domains, in addition to the 
first NMR structure for a duel BON domain protein. Although this study highlights the 
requirement for further investigation to determine the means by which PE is inserted into the 
membrane. The results reported as part of this study have significantly advanced our 
understanding of bacterial membrane biogenesis. 
Having extensively characterised plpA mutation and determined its role in membrane 
homeostasis in both E. coli K12 and S. Typhimurium, the following chapter will focus on 
characterising a subset of other mutations also identified in chapter 3.    
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CHAPTER 5 
 
ROLE OF NONESSENTIAL GENES IN 
MAINTENANCE OF S. TYPHIMURIUM OUTER 
MEMBRANE BARRIER FUNCTION AND 
PATHOGENESIS 
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5.1. INTRODUCTION 
As described previously, the OM excludes potential toxic and bactericidal compounds, 
whilst still allowing for the secretion and assembly of surface structures and uptake of 
nutrients that enable bacteria to colonise diverse and difficult environments (1, 2). In aiding 
bacterial survival, the selective nature of the OM also hinders antibacterial treatment by 
limiting the entry of antimicrobials (191, 234).  
Our previous investigations on non-essential genes required for the maintenance of 
membrane homeostasis were performed in the evolved laboratory strain E. coli K12 
BW25113. E. coli K12 has been significantly manipulated over time, subjected to 
mutagenizing agents including; ionizing radiation and UV light, which has resulted in the 
numerous genetic alterations, including the inability to synthesis OM structures, such as O-
antigen (178).  Therefore, we chose to further investigate the roles of some non-essential 
genes in a more physiologically relevant viz. S. Typhimurium. As discussed previously, S. 
Typhimurium, causes infection in a variety of hosts, including humans, mice, cattle, pigs and 
birds (148), most commonly as a result ingestion of contaminated food and water. During the 
course of infection S. Typhimurium faces an array of challenging environments during transit 
through the gastrointestinal tract, before transversing specialised epithelial to reside 
intracellularly in macrophages and DCs (155).  
In a number of instances the nonessential genes described in chapter 3 have been 
previously characterised in pathogenic organisms, including S. Typhimurium. For example, 
genes associated with LPS modifications (rfa, msbB and htrB) have been shown upon deletion 
to significantly attenuate the ability of bacteria to cause infection in mice (216, 234-236). 
Transcriptional regulators, Hfq and OmpR are both required for virulence, through the 
regulation of small non-coding RNAs and a number of virulence genes, respectively (237, 
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238). Other OM features such as OmpA have been shown to be critical for virulence in 
pathogenic E. coli K1 and UPEC strains, where it promotes persistence in the bladder and has 
been thoroughly investigated as potential vaccine candidates (232, 233, 239). Efflux pumps 
and their individual components, including AcrA, AcrB and TolC have been extensively 
studied by others (206, 234, 240, 241).  
The nonessential components of the BAM complex have been extensively studied in 
E. coli and shown not to be required for AT biogenesis, but are responsible for maintaining 
the stability of the complex (BamCE stabilise the interaction between BamAD) and the 
insertion of a number of other OMPs, whereby bamB single mutants and bamC bamE double 
mutants have reduced OMP profiles in the OM, including reductions in OmpA levels (67, 
100). Investigations in Salmonella have characterised bamB and bamE mutants, from S. 
Enteritidis and S. Typhimurium, respectively (242, 243). In both cases the mutants were 
shown to have elevated sensitivity to a range of compounds, including the antibiotics such as 
rifampicin and vancomycin (bamB only) and SDS-EDTA (bamE only) (242, 243). Both 
mutations cause attenuation in virulence when administered orally, though bamB mutants are 
also less capable of causing lethal infection, whereby more than 50% of the cohort survive 
beyond 20 days, in comparison to the parental strain, which causes lethality in 10 days (242). 
Similarly, bamE mutants are incapable of competing with wild type strains in vivo, with a 
competitive index of between 0.08-0.12 when administered at equal inoculums, via the IP 
route (243). 
The periplasmic chaperones SurA, Skp, DegP and FkpA have all been associated with 
transit of OMP and AT precursors across the periplasm to the BAM complex, preventing their 
aggregation during transit and promoting their degradation, upon either accumulation or 
misfolding (19, 22, 244, 245). Deletion of these chaperones has been investigated in a number 
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of organisms, resulting in varying degrees of attenuated virulence (18, 37, 246-248). For 
example the disruption of fkpA in S. Typhimurium, results in only minor defects in survival in 
the murine macrophage cell line J774 and epithelial cell line Caco-2, with no difference in 
LD50  or rate of lethality when compared to the parental strain (248). In vivo competition 
against the parental strain shows no significant difference, though when combined with a surA 
mutation, the mutant is significantly attenuated with a competitive index of 0.0121 (248).  
The recently discovered TAM complex has been shown to be required for AT 
passenger domain secretion in C. rodentium and E. coli, whereby deletion of tamA results in 
the loss of AT protein p1121 from C. rodentium OM (103). Furthermore, a double tamAB 
mutant in E. coli MG1655 over-expressing the ATs, Ag43 and EhaB resulted in significant 
reductions in their ability to autoaggregate, a phenotype previously shown to be induced by 
both of these ATs (103, 125, 249).  Additionally, ytfP is also transcribed within the same 
genomic operon, as tamA and tamB, though its contribution to the function of this complex is 
currently unknown.  
During this study we aimed to investigate the role of a selection of nonessential genes, 
required for maintaining membrane barrier function and examine how these contributed to 
virulence in S. Typhimurium, using both in vitro assays and the murine model of in vivo 
infection.  
 
5.2. RESULTS 
5.2.1. Creation of single gene disruption mutants in S. Typhimurium 
To further elucidate the roles of non-essential genes in membrane homeostasis, a 
selection of the mutations highlighted in chapter 3 (including those which were initially 
shown to be sensitive prior to P1 transduction), were transferred to the broad host range 
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pathogen S. Typhimurium, to assess the impact of these deletions in a more clinically relevant 
strain. Several other genes were also included in this study, due to their proposed roles in the 
biogenesis of OM complexes and virulence factors. The mutants were constructed using 
either, Datsenko and Warner method for single gene inactivation or gene doctoring 
techniques, using primers described in appendix Table 1.  All resultant colonies were screened 
by PCR (Fig. 5.1), to confirm recombination of the resistance cassette and loss of the original 
gene. The mutations were subsequently P22 transduced into the S. Typhimurium strains; 
SL1344 (virulent) and SL3261 (attenuated) and reconfirmed by PCR prior to further use. In 
all instances, the mutations were recreated in both the virulent SL1344 and attenuated SL3261 
strains; to account for potential differences in sensitivity caused by the aroA mutation in 
SL3261. 
In all instances the growth kinetics were assessed under standard laboratory growth 
conditions (LB broth at 37
o
C). In contrast to that observations for E. coli BW25113, none of 
the mutants demonstrated reduced growth kinetics when compared to the parental strains (Fig. 
5.1). 
 
5.2.2. Screening for membrane defects in S. Typhimurium mutants 
Having determined the growth kinetics for all of the mutants, and shown no significant 
differences, we used the streak plating techniques highlighted in chapter 3 to assess the ability 
of the S. Typhimurium parental and mutant strains to grow on LB agar and LB agar 
supplemented with vancomycin (100-200 μg/mL) or SDS (4.8%). Several of the mutants 
selected for examination were initially shown to be sensitive in E. coli K12, however lost 
their phenotype upon P1 transduction. Though having already constructed these mutations we 
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Figure 5.1. – Creation of S. Typhimurium mutants and Growth kinetics 
A. PCR gels confirming the mutations for S. Typhimurium, SL1344hlpA::aph and 
SL1344bamB::aph, + control refers to SL1344 with gene specific flanking primers, flanking 
refers to gene specific flanking primers in combination, fwd Km refers to internal kanamycin 
forward primer in conjunction with reverse gene specific primer, while rvs Km is the 
opposite, forward gene specific primer with reverse internal kanamycin. B. Growth kinetics 
for SL1344 strains and C. SL3261 strains, under standard laboratory conditions, in LBB at 
37
o
C. Results represent the average optical density (OD) from three independent assays, error 
bars represent the calculated standard deviation from the three data sets. 
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felt that screening them in S. Typhimurium would still provide useful information. Other 
mutants (including the tamAB and ytfP) had also been shown to have heightened sensitivity 
vancomycin by other groups. Interestingly, a number of the mutants failed to display the same 
phenotype as that observed for the corresponding E. coli mutants (Table 5.1 and Fig. 5.2). The 
presence of long chain LPS and branch modifications, which are present in S. Typhimurium, 
are known to enhance resistance to antimicrobial compounds (234). Therefore, the phenotypes 
of the mutants was re-examined using higher concentrations of vancomycin (150 and 200 
μg/mL). In the presence of increased concentrations of vancomycin, several mutants showed 
elevated sensitivity; in S. Typhimurium SL1344 both hlpA and surA mutants were reduced in 
growth and completely inhibited at 150 and 200 μg/mL of vancomycin, respectively. S. 
Typhimurium SL3261 mutants behaved similarly. Furthermore, S. Typhimurium SL3261 
bamC and bamE mutants also showed weak and complete inhibition of growth at 200 μg/mL 
vancomycin, respectively.  Due to the majority of the S. Typhimurium mutants demonstrating 
a phenotype similar to that of the parental strain, only a selection of were pursed for further 
investigation; bamB, surA, tamA, tamB, ytfP. 
 
5.2.3. Membrane barrier defects are not a marker for serum sensitivity 
Complement glycoproteins responsible for complete-mediated killing of bacteria, 
affect the stability of the membrane, resulting in susceptibility to changes in osmotic pressure 
and increased potential for cell lysis (250). However, several investigations have shown 
Gram-negative pathogens resist complement-mediated killing through binding of TAA stalk 
domains to complement inhibitor factors H, C4BP and C3, as shown for YadA and UspA2 
from Yersinia enterocolitica and Moraxella catarrhalis, respectively (144).  As the some of 
the genes being investigated were shown to induce membrane defects and are associated with 
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Table 5.1. – Sensitivity of various S. Typhimurium mutants to vancomycin and SDS 
 
a
 – Defects in membrane barrier permeability as determined by inhibition of growth; 
sensitivity as observed as no growth, Weak; sensitivity as reduced growth,  growth 
comparable with the parental strain 
b
 - * Where sensitivity was not maintained after transduction, 
+
 highlighted as sensitive by 
others  
 
 
 
 Compound and Concentration 
a
 E. coli K12 
b
  
Strain   SDS 
4.8% 
vancomycin 
100 μg/mL 
vancomycin 
150 μg/mL 
vancomycin 
200 μg/mL 
SDS 
4.8% 
vancomycin 
100 μg/mL 
SL1344     NA NA 
SL1344 bamB::aph Weak     
SL1344 bamC::aph      
SL1344 bamE::aph      
SL1344 degP::aph      *
SL1344 fkpA::aph      *
SL1344 skp::aph   Weak   *
SL1344 surA::aph Weak  Weak   
SL1344 tamA::aph     
+ +
SL1344 tamB::aph     
+ + 
SL1344 ytfP::aph      
       
SL3261     NA NA 
SL3261 bamB::aph      
SL3261 bamC::aph Weak   Weak  
SL3261 bamE::aph   Weak   
SL3261 degP::aph Weak     *
SL3261 fkpA::aph      *
SL3261 skp::aph   Weak   *
SL3261 surA::aph   Weak   
SL3261 tamA::aph     
+ +
SL3261 tamB::aph     
+ + 
SL3261 ytfP::aph      
147 
 
 
  
  
  
 
 
 
 
Figure 5.2. Representative plates from S. Typhimurium screening.  
Images A and B represent growth on LBA supplemented with 200 μg/mL vancomycin, while 
C and D show growth in the presence of 4.8% SDS, for various S. Typhimurium strains. 
Annotations marked on the plates denote the location of various mutants, while 13 denotes 
SL1344, and 32 represents an SL3261 background.  
C  
B  
D
  
A
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the biogenesis of ATs, we choose to investigate how their deletion may affect their resistance 
to complement-mediated killing. The surA, tamA, tamB and ytfP mutants all demonstrate 
elevated sensitivity to human serum, compared to the parental strain, S. Typhimurium SL1344 
Fig. 5.3). In contrast, the bamB mutant failed to show any alteration in serum resistance, with 
comparable survival to that of the parent strain. This is surprising given this mutation induced 
a severe membrane defect, more so than that observed for S. Typhimurium surA mutants, 
whereby bamB mutants were susceptible to vancomycin 100 μg/mL (presented as part of this 
study), in contrast to surA which only demonstrated complete inhibition of growth at 200 
μg/mL vancomycin under the same test conditions.  Interestingly, the OM protein TamA and 
its IM counterpart TamB, shows the most severe susceptibility, while the predicted 
cytoplasmic component of this complex (YtfP), although significantly more serum sensitive 
than the parental strain, can survive for longer than the tamA and tamB mutants.  
 
5.2.4. Some mutants display reduced virulence during systemic infection 
Having shown that the mutants are in most instances susceptible to complement 
mediated killing, we wanted to further investigate how this may impact upon in vivo infection. 
We examined the ability of the mutants to colonise and cause persistent infection using the 
murine model for systemic S. Typhimurium infection, using the SL3261 mutants administered 
via the IP route. The results show both surA and bamB mutants are highly attenuated in both 
spleen and liver colonisation at all time points (p = 0.004 for both mutants in spleen) (Fig. 
5.4). The ytfP mutant showed severe reductions in bacterial colonisation at day 7 (p= 0.004), 
but recover by day 18 (p= 0.7758), with comparable burdens by day 28 (p= 0.1091), in both 
the spleen and liver, indicating the defect was not site specific.  
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Figure 5.3. Serum resistance of various S. Typhimurium mutants  
Serum resistance of various SL1344 mutants when incubated with healthy human serum, for 
various durations. Bacterial resistance determined as no change in Log10 of bacterial 
CFU/mL, as calculated from three biological replicates. 
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Figure 5.4. Bacterial burdens of various S. Typhimurium SL3261 mutants  
Bacteria burdens per organ, (A) Spleen, (B) Liver, for C57BL6 mice infected with SL3261 
mutants via IP route over a time course. Significance determined using Mann-Whitney t-test, 
whereby * <0.05, **<0.009 
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Unfortunately, at the time of completion a tamA mutant was not available. However, a tamB 
mutant failed to show any defect in colonisation or persistence. In contrast, when tamA or 
tamB mutants are competed against wild type C. rodentium, both fail to colonise efficiency 
(103). Therefore to determine whether a similar phenotype would be observed with S. 
Typhimurium tamB and ytfP mutants, we performed in vivo competition assays, evaluating 
bacterial colonisation when either mutant was co-administered with the S. Typhimurium 
parental strain, SL3261 (Fig. 5.5). The results show the competitive index for each mutant 
against the parental strain, over time. The tamB mutants demonstrated a mild attenuation at 
day seven, though at time points day 18 and 28, the tamB mutants were shown to colonise and 
persist to a degree comparable with or better than the parental strain (spleen day 28, 
competitive index 22.7).  While the ytfP mutant demonstrated a significant decrease in its 
competitive ability at day seven, with competitive index of 0.002 and 0.04, for spleen and 
liver respectively, with recovering competitive indices at days 18 and 28, though this mutant 
failed to colonise quite as effectively as the parental strain, with competitive indices of 0.57 
and 0.43 for the spleen and liver respectively, at day 28.  
 
5.2.5. Oral administration marginally affects S. Typhimurium bamB colonisation 
The previous assessments of in vivo infection were performed using IP 
administration, modelling systemic infection. As this is not a true representation of the normal 
route of Salmonella infection, which is commonly oral-gastric, we examined ability of the 
bamB mutant colonise and cause infection four days after oral gavage. The results do not 
show significant attenuation, though a slight reduction is observed in bacterial numbers at all 
sites (spleen, liver, mesenteric lymph nodes or payers patches) (Fig. 5.6).  
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Figure 5.5. Bacterial burdens of S. Typhimurium Competition Strains  
Bacteria burdens per organ, (A) Spleen, (B) Liver, for C57BL6 mice infected with SL3261 in 
competition with either SL3261 tamB::aph or SL3261 ytfP::aph, via IP route, over a time 
course. Mutants bacterial burdens determined by selecting for kanamycin resistance and 
comparing with LBA only.  
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Figure 5.6. Bacterial burdens of S. Typhimurium bamB mutant Oral Challenge  
Bacteria burdens per organ, for C57BL6 mice infected with SL1344 or SL1344 bamB::aph 
via oral gavage. Bacterial burdens determined after four days. MEL refers to mesenteric 
lymph nodes.  
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5.3. DISCUSSION 
A selection of single gene disruption mutants, associated with the BAM complex and 
periplasmic chaperones which were highlighted as inducing severe membrane defects in 
E.coli K12 were transferred to the broad host range pathogen S. Typhimurium, to further 
investigate the phenotypes affected. In addition, other genes associated with the TAM 
complex required for AT passenger domain secretion, were also disrupted. In all instances the 
mutations were introduced into the virulent and attenuated S. Typhimurium strains, SL1344 
and SL3261, respectively. To account for potentially heightened sensitivity of S. 
Typhimurium SL3261, caused by the aroA deletion, which is known to induce membrane 
defects resulting in elevated sensitivity to EDTA, complement mediated killing and albumen 
(251). In addition to altering innate immune responses, as has been shown by the lack of pro-
inflammatory cytokine stimulation in gnotobiotic pigs (252). During our investigations we 
have shown that the barrier defects previously observed were not an artefact of using a 
laboratory adapted E. coli K12 strain, and represent true phenotypes, reproducible in a 
pathogenic strain. The enhanced susceptibility to both a previously ineffective antibiotic and 
detergent, highlighting the potential for these proteins to formulate secondary drug targets for 
future drug development. 
To complement these investigations we have investigated both innate and adaptive 
immune responses to a selection of these mutants. The phenotypes observed for the surA 
mutant are unsurprising, in addition to inducing a severe membrane defect, the protein 
encoded serves as a major periplasmic chaperone (18, 248). Transporting a number of OMP 
and AT precursors from the Sec Machinery at the IM to the BAM complex (18). The decrease 
in serum resistance in this strain maybe in part attributed to (possible) reduced efficiency of 
AT biogenesis in this mutant. Although the levels of S. Typhimurium AT proteins were not 
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examined during this study, it has been previously shown that deletion of surA does affect the 
biogenesis of the type Va protein EspP (16). Although no studies have yet to confirm the role 
of SurA in the biogenesis of TAAs, DegP has been shown to degrade misfolded YadA 
precursors (253), confirming a role for periplasmic chaperones in TAA biogenesis. Although 
investigations performed to date implicate only TAAs in mediating serum resistance (138, 
144), this phenotype has not been explored for the type Va proteins from S. Typhimurium, 
thus their contributions cannot be excluded at this time.  
Consistent with previous observations from S. Typhimurium, Shigella flexneri and 
UPEC strain UT189 (18), during this study we have also confirmed surA is critical for 
virulence. Our investigations with bamB mutants from S. Typhimurium, complement previous 
reports from E. coli and S. Enteritidis. BamB is not essential for secretion of the EAEC or 
UPEC ATs Pet and Sat, respectively (100). Consistent with the hypothesis that the elevated 
sensitivity to complement-mediated killing observed with other mutants is as a result of 
reduced ATs in the OM.  
In contrast to the well documented association of BamB with the OM BAM complex, 
investigations with S. Enteritidis have shown BamB also affects the transcription of a several 
SPI1 and SPI2 associated genes, including T3SS structure and effector proteins, resulting in a 
attenuated virulence in this mutant (242). Consistent with the role of SPI1 and SPI2 T3SSs 
with invasion and survival of Salmonella in macrophages, bamB mutants were shown to be 
significantly attenuated at all time points when assessing systemic infection during this study, 
though bacterial burdens were only mildly reduced after oral challenge. Though closer 
inspection of the results presented here with that from S. Enteritidis investigations (242), 
indicates the differences in bacterial burdens between the mutants and their respective 
parental strains are marginal. Thus, potentially having extended our study over a longer 
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duration (six days instead of four) with a larger cohort of animals, may have yielded 
statistically significant differences. 
The TAM complex has been shown to be associated with secretion of AT passenger 
domains, working in conjunction with the BAM complex. TamA forms the OM protein with 
similar homology to the Omp85 family proteins, including BamA (103). While TamB is an 
IM bound protein, which protrudes into the periplasm, interacting with the POTRA domains 
of TamA (103). The heightened sensitivity of tamA and tamB mutants to complemented-
mediated killing is consistent with the role of this complex. Although the degree of mature 
AT proteins present in the OM of these single mutants has not been investigated during this 
study, it has been shown that tamAB double mutants have reduced levels of at least one AT in 
S. Typhimurium, ApeE (Personal communication Dr. Matthew Belousoff, Monash 
University).  
In C. rodentium, tamA and tamB mutants, show significant attenuation in virulence, 
when completed against the relevant parental strain (103). Unfortunately, the tamA mutant 
was not available at the time of performing the in vivo studies, though in contrast to C. 
rodentium we failed to observe any attenuation in virulence for a tamB mutant when 
administered singly and only a mild reduction in competitive index when competed against 
the parental strain at day seven, which was not replicated at the later time points. These may 
in part be due to the route of administration used in this study, whereby two of three 
characterised S. Typhimurium AT proteins (MisL and ShdA) are associated with intestinal 
colonisation (123, 124, 135). Repeating these studies using oral gavage, may therefore prove 
to be more insightful.  
In the case of ytfP, although transcribed within the same operon as tamA and tamB, its 
associated function with this complex has yet to be determined. However, disruption of ytfP 
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in S. Typhimurium resulted in significantly attenuated virulence (day 7  IP), similar to that 
observed previously for plpA mutants (chapter 4). This may be indicative of heightened 
sensitivity to innate immune responses, as observed with plpA mutants, though this hypothesis 
remains to be tested.  
Based on the results presented as part of this study and in consideration with that 
presented by others previously, SurA and BamB make attractive drug targets. Their cellular 
localisation within the periplasmic space and inner leaflet of the OM, respectively, would 
provide ease of access for small inhibitory molecules (capable of penetrating the OM). Both 
of these mutations result in significant attenuation, though we hypothesised this attenuation 
stems from different means. The TAM complex provides an alternative target for antibacterial 
drug development, due to its association with the secretion of AT protein passenger domains.  
 The results presented during this study highlighting the critical need for further 
investigation into the immune responses stimulated by these mutants. To ensure they do not 
adversely affect the stimulation of pro-inflammatory cytokines, required for clearance and 
control of bacterial infections. Or the development of suitable memory mediated AB 
responses.  Further studies are planned to examine how AB responses to various surface 
structures (including LPS, purified ATs and OMPs) are affected in these mutants, to ensure 
that a balanced AB response is maintained, and not predominately enhanced in for potentially 
anti-bactericidal ABs, such as to LPS.    
Despite requiring further investigation, this study has provided key insight to the 
virulence associated phenotypes of a number of genes, and investigated the impact of their 
deletion on bacterial virulence and the host immune response; critical investigations if the 
proteins encoded are to be pursued as potential drug targets for future development. As 
several of the genes investigated during this study are known to be associated with AT protein 
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biogenesis and secretion, the phenotypic roles of these proteins from S. Typhimurium will be 
investigated further in the next chapter. 
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CHAPTER 6 
CHARACTERISATION OF THE 
AUTOTRANSPORTERS OF SALMONELLA ENTERICA 
SEROVAR TYPHIMURIUM 
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6.1. INTRODUCTION 
The T5SS or AT pathway is the simplest and most widespread protein secretion 
pathway in Gram negative bacteria, with the majority of the characterised proteins shown to 
have a role in virulence. S. Typhimurium contains genes encoding five AT proteins, four of 
which belong to the Va subclass; ApeE, MisL, SapP (STM0373) and ShdA, and a single 
trimeric Vc protein; SadA (STM3691). Three of the Va proteins (MisL, SapP and ShdA) are 
predicted to form traditional passenger domain structures, which fold to form a right handed 
β-helical structure, conserved across 97% of the Va proteins (94). The remaining Va protein 
(ApeE) is predicted to form a globular passenger domain, rich in α-helices, observed in <3% 
of classical AT proteins. The Vc protein encoded by S. Typhimurium is SadA, similar in 
domain organisation to Va proteins, with the key difference being Vc proteins have a smaller 
translocation domain and must form homotrimers in the OM to produce a functional 12 
stranded β barrel (116-118). The passenger domains of the three individual polypeptides 
combine to form the functional region of the protein, which is comprised of the head, neck 
and stalk domains (254-256).  
Of the five AT proteins in S. Typhimurium only three have been previously 
characterised; ApeE, MisL and ShdA. ApeE is regulated by the transcriptional repressor apeR 
and phoBR regulon, with expression induced under phosphate limiting conditions (257). The 
protein encodes an esterase, responsible for the hydrolysis of fatty acid naphthyl esters, 
though it does not hydrolyze peptide bonds or act as a protease (258). Despite ApeE having 
first been described over a decade ago, the physiological relevance of these findings with 
regards to pathogenesis has yet to be determined.  
MisL (membrane insertion and secretion) is produced from the gene of the same name 
located on SPI3 and transcriptionally activated by MarT, also located on SPI3, which is 
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predicted to relieve HNS mediated gene silencing (259, 260). Despite previous attempts, 
expression of misL from its native promoter has not been detected in vitro. However, 
expression has been shown during in vivo oral infection of chickens, where MisL is required 
for virulence (261). Furthermore during murine infection, MisL is required for persistent 
colonisation of the caecum and faecal shedding (123). When expressed under the control of an 
inducible promoter in vitro, MisL increases binding to the ECM molecule fibronectin and 
promotes bacterial invasion of T84 human epithelial cells derived from colonic carcinoma 
(123).  
The final characterised AT protein, ShdA, is also an intestinal colonisation factor. Like 
MisL, ShdA is associated with colonisation of the caecum (lumen and mucosal layer), and is 
required for continued faecal shedding during the course of infection (124). Prolonged 
shedding is associated with the ability of ShdA to bind fibronectin and collagen I by means of 
an ionic interaction that mimics the binding of the natural host molecule, heparin (124, 135, 
137, 262).  
Deletion of either misL or shdA individually does not significantly attenuate S. 
Typhimurium virulence in the mouse model (135, 260). However, when either mutant is 
competed against its respective parental strain (or relevant other mutant), reductions in mutant 
strain colonisation of the Peyers patches and caecum are observed (123, 136). Further to this, 
the combined deletion of misL and shdA, results in significant reductions in the numbers of 
recovered double mutants from the spleen, the caecum, Peyer's patches and small intestine 
when competed against a phoN mutant (which does not display a colonisation defect) (123, 
136). Despite investigations into the role of these proteins in gut colonisation, no further 
investigations have been performed into their role in systemic infection and it remains unclear 
if a double mutant is avirulent.  
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As some of the genes examined in the previous chapter are associated with AT 
biogenesis and demonstrated varying degrees of attenuation in vivo we chose to investigate 
the role of S. Typhimurium ATs in pathogenesis, characterising the roles of individual 
proteins, in addition to examining the potential for functional redundancy.  
 
6.2. RESULTS 
6.2.1. Construction of S. Typhimurium AT deletion strains  
In order to examine the role of various AT proteins from S. Typhimurium, we 
constructed a series of both single and multiple deletion strains, in both the S. Typhimurium 
pathogenic (SL1344) and attenuated (SL3261) strains. Single gene disruption mutants for all 
S. Typhimurium ATs were constructed using the Datsenko and Warner method for single 
gene inactivation (as previously described) with the exception of the S. Typhimurium 
SL1344shdA::aph mutant which was kindly provided by Dr. R. Kingsley. These mutations 
were subsequently P22 transduced back into the both the attenuated and pathogenic strains 
prior to use (Fig. 6.1), with the exception of S. Typhimurium SL1344 shdA::aph, which 
despite several attempts we were unable to transduce the single mutation into S. Typhimurium 
SL3261.    
In order to further examine the potential for functional redundancy amongst these 
proteins, we constructed a series of multiple deletion mutants in both S. Typhimurium 
SL1344 and SL3261. These multiple deletions were produced by combining the single 
mutations created above, using P22 transduction. Upon confirmation of the mutation, the 
cassette was then removed as described previously (263), and the next mutation added via P22 
transduction. In each instance, both the gene being disrupted and previously deleted genes 
were PCR checked, to confirm these had not reverted to WT during the transduction or had 
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undergone abnormal recombination events between the remaining FRT sites located at 
various positions around the chromosome (Fig. 6.1).  We constructed multiple deletions based 
on the type V classification and predicted AT structure, thus producing a 3 in 1 mutant where 
the classical ATs were deleted (ΔsapP, ΔmisL and shdA::aph), combined with either the 
esterase or trimeric AT (3 in 1 containing either ΔapeE or ΔsadA) termed 4 in 1 apeE or sadA 
(referring to the gene deleted) or all five ATs simultaneously (ΔsapP, ΔmisL, ΔapeE, ΔsadA 
and shdA::aph), termed 5 in 1.  
 
6.2.2. Virulence of single and multiple AT deletion strains  
6.2.2.1. Single mutants are mildly attenuated after oral administration 
As S. Typhimurium infection most commonly occurs as a result of consuming 
contaminated food and water, we initially examined the ability of the mutants to cause 
infection when administered via a physiologically relevant route, oral gavage. We examined 
the bacterial burdens in the spleen and liver at four and six days post infection with virulent S. 
Typhimurium SL1344 (Fig. 6.2).  At both time points the S. Typhimurium SL1344 sapP::aph 
mutant was attenuated in both the spleen and liver, with bacterial burdens reduced by 
approximately 1.5 and 3 logs compared to that of the parental strain. In contrast the S. 
Typhimurium SL1344 sadA::aph, showed enhanced survival at day four, with slightly 
reduced and equal bacterial burdens by day six. While both S. Typhimurium SL1344 
apeE::aph and SL1344 misL::aph mutants demonstrated only slight decreases in bacterial 
burdens at day four (approximately 0.5 log decrease in spleen bacterial burdens), which were 
enhanced by day six (to approximately 1.5 log decrease in bacterial burdens). 
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Figure 6.1. Construction of S. Typhimurium single and multple deletion strains 
PCR confirmation of the mutants constructed in S. Typhimurium strains A. Single S. 
Typhimurium SL1344sapP::aph, using gene specific flanking primers to compare the 
fragement size between the parental strain, and test colonies. Fwd Km refers to the use of the 
internal kanamycin forward primer in conjunction with the gene specific reverse primer, while 
Rvs Km refers to the opposite, an internal reverse kanamycin primer in conjunction with the 
gene specific forward flanking primer. B. Confirmation of the pentuplet mutant in S. 
Typhimurium SL3261, using gene specific flanking primers in each instance, comparing the 
parental strain, with that of a known disruption and deletion mutant (where appropriate).    
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Figure 6.2. Bacterial burdens post four and six days oral infection 
Bacterial burdens in the A. spleen, B. liver, post four and six days infection with single 
mutants in S. Typhimurium SL1344 background.  
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6.2.2.2. Single mutants are also attenuated during later stages of systemic infection 
Despite oral infection being the most physiologically relevant route, we questioned 
whether the ATs being investigated may also be required for systemic infection. For example, 
as sapP mutants were attenuated after oral administration, we questioned whether this AT 
maybe required for murine infection generally or whether its roles were limited 
gastrointestinal colonisation, in a manner analogous to MisL and ShdA which are required for 
intestinal colonisation and persistent infection (123). We also choose to investigate the role of 
MisL in systemic infection, as this mutant had not previously been investigated in this manner 
(all prior studies administering misL mutants via IP, were done so in competition). Finally, 
sadA mutants were not attenuated after oral challenge despite the fact several other TAAs, 
including YadA and UpaG, are required for serum resistance, biofilm formation and 
adherence and invasion of specific cell types (119, 143), phenotypes that are associated with 
causing and maintaining persistent systemic infection. Therefore, we chose to examine the 
ability of the S. Typhimurium SL3261 sapP, misL and sadA single mutants to cause systemic 
infection over a time course of seven, 21 and 35 days after IP administration (Fig. 6.3). 
At days seven and 21 the sadA mutant demonstrated no attenuation in virulence, in 
either the spleen or liver and was therefore excluded from the day 35 study. The sapP and 
misL bacterial burdens were slightly reduced at day seven, though not significant in either the 
spleen or liver. In contrast, at days 21 and 35 the sapP mutant was significantly attenuated at 
both sites (p= 0.0286), while the misL mutants were significantly reduced in spleen at day 21 
and the liver at day 35 (p= 0.0286) suggesting that both SapP and MisL are required for 
systemic virulence in the murine model.   
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Figure 6.3. Bacterial burdens after systemic infection with S. Typhimurium     
Bacterial burdens from A. spleen and B. liver of C57BL6 mice dosed with various S. 
Typhimurium single mutants, in SL3261 strain. Examining bacterial colonisation and 
persistance over a period of seven, 21 and 35 days.  
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6.2.2.3. Multiple deletion strains show graded attenuation in systemic infection 
As the single sapP and misL deletion mutants showed significant attenuation in 
virulence when administered IP, we questioned whether these reductions in bacterial burdens 
could be enhanced in the absence of the other Type Va AT ShdA. Additionally despite sadA 
mutants showing no attenuation in virulence, we questioned whether the deletion of this 
protein was compensated for by the Type Va ATs. Therefore, we chose to examine the 
virulence profiles of the S. Typhimurium SL3261 multiple deletion mutants after systemic 
infection over a time course of seven, 21 and 35 days. Based on the previously reported roles 
of MisL and ShdA in intestinal colonisation (123, 136) combined with our earlier results 
indicating sapP mutants are attenuated when administered orally, we felt commencing our 
investigations with the multiple deletion strains using systemic (IP) infection would be more 
insightful. We feared if oral administration was used and the mutants were unable to colonise 
the gut and achieve systemic infection, we may gain limited information from these 
experiments, thus IP administration was selected (using the SL3261 variants) for our 
investigations despite this not being a physiologically relevant route of infection.  
Interestingly, despite our previous investigations showing that both misL and sapP 
single mutants were attenuated at days 21 and 35, no significant attenuation is observed when 
these mutation are combined with disruption of shdA, at any time point examined in either the 
spleen or liver (Fig. 6.4). Our previous investigations had suggested SadA was not required 
for virulence in the murine model, though the combination of this mutation, with that of misL, 
shdA and sapP, does significantly reduce the spleen bacterial burdens at day 21 (P=0.0286), 
However, the reductions in the liver are not significant. By day 35 this mutant appears to 
colonise and persist to the same degree and better than that of the parent in the spleen and 
liver, respectively. As ApeE is the only remaining AT in this strain, this result may be 
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Figure 6.4. Virulence of S. Typhimurium multiple AT deletion mutants  
Systemic infection of C57BL6 mice with attenuated SL3261 and various multiple AT deletion 
strains. Bacterial burdens determined per organ for Spleen (A) and Liver (B) at seven, 21 and 
35 days post infection, via the IP route. Deletion of multiple AT proteins results in a gradual 
attenuation in virulence, at day 7. However by day 21 ApeE appears to provide a more critical 
role in persistent infection in the liver and day 35 in the spleen, where by the 4 in 1 apeE 
mutant is comparable with a 5 in 1 mutant. Similarly mutants with only functional ApeE 
appear to persist better than parental strain in the liver at day 35 and to equal degree as wild 
type in the spleen. By day 35, deletion of all 5 ATs results in significant attenuation 
predominantly observed in the liver. 
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indicative of a role for ApeE in persistent infection, particularly that of the liver. Consistent 
with this hypothesis, a four in one mutant of misL, shdA, sapP and apeE was shown to be 
significantly attenuated in the liver at both days 7 and 21 (P=0.0286), though comparable with 
the parental strain at day 35, while in the spleen this quadruple mutant was attenuated at both 
days 21 and 35 (p=0.0286). This suggests that ApeE may be required for persistent murine 
infection. However, this result does not differentiate between whether this effect is specific to 
the loss of ApeE alone, or is a result of combination with the deletion of other type Va ATs. 
Interestingly, when all five AT proteins are deleted simultaneously, the pentuple mutant is 
significantly attenuated at all timepoints, in the colonisation of both the spleen and liver 
(p=0.0286 spleen and liver).  
  
6.2.3. Bioinformatics Analyses of S. Typhimurium AT proteins 
As MisL and ShdA were largely already characterised, we chose to focus our 
investigations on ApeE, SadA and SapP. Therefore, we examined each of these genes and 
their encoded amino acid sequences using bioinformatics, to examine the protein domain 
structure and confirm their predicted type V subclassification. In addition, we examined their 
distribution across other Gram-negative organisms, in an attempt to identify characterised 
homologues present in other species.  
 
6.2.3.1. Structure and distribution of ApeE   
ApeE has been previously described and shown to be encoded by a 1971 bp gene of 
the same name, producing a mature protein of approximately 67 kDa (post signal sequence 
cleavage) with esterase activity (257, 258, 264). Analysis of ApeE amino acid sequence 
indicates the protein contains three distinct domains; a Sec-dependant signal sequence, 
predicted to be cleaved after amino acid residue 25, Pfam: Lipase_GDSL domain (29 -342) 
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and C-terminal Pfam: Autotransporter domain, located between residues 386 - 645, encoding 
the catalytic passenger domain and membrane spanning, 12 stranded β-barrel, respectively 
(Fig. 6.5). Models of the ApeE tertiary structure show the GSDL lipase passenger domain 
folds to form a globular domain rich in α-helical (Fig. 6.5), bringing together a triad of 
catalytic residues, containing; serine, aspartate and histidine, located at positions 10, 301 and 
304 (residues are numbered based on post signal sequence cleavage) (Dr V. Bavro, personal 
communication). 
To determine the prevalence of apeE across other Gram negative bacterial species, the 
amino acid sequence was used to probe all Gram-negative genomes available in NCBI. The 
protein was shown to be highly conserved and present in most Salmonella spp in addition to 
significant distribution across both Pseudomonadacae and Xanthomonadacae species, where 
it’s annotated as EstA and EstE, respectively (126, 265) (Fig. 6.5). Interestingly the protein is 
also shown to be present across a diverse number of proteobacteria and one cyanobacteria, 
however, as described previously by Carinato et al (258) no homologue is found in E. coli.  
 
6.2.3.2. Structure and distribution of SadA 
The 4,383 bp gene STM3691, encodes the only Type Vc TAA in S. Typhimurium 
termed SadA; Salmonella Adhesin protein A (266). Structural analysis shows the sequence 
contains all the features of a TAA; including a conserved N-terminal extended signal peptide 
region (ESPR) predicted to be cleaved after amino acid 50, a 1333 amino acid passenger 
domain. Which is composed of three structurally conserved regions; head, neck and stalk 
(118, 267), as depicted by Pfam:Hep_Hag (PF05658) motifs (head), a single Pfam:HIM 
(PF05662) motif (neck) and a series of small unconserved repeats comprising the stalk (118). 
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Figure 6.5. Structure and distribution of ApeE 
A. Predicted domain structure of ApeE as determined by SMART analysis of the amino acid 
sequence. Protein contains a Sec-dependant signal sequence, predicted to be cleaved after 
residue 25. GSDL Lipase passenger domain and, Pfam; Autotransporter domain, encoding a 
12 stranded β-barrel. B. Predicted tertiary structure of ApeE, as modelled by Dr. V. Bavro C. 
NCBI BLASTP search probing all Gram negative bacteria genomes indicates ApeE is present 
in all sequenced Salmonella strains. ApeE homologues are present in a number of 
proteobacteria, including human, animal, insect and plant pathogens. 
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While the 78 amino acids C-terminal translocator domain, identifiable as the Pfam:YadA 
(PF03895) forms a homo-trimer to create the 12 stranded β-barrel (Fig. 6.6).  
To identify SadA homologues all Gram-negative genomes, NCBI was probed using 
the protein sequence and BLASTP search. For which only resultant sequences with the same 
domain architecture and >50% similarity were accepted. Homologues were identified in E. 
coli, Shigella sonnei, Citrobacter youngae and Salmonella enterica serovars, as shown in Fig. 
6.6. In all instances sadA is present in the same genomic position, adjacent to lld locus, as 
shown in Fig. 6.6. Sequence alignments of Salmonella sadA homologues indicated over 98% 
similarity, with increasing variability between E. coli homologues. However, the homologues 
from intestinal E. coli strains were more conserved than those from extra-intestinal, 
uropathogenic and environmental strains (174). Through from this multiple sequence 
alignment the positional homologue, UpaG (uropathogenic E. coli strain CFT073) was 
identified (119).  
 
6.2.3.3. Structure and distribution of SapP 
 The 978 amino acid protein SapP; Salmonella Adhesion and Pathogenicity Protein, is 
encoded by the gene STM0373. Structural analyses of the amino acid sequence indicated the 
protein contains a Sec dependant signal sequence, predicted to be cleaved after amino acid 27, 
the passenger domain; comprising of a Pertactin like region (forming a predicted single 
stranded right-handed β helix), an AC domain and an α helix, in addition to the 250 amino 
acid Pfam: Autotransporter domain, which encodes the 12 stranded β-barrel (Fig. 6.7). 
Modelling of the SapP tertiary structure indicates the AC domain is exposed on the surface, 
while the α helix resides in the lumen of the barrel, consistent with other Type Va proteins. 
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Figure 6.6. Domain organisation and distribution of SadA 
In silico analysis of SadA A). Schematic diagram comparing SadA and its homology UpaG. 
Structural domains are shown as coloured boxes, with SP (pink) referring to the signal 
peptide, the passenger domain which is composed of a head (yellow), with alternating neck 
(orange) and stalk (black) domains, the translocation (green) domain is described as YadA 
like domain, whereby each single polypeptide contributes four β strands to the final 12 
stranded β barrel. UpaG encodes a larger head domain, with increased neck and stalk 
domains. B). Unrooted phylogram of full length sadA orthologues from 32 genomes, where 
bootstrap values taken from 1000 replicates. Genomes are highlighted according to 
pathogenic groups. C). Genomic region alignments for S. Typhimurium with the orthologues 
regions in E. coli CFT073 and E. coli K12. Figure taken from Raghunathan et al (174). 
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To identify SapP homologues, all Gram-negative genomes in NCBI were probed using 
the protein sequence (Fig. 6.7). SapP is present in numerous Enterobacteriaceae including 
Salmonella species, E. coli, C. rodentium, Klebsiella oxytoca and Yokenella regensburgei, to 
name but a few. Closer inspection shows sapP positional homologues are identifiable in E. 
coli, C. rodentium and E. cloacae though not in Klebsiella pneumonia (Fig. 6.7).  
  
6.2.4. ApeE and SadA are expressed in vitro and surface localised 
6.2.4.1. ApeE is detectable at the OM 
As with all AT proteins, ApeE and SadA are predicted to be localised to the OM, with 
the passenger domains exposed on the extracellular side. In the case of ApeE the passenger 
domain is predicted to remain attached to the translocator domain, as is observed for other 
GSDL ATs (127). To investigate this hypothesis we prepared OM fractions using Triton X 
100 extraction. The membranes were treated with urea, to remove loosely associated material 
or aggregates prior to western blotting using anti-ApeE antibody (Fig. 6.8). ApeE is only 
detectable as full length (67 kDa) protein, localised to the OM fraction in the S. Typhimurium 
strain SL1344 and complemented mutant. In contrast, ApeE is not detectable in the apeE null 
mutant OM fraction. This result confirms that ApeE does localise to the OM and is not 
cleaved from the β-barrel.   
 
6.2.4.2. SadA is expression is enhanced at higher temperatures 
SadA is a predicted to form a TAA, forming a homotrimer of 426 kDa, localised to the 
OM with the passenger domain attached. However, expression of previously characterised S. 
Typhimurium ATs, MisL and ShdA is only detectable under in vivo conditions, despite 
varying media types and pH in vitro (123, 124). Therefore to confirm the expression of sadA 
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Figure 6.7. Structure and distribution of SapP 
A. Predicted domain structure of SapP as determined using the amino acid sequence, with the 
predicted tertiary structure of each domain shown below. Protein contains a Sec-dependant 
signal sequence, predicted to be cleaved after residue 27. Pertactin like passenger domain, 
with a right handed β helical structure (green), AC domain (purple), α helix residing in the 
barrel lumen (red) and the 12 stranded C-terminal β-barrel. B. NCBI BLASTP search probing 
all Gram negative bacteria genomes indicates SapP is broadly distributed, with homologues 
present in Salmonella strains and closely related species such as E. coli, C. rodentium, in 
addition to more diverse species including H. alvei and E. cloacae. C. Genomic alignments 
for S. enterica, E. coli, C. rodentium, E. cloacae and K. pneumoniae indicating sapP is 
present in the same genomic location in each instance, with the exception of K. pneumonia, 
which does not encode a sapP homologue.  
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Figure 6.8. OM localisation of ApeE.  
Western blot of Triton X 100 extracted S. Typhimurium OM fractions, post urea washing, 
probed with α-ApeE antibodies. L; Ladder, 1. SL1344, 2. SL1344 apeE::aph, 3. SL1344 
apeE::aph pQE60apeE (note compliment sample diluted 1:10 compared to samples in lanes 1 
and 2). Full length (67 kDa) ApeE protein is only detectable in the OM fractions of the 
parental strain and complemented mutant.  
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 in vitro RT-PCR was performed after growth in LB broth at 37
o
C using the primer 
combination, sadA internal forward and reverse. The sadA transcript was detectable in the 
parental strain, but absent from the sadA mutant confirming the gene is transcribed under in 
vitro conditions (Fig. 6.9).  
Having confirmed the presence of sadA transcript, we next sought to confirm that the 
protein was detectable and localised to the OM. OM fractions were prepared from E. coli 
BL21 pET22b with and without SadA, the S. Typhimurium parental strain SL1344, sadA 
mutant or complemented mutant grown in different media types and at different temperatures. 
OM preparations were western blotted using anti-SadA primary antibodies. Over expression 
of SadA in E. coli produced two proteins corresponding to the monomeric form 
(approximately 142 kDa) and the trimeric form of SadA (over 400 kDa) indicating SadA 
adopts its native conformation, when over expressed in E. coli. SadA was weakly detected in 
OM of S. Typhimurium SL1344, when grown in LBB at 37
o
C and absent in the mutant (Fig. 
6.9).  
Testing a range of growth temperatures (25
o
C, 37
o
C, 42
oC) and media’s; PCN (268), 
shown to enhance expression of SPI2 (160), MM5.8 Bis/Tris media (269), known to mimic 
the intracellular conditions of the macrophage vacuole (270) and standard M9 minimal media, 
which more closely replicate the environment in vivo, SadA expression was observed when 
cultured at either 37
o
C or 42
o
C, though protein levels were enhanced when grown in either 
PCN or MM5.8 media, and significantly at 42
o
C.  
Despite confirming SadA expression and localisation to the OM, this technique failed 
to confirm that SadA was present on the outer leaflet with a surface exposed passenger 
domain. Therefore, immunofluorescence was performed using non-permeabilised S. 
Typhimurium SL1344 and sadA mutant (Fig. 6.9). Non permeabilised S. Typhimurium cells, 
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Figure 6.9. Expression and localisation of SadA 
A). RT-PCR using primers internal to sadA, L refers to Hyperladder 1, i). parental strain 
SL1344, ii). SL1344 ΔsadA. The results confirming sadA transcript can only be detected in 
the parental strain and not the sadA mutant. Confirming sadA is expressed under standard 
growth conditions at 37
o
C in LBB. B). Western blot of OM prep for i). SL1344, ii). SL1344 
ΔsadA iii). SL1344 ΔsadA pQ60sadA (pDR3), blotted using α-SadA primary antibodies. C). 
Immunofluorescence of SL1344, SL1344 ΔsadA and SL1344 ΔsadA pQ60sadA (pDR3). 
Using whole non permeabilised cells, staining with α-SadA primary antibodies and GAR 
alexa fluor488 secondary antibody, indicate SadA displays punctuated labelling at the surface 
in the parental strain and mutant, but absences in the sadA mutant strain. Figure adapted from 
(174) 
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stained with anti-SadA primary antibody and Alexa-flour secondary antibody displaying 
punctuated labelling in both the parental strain and complemented mutant, that was absent in 
the sadA mutant (174).  The distribution of AB labelling observed for SadA is consistent with 
previous observations for YadA (253) though contrasts with other reports suggesting ATs are 
polarly localised (271). As some TAAs are capable of non-specific binding of 
immunoglobulin’s (143), the following controls were also tested; a). labelling with secondary 
antibody only and b). labelling with an alternative primary antibody for which there is no 
corresponding protein in S. Typhimurium, anti-Pet antibodies (AT from EAEC). In both 
instances no labelling was observed, confirming the labelling with anti-SadA.  
 
6.2.5. Characterisation of ApeE catalytic activity 
6.2.5.1. ApeE demonstrates esterase activity against TWEEN 80 
As the bioinformatic analyses showed ApeE encodes a surface localised GSDL lipase 
passenger domain with esterase activity, we sought to investigate the substrate specificity of 
this protein using BioLog Phenotype Microarrays. These assays compare the growth kinetics 
of parental S. Typhimurium with an apeE mutant, under 2000 different conditions (data not 
shown). From these experiments we observed the growth of the apeE mutant was consistent 
with that of the parental strain for the majority of the conditions tested, though in keeping 
previous observations, the growth kinetics were significantly reduced when using TWEEN 80 
as the sole carbon source. To confirm this result, we examined the growth kinetics of S. 
Typhimurium SL1344, apeE mutant and the complemented mutant, in M9 modified minimal 
media supplemented with 1% TWEEN 80 as the sole carbon source for growth (Fig. 6.10). 
The results clearly indicate deletion of apeE renders the bacteria unable to utilise TWEEN 80 
as a sole carbon source for growth.   
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Figure 6.10. Growth kinetics when using TWEEN 80 as the sole carbon source 
A). Growth kinetics for S. Typhimurium strains in modified M9 media containing 1% 
TWEEN 80 as the sole carbon source for growth. Indicating only the parental strain and 
complimented mutant can utilise TWEEN 80 for growth B). Growth kinetics for BW25113 
strains, expressing wild type ApeE protein or ApeES10A mutant protein, whereby the catalytic 
serine has been mutated to alanine, in BW25113 
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To confirm ApeE was responsible for this phenotype, we choose to examine the 
growth of E. coli K12 strain BW25113 under the same conditions, as this strain does not 
contain a natural homologue of ApeE. By comparing E. coli, BW25113 containing either the 
empty vector or plasmid expressing WT ApeE we were able to show that ApeE enables E. 
coli to utilise TWEEN 80 as a carbon source (Fig. 6.10).  
In the case of the ApeE homologue EstA catalytic activity is as a direct result of the 
catalytic serine at position 14 (126). To investigate whether the ApeE serine at position 10 
performed a similar role, we mutated this residue to alanine using site directed mutagenesis, 
to create ApeES10A (courtesy of Dr. A. E. Rossiter). By examining the growth of E. coli 
BW25113 expressing either the WT ApeE (as above) or ApeES10A mutant, we were able to 
confirm that the ability of the bacteria to utilise TWEEN 80 as a carbon source is dependant 
upon functional catalytic activity (Fig. 6.10). 
 
6.2.5.2 ApeE hydrolyses TWEEN 80 to utilise the fatty acid for growth 
The requirement for a catalytic activity suggests that ApeE must cleave TWEEN 80, 
in order to be used as a carbon source. TWEEN 80 is a polyester of the glucose alcohol 
sorbitan and a fatty oleic acid, where ApeE is predicted to hydrolyze the molecule between 
these two components. To determine if the bacteria utilized the sorbitan or fatty acid 
component as the carbon source, we removed the ability of the bacteria to take up all long 
chain fatty acids. To do this we obtained the fadD and fadL mutants from the KEIO Library. 
These genes encode for components of the Fatty Acid Degradation pathway, with fadD 
encoding the IM component, fadL encoding the OM component and while fadH acts as the 
transcriptional regulator for the system. By expressing either functional ApeE or ApeES10A in 
these mutant backgrounds we were able to show that utilization of TWEEN 80 as a sole 
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carbon source, is dependent on a functional FAD system to take up the fatty acid chain (Fig. 
6.11), whereby deletion of either the IM or OM FAD components renders the bacteria unable 
to grow, even in the presence of catalytically active ApeE. Additionally, it should be noted, 
that all strains show comparable growth kinetics when supplemented with glucose as the 
carbon source.  
 
6.2.5.3. ApeE degrades the tomato cuticle 
Previously, our collaborators had noticed that numerous Salmonella enterica serovars 
(including Typhimurium, Senftenburg, Thompson, Agona, Arizona and Gallinarum) locally 
degraded the cuticle of tomato skins, during tomato binding assays. As long chain fatty acids 
are a component of the tomato cell wall biopolymer, cutin (272), we hypothesized that ApeE 
may be responsible for this phenotype. Having confirmed the role of ApeE in the utilization 
of TWEEN 80 and the similarity of the structures of TWEEN to that of oleic acid, we sought 
to investigate whether ApeE was potentially involved in the adhesion and/or survival of S. 
Typhimurium to tomato skins. With the assistance of Dr. R. K. Shaw and Prof. G. Frankel we 
investigated the ability of S. Typhimurium parental strain, apeE mutant, complemented 
mutant and E. coli BL21 strains with and without ApeE to adhere and survive on tomato skins 
for a period of 20 h (Fig. 6.12). The results show that although ApeE is not required for 
adhesion or short term survival of S. Typhimurium on the tomato skin, as determined by the 
recoverable bacterial counts 20 h post inoculation. The presence of ApeE, results in the 
appearance of a ‘zone of degradation’ surrounding the bacterial cell for both S. Typhimurium 
and E. coli strains, as observable in the SEM images for the parental strain, complemented 
mutant and E. coli BL21 expressing ApeE, but not the S. Typhimurium apeE mutant or BL21 
empty vector, consistent with ApeE functioning as an esterase, locally degrading the tomato 
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Figure 6.11. Growth kinetics for FAD mutants with TWEEN 80 as the carbon source 
Growth kinetics for BW25113 parental strain, fadD or fadL mutant strains, expressing wild 
type ApeE protein or an ApeE serine mutant protein, whereby the catalytic serine has been 
mutated to alanine, with TWEEN 80 as the sole carbon source for growth. Indicating the 
requirement for both catalytically functional ApeE and FAD system to utilise TWEEN for 
growth.  
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Figure 6.12. Adherence and survival of S. Typhimurium and E. coli expressing ApeE 
A). SL1344, B). SL1344ΔapeE, C). SL1344ΔapeE pQE60apeE D). Adherence of various S. 
Typhimurium strains post 20 hours incubation, E).  BL21 pET22bapeE F). BL21 pET22b 
empty vector. Samples were induced with 10 mM IPTG, where appropriate and incubated on 
tomato skins for 20 hours at room temperature. Zones of degradation are clearly visible in the 
strains expressing ApeE, but absent from the mutant and empty vector strain. 
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cuticle and possibly utilizing this as a carbon source for growth. However, the absence of any 
change in bacterial numbers post 20 h incubation contradicted the hypothesis that this 
phenotype was required to obtain a carbon source for growth.  
To address this issue, we extended the incubation period to four days, to investigate 
whether the bacterial survival rates observed after 20 h incubation were an artifact of the 
relatively short incubation period selected previously. In order to provide a more 
physiologically relevant environment for this experiment we elected to use whole tomatoes, as 
opposed to discs of tomato skins utilized previously. Bacterial cultures (adjusted to the same 
inoculum) were spotted onto the surface of the tomato and incubated for four days in sealed 
containers at room temperature. After four days incubation bacterial counts were determined 
by removing the treated area (tomato skin and the underlying fleshy tissues) and 
homogenizing in PBS, prior to plating on LB agar. Samples of the tomato skin and underlying 
fleshy tissues were also collected in parallel for TEM analysis. Using this extended incubation 
period, we demonstrated that only strains expressing ApeE (i.e. the parental S. Typhimurium 
strain SL1344, complemented mutant or E. coli strain BL21 expressing apeE from pET22b), 
were recoverable post four days (Fig. 6.13). TEM analysis of the cuticle samples from tomato 
sections treated with strains expressing apeE showed the cuticles were significantly damaged, 
with necrosis into the underlying fleshy tissues (Fig. 6.13). In contrast, the tomato section 
treated with the apeE mutant showed no damaged to the cuticle. 
The results presented as part of this study highlight ApeE mediates the survival of 
Salmonella enterica serovars on tomatoes, enabling the bacteria to not only degrade the 
cuticle providing a means of accessing the fleshy, sugar rich, underlying tissues, but also 
utilize the cuticle as a carbon source for survival during the nutrient limited environment of 
the outer tomato surface.  
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Figure 6.13. Survival of S. Typhimurium and E. coli strains post four days incubation on 
tomatoes  
A). Bacterial survival, as determined by recoverable CFU/mL, post four days incubation on 
tomatoes, incubated at room temperature, under sealed conditions. B). TEM analysis of 
tomatoes, sampling from the cuticle down into the underlying fleshy tissue. i). SL1344, 
ii).Increased magnification of the cuticle, when incubated with SL1344, iii). SL1344 ΔapeE. 
Indicating only strains with ApeE are capable of survival on tomato skins under extended 
durations (four days) or causing necrosis of the tomato cuticle, providing access to the 
underlying fleshy tissues. 
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6.2.6. Deciphering the mechanisms by which Type V proteins contribute to virulence 
6.2.6.1 S. Typhimurium ATs promote adhesion to ECM molecules 
As ATs and TAAs are commonly associated with binding to ECM molecules, we 
sought to investigate whether SapP and SadA were also capable of this phenotype. Previous 
investigations with MisL and ShdA have shown both of these proteins are capable of binding 
to ECM molecules, including fibronectin and collagen IV (MisL only) (123, 124). 
Additionally the SadA homologues UpaG and EhaG have been shown to bind fibronectin, 
laminin, and collagen I, II, III, and V (128). To examine the possibility that the SapP and 
SadA may also be involved in binding other ECM molecules, we investigated this hypothesis 
by expressing these proteins in the E. coli K12 strain BL21, to exclude the possibility that the 
results maybe distorted by the presence of other OM features such as long chain LPS (Fig. 
6.14). The results show that in contrast to other TAAs and characterised homologues, SadA 
does not promote binding to collagen III, IV or fibronectin, while SapP can promote binding 
to all of these molecules, to varying degrees.  
 
6.2.6.2. SadA does promote adhesion and invasion of epithelial cells 
As several characterised TAAs have been shown to be associated to binding to various 
different cell types, we next sought to examine whether SadA mediated adhesion to epithelial 
cells. To investigate this hypothesis we examined the ability of both the S. Typhimurium 
parental strain and sadA mutant, alongside the E. coli K12 strains over-expressing SadA to 
adhere too and invade human intestinal cell line; CaCo-2 (Fig. 6.15). No differences were 
observed between the S. Typhimurium strains, however expression of SadA from E. coli M15 
significantly increased their ability to adhere to and invade CaCo-2’s, P=<0.05 and P=<0.01, 
for adhesion and invasion, respectively. 
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Figure 6.14. SapP promotes binding to ECM molecules 
Binding of E. coli BL21 strains expressing either SapP or SadA, indicates SapP can promote 
binding to Collagen III, IV and fibronectin. In contrast SadA does not promote binding to any 
of the ECM molecules tested  
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Figure 6.15. Adhesion and invasion of CaCo-2 intestinal cells and J774 macrophages  
Adhesion and Invasion of S. Typhimurium SL1344 and SL1344 sadA::aph and E. coli M15 
pQE60, or M15 pQE60sadA, to A). CaCo-2 intestinal cells or B). J774 macrophages. E. coli 
expressing SadA, demonstrated a significant increase in its ability to both adhere to and 
invade CaCo-2 cells, compared with the empty vector, where P=<0.05 and P=<0.01, 
respectively. No differences were observed between the ability of any strain to adhere or 
invade J774 macrophages. Figure adapted from Raghunathan et al (174).   
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 As S. Typhimurium is capable of systemic infection, whereby adhesion and invasion 
of macrophages is critical for dissemination throughout the lymphatic system, we next sought 
to examine whether SadA could also promote adhesion and invasion of the murine 
macrophage cell line, J774. Using the same strain set as described previously we confirmed 
that SadA does not promote adhesion or invasion in this particular cell type (Fig. 6.15). 
 Although we had conclusively shown SadA was not required for adhesion or invasion 
to murine macrophages, we questioned whether the other type V proteins of S. Typhimurium 
may be associated with this phenotype. In order to test this hypothesis we examined the 
ability of S. Typhimurium multiple deletion strains to adhere to and invade three separate 
macrophage cell lines, the murine macrophages; J774 and RAW 264.7 and human 
differentiated monocytes, THP1, to confirm the results were not cell type specific. Fig. 6.16 
indicates no significant differences were observed in the ability of any strain to adhere to or 
invade macrophages. 
 
6.2.6.3. SadA does promote autoaggregation and biofilm formation 
Several TAAs are associated with biofilm formation and autoaggregation, including 
the SadA homologue UpaG (119, 138, 143). To determine whether SadA was associated with 
these phenotypes, we examined the ability of S. Typhimurium strains SL1344, sadA mutant, 
complemented mutant and SadA expressing E. coli to undergo aggregation and biofilm 
formation (Fig. 6.17). No statistically significant differences were observed in the ability of S. 
Typhimurium strains to undertake either phenotype. In contrast, SadA expressed in an E. coli 
K12 background (defective for O-antigen) significantly enhanced aggregation and biofilm 
formation (p=<0.001). Previous reports have highlighted the importance of self to self 
recognition between Type V proteins to promote these phenotypes, whereby OM features 
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Figure 6.16. Adhesion and invasion of macrophage cell lines with S. Typhimurium AT 
multiple knockouts   
A). J774 murine macrophages, B). RAW 264.7 murine macrophages, C). THP1, human 
monocytes differentiated into macrophages. Results are the average of three separate 
experiments, with a minimum of three biological replicates for each. Data expressed as log10 
CFU/mL of adherent or intracellular bacterial. The results indicate that deletion of the ATs 
does not affect either adhesion or invasion of S. Typhimurium on any macrophage cell lines, 
and this result is not cell line specific. 
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including; capsular polysaccride, O and K antigens and Type 1 fimbriae are capable of 
blocking these interactions through steric hindrance (273). Therefore, we examined whether 
O-antigen in S. Typhimurium was potentially blocking the self to self interaction of SadA. To 
achieve this we constructed the double mutant SL3261 ΔsadA, galE::aph, using P22 
transduction. Disruption of galE results in a rough LPS phenotype, lacking O-antigen, due to 
the inability to catalysing the conversion of UDP-glucose to UDP-galactose during cell wall 
synthesis (274). By comparing the double ΔsadA, galE::aph mutant with the same strain over 
expressing SadA, we revealed SadA significantly increases in the ability to undertake both 
phenotypes, as shown in Fig. 6.17 confirming SadA can promote both phenotypes but is 
susceptible to steric hindrance by other OM structures. 
 
6.2.6.4. SadA does not promote serum resistance  
As sadA is the only gene encoding a TAA in S. Typhimurium we choose to examine 
whether this protein contributed to serum resistance, as observed for the prototypical TAA 
YadA (143, 174). Thus, we initially examined whether deletion of sadA resulted in elevated 
sensitivity to complement-mediated killing in healthy human serum. By examining the 
survival of S. Typhimurium parental strain SL1344 and sadA mutant, we confirmed that 
deletion of sadA does not affect the ability of S. Typhimurium to resist complement-mediated 
killing in vitro (Fig. 6.18). Therefore, this result raised the possibility that other AT proteins 
in S. Typhimurium may be capable of promoting serum resistance. To investigate this, we 
compared the survival of the S. Typhimurium parental SL3261 strain with the various 
multiple deletion strains. As this assay was performed using the S. Typhimurium SL3261 
mutants, all strains showed some level of sensitivity to complement-mediated killing, (as 
determined by decreasing CFUs post 45 minutes), though the 4 in 1 sadA and 5 in 1 mutants, 
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Figure 6.17. Autoaggregation and biofilm formation 
A). Settling profiles of STm and E. coli expressing SadA strains, images show settling from 
static liquid suspensions in the SadA expressing E. coli M15 strain.where by only E. coli M15 
expressing SadA (pDR3) shows significant aggregation compared to the parental STm strain 
or M15 empty vector. B). Biofilm formation of the same strains in polystyrene plates. The 
data is the average of eight replicate samples, performed on three separate occasions C). 
Settling profiles for STm galE::aph and ΔsadA galE::aph double mutants, with either the 
empty vector or complemented pDR3, only over expression of SadA in a galE deletion 
background enhances aggregation of the bacteria. D). Analysis of biofilm formation using 
flow cell chambers, for the ΔsadA galE::aph double mutant, with either the empty vector or 
complement, pDR3 post 18hours growth. Figure taken from Raghunathan et al (174). 
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Figure 6.18. Serum resistance of S. Typhimurium in healthy human serum 
A. Resistance of S. Typhimurium SL1344 parental strain and sadA mutant. B. Serum 
resistance of S. Typhimurium SL3261 parental strain and multiple deletion strains in healthy 
human serum, as determined by reducing log10 changes in bacterial CFU/mL over time. All 
strains show sensitivity to serum, though in the absence of other classical ATs, deletion of 
sadA (i.e. the 4 in 1 sadA and 5 in 1 mutant) show slightly enhanced sensitivity to serum 
compared with the other mutants, particularly the 5 in 1 mutant which is killed by 90 minutes, 
compared to all other strains which are killed by 180 minutes.  
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showed the most significant decrease, while the 3 in 1 and 4 in 1 apeE mutant were more 
comparable with the parental strain. The 5 in 1 mutant did display slightly increased 
susceptibility compared to the other strains, with complete killing by 90 min, in contrast to the 
other mutants, which were killed by 180 min (Fig. 6.18), indicating that ATs may contribute 
to serum resistance of S. Typhimurium.  
 
6.2.7. Immunomodulatory effects of S. Typhimurium SadA  
Despite the fact that SadA is not critical for virulence in the murine model, this protein 
forms a large surface exposed structure, accessible to the immune system during the course of 
infection, we therefore chose to examine whether SadA was immunogenic and a suitable 
vaccine candidate. In order to achieve this SadA was purified, refolded as determined by 
tryptophan fluorescence, shown to be endotoxin free, within the limits of detection using a 
Sigma E-toxate kit and protein concentration determined using the Tannin assay (174). Using 
purified SadA we aimed to answer two hypotheses; i). was SadA immunogenic and ii). could 
a SadA AB response protect against infection. The challenge study protocol is shown in Fig. 
6.19. Mice were imunised with either purified SadA, SadA bound to Alum (known adjuvant) 
or PBS at days 0 and 30, prior to challenge with virulent S. Typhimurium SL1344 at day 44 
and sacrificed at day 46, with bacterial burdens assessed in the liver and spleen. ELISAs were 
performed on blood samples taken prior to challenge (day 44) and sacrifice (day 46) to 
determine the relative amounts of SadA specific antibodies.  
ELISAs using the pre and post challenge serum demonstrated SadA is immunogenic, 
stimulating an IgG and IgM response, though the relative antibody titres are enhanced by 
combination with alum. We were able to show SadA is expressed during infection, with a 
SadA specific IgM responses induced in the PBS control group 48 hours post infection. AB 
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Figure 6.19. SadA is immunogenic and provides limited protection against infection 
A). The experimental design of the challenge study. C57BL6 mice were immunised with 
either PBS only (control) or 10 μg purified SadA with or without Alum on two separate 
occasions prior to challenge with virulent SL1344. Blood samples taken prior to challenge 
(day 44) and immediately prior to sacrifice (day 46). B). Bacterial burdens determined as 
CFU/organ, for liver and spleen two days post challenge. Animals having received pre-
exposure to SadA, demonstrate limited protection against infection, compared to the PBS 
treated control group. C). IgG response to purified SadA from pre-challenge serum, expressed 
as relative amounts. SadA is clearly immunogenic and stimulates and IgG response, when 
administered alone, though this is enhanced by precipitation with alum. Control (PBS) group 
do not have an IgG response to SadA pre-challenge. D). IgM response to SadA is observed in 
the control (PBS) group 48 hours post challenge, but not pre-challenge, indicating SadA is 
expressed during infection. E). Bacterial burden per spleen from C57BL6 mice post five days 
infection with STm; SL3261 opsonised with heat-inactivated pre-challenge serum taken from 
animals exposed to either purified SadA or PBS only, to confirm the limited  protection 
observed in the challenge study is as a result of SadA antibody mediated response. Figure 
taken from Raghunathan et al (174). 
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responses stimulated by SadA were mildly protective, as determined by the 6.5 and 10 fold 
reduction in bacterial burdens in the spleen and liver of SadA-Alum treated mice, when 
compared to the PBS controls, p= <0.05 and p=<0.01 for spleen and liver respectively. SadA-
only treated mice showed a 10 fold reduction in bacterial burden in the liver (p=<0.01), 
though no differences were observed in the spleens.  
To confirm the protective effects were due to SadA mediated AB responses we 
opsonised S. Typhimurium SL3261, with heat inactivated (to destroy complement) pre-
challenge sera from either SadA only or PBS treated mice, prior to IP administration. 
Bacterial burdens were determined after five days and the SadA opsonised group displayed a 
similar, 10 fold reduction in spleen bacterial burdens when compared to the PBS opsonised 
group indicating SadA does induce an AB response that provides mild protection.  
 
6.3 Discussion 
Characterised type V proteins are typically virulence factors associated with wide 
ranging functions, including mediating serum resistance, binding to ECM molecules and 
adhesion and invasion of eukaryotic cells, including animal and plant cells (119, 138, 144, 
275, 276). Despite previous investigations into ApeE, MisL and ShdA from S. Typhimurium, 
the context of previous findings regarding substrate specificity of ApeE has not been linked to 
pathogenesis in any host, nor has the potential for functional redundancy been investigated 
despite the significant functional overlap observed for MisL and ShdA (123, 124, 135, 257, 
258). During this investigation we therefore aimed to characterise the functions of S. 
Typhimurium ATs proteins, with regards to pathogenesis in known hosts and vehicles of S. 
Typhimurium transmission. The investigations presented as part of this study have enhanced 
our understanding of several aspects; the role of S. Typhimurium AT proteins in murine 
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pathogenesis and their functional redundancy, the biological context of ApeE substrate 
specificity and how Salmonella exploit this to use fruits as a vehicle of transmission and we 
have provided the first peer-reviewed characterisation of a TAA from Salmonella (174).  
Previous characterisations of MisL and ShdA have shown both of these ATs are 
required for intestinal colonisation and faecal shedding (123, 135). Therefore, we chose to 
examine whether other uncharacterised proteins also contributed to virulence in the murine 
model. By examining bacterial burdens post oral and IP infection, we have confirmed SapP is 
required for full virulence. In contrast, SadA is not required to mediate infection in this host. 
These results partially conflict the recently published TRADIS data examining the role of 
non-essential genes in S. Typhimurium, whereby mutations in both sadA and sapP (annotated 
as yaiU) resulted in attenuated virulence in chickens, cattle and pigs but not mice, when 
administered orally (220). Our subsequent investigations of SadA are consistent with this 
hypothesis, in that we observed sadA expression was enhanced at higher temperatures, which 
parallel the normal body temperature of poultry, birds and livestock, which ranges between 
38.5-43.8
o
C, between resting and high activity states for birds respectively, while pigs and 
cattle range between 37.8–39.9°C (277-279). Suggesting this virulence factor maybe more 
critical for infection in other hosts. The differences between the literature and the results 
presented during this study for SapP cannot be easily explained and therefore require more 
extensive characterisation of this protein to determine its role in other aspects of pathogenesis.  
Despite reports of overlapping function between the previously characterised MisL 
and ShdA, this is the first instance where these genes in addition to the other ‘classical AT’ 
sapP (STM0373) have been deleted simultaneously, with the additional deletion of either 
apeE and/or sadA. This offers the unique opportunity to study the degree of functional 
redundancy among the type V proteins of S. Typhimurium and the contributions of ApeE and 
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SadA in absence of other Va proteins. Using these multiple deletion strains; we have been 
able to identify unique events previously unobserved in single deletion strains. For example, 
the persistent infection observed in the liver for strains retaining only ApeE may reside from 
ApeE’s functions as an esterase, potentially hydrolysing fatty acid substrates, including liver 
triglycerides for utilisation as a carbon source. This is consistent with our investigations 
showing ApeE is required for the hydrolysis of fatty acids and the characterised substrate 
specificity of thioesterase proteins from P. aeruginosa, responsible for the degradation 
triglycerides, including glycerophosphocholine (280). Unfortunately, due to the time 
constraints of the project, this phenotype has yet to be explored fully, and requires significant 
further investigation, though if found to be correct provides new insights as to the role of 
ApeE in persistent infection and would be the first report of ApeE functioning as a key 
virulence factor for the long term survival and persistence of S. Typhimurium infections in the 
mouse liver.  
Our investigations into the substrate specificity of ApeE has provided biological 
context to this previously known phenotype. During this study, we have shown ApeE is 
required for degradation of the tomato cuticle and identified the component, oleic acid, which 
ApeE most likely uses as a carbon source. Degradation of the cuticle allows the bacteria to 
both penetrate to the underlying sugar rich, fleshy tissues, but also provide a carbon source for 
growth during nutrient limiting conditions. This enhances our understanding of the role of this 
specific protein in the pathogenesis of numerous Salmonella serovars, but also expands our 
understanding of how bacteria uses fruit and vegetables as a vehicle for transmission to other 
hosts. In contrast to public perception, a leading cause of gastroenteritis caused by S. 
Typhimurium in developed countries, such as the USA and Canada, is as a result of 
consuming contained fruit and vegetables, with outbreaks in the USA now more commonly 
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attributed to this than poultry (152-154). A wide range of fresh produce has been attributed to 
outbreaks of Salmonellosis including melons, serrano peppers, lettuce and basil, but
 
most 
frequently to the consumption of contaminated tomatoes (281-287). Though previous 
investigations into the mechanisms by which Salmonella adhere to fruit and vegetables has 
largely focused on OM features such as flagella, curli, cellulose and O antigen, with 
mechanisms shown to be serovar specific in most instances (288). In contrast, little 
investigation has involved the role of type V proteins, with MisL being the first reported S. 
Typhimurium AT to be involved in adhesion to lettuce leaves (276). This study has uniquely 
provided evidence for a mechanism which is not serovar specific, in addition to characterizing 
the molecular pathways involved. We have confirmed the role of the catalytic serine, as with 
other GSDL ATs and the requirement for a function FAD system, for fatty acid uptake. 
Unfortunately, we have yet to confirm this substrate specificity with more physiologically 
relevant fatty acids, therefore future experiments are planned using cutin, to confirm both the 
role of ApeE in hydrolysis and also the utilisation of the fatty acid molecule as a carbon 
source for growth.  
Furthermore, our investigations characterising the specific roles of SadA and in part 
SapP, have shown the functions of this particular TAA and AT are unique from their 
respective homologues. TAAs for example are commonly associated with functional roles 
including regarding adhesion to eukaryotic cells and ECM molecules, biofilm formation and 
autoaggregation and serum resistance. Although we have been able to confirm roles for SadA 
in mediating phenotypes such as autoaggregation, biofilm and adherence to epithelial cells, 
we have shown the functions of this protein are susceptible to steric hindrance as these 
phenotypes could only be observed when using S. Typhimurium strains with rough LPS and 
with rough E. coli K12 strains. In contrast to the characterised role of EhaG and UpaG (SadA 
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homologues) from EHEC and UPEC, respectively, we were unable to identify binding of 
SadA to any ECM molecules. As described previously, we were also unable to clarify the role 
of SadA in mediating serum resistance.  
Although our investigations into the role of SapP are preliminary, we have determined 
key phenotypes for which SapP is associated and these may contribute to virulence of S. 
Typhimurium. In contrast to the homologue EhaB from EHEC, we have shown SapP is 
uniquely capable of binding collagen III, but also collagen IV and fibronectin, similar to that 
previously described for MisL and ShdA (123-125). This may in part contribute to the 
reduced virulence observed when sapP single mutants are administered orally. However, this 
hypothesis requires confirmation, by examining bacterial colonisation at specific 
gastrointestinal sites, such as the Peyers patches and MEL, in addition to in vitro assessments 
examining the adhesion of sapP mutants various epithelial cell lines. Unfortunately due to the 
time constraints these assays have yet to be performed, though the outcomes will significantly 
contribute to our understanding of the role of this protein in pathogenesis.   
As type V proteins contribute large surface structures which in the cases of MisL, 
ShdA and SadA, are known to be expressed during in vivo infection, we wanted to examine 
their potential as suitable vaccine candidates for future investigations. Unfortunately, we have 
only performed these investigations for SadA; this protein is immunogenic, promoting an IgG 
and IgM AB response that is mildly protective against infection. Unfortunately, limited IgA 
responses were observed, however this maybe relate of the route of administration (this study 
IP) as it has been shown previously that oral administration induces a more significant 
secretory IgA response (289). However, the challenges associated with oral administration 
(i.e., protein stability and folding on transit through the stomach) make this an unfavourable 
route for the assessment of vaccine efficacy.  
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Although alone SadA would not be suitable as a vaccine candidate, this does raise the 
possibility that it may provide a suitable component towards a multivalent vaccine against S. 
Typhimurium. Within our group, current investigations are underway to express all S. 
Typhimurium AT proteins using the Pet AT platform of secretion (106), to provide a means 
of investigating the immunogenicity of all these proteins and their potential as vaccine 
candidates, examining their ability to induce specific AB and memory mediated T-cell 
responses. 
As described above, due to the time constraints many aspects of the project are still at 
the preliminary stages, though provides numerous avenues for further investigation; including 
i). the further characterisation of SapP, to confirm how this protein contributes to specific 
phenotypes associated with virulence. ii). How regulation of ATs and the TAA SadA is 
affected by single or multiple deletions of other type V proteins in these strains, i.e. could 
increases in protein expression account for alterations in phenotype? iii). how does deletion of 
these ATs affect adhesion and invasion of epithelial cell lines and does this correlate with an 
effect during oral infection and gut colonisation; do proteins like ApeE and SadA contribute 
to virulence and colonisation in the absence of known factors such as MisL and ShdA? iv). 
How does removal of these large surface structures affect AB and T cell responses against S. 
Typhimurium, for example is there an elevated LPS specific AB response? Studies are 
planned to investigate these avenues further to enhance our understanding of this family of 
proteins in S. Typhimurium virulence and survival in various hosts, and further explore their 
potential  as multivalent vaccine candidates of the future.  
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CHAPTER 7 
 
FINAL DISCUSSION 
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The investigations presented as part of this study have enhanced our understanding of 
OM homeostasis in two separate Gram-negative bacterial strains, the evolved laboratory 
strain E. coli K12 and the broad host range pathogen S. Typhimurium providing insight into 
three main features; the roles of nonessential genes in maintaining membrane barrier function, 
the mechanism by which OM phospholipids are localised and the roles of S. Typhimurium 
ATs in virulence. The impacts of these findings are discussed below. 
 
Membrane homeostasis and virulence 
 The role of nonessential genes in maintaining cell envelope homeostasis has been 
investigated previously by numerous groups. Early investigations charactered the roles of 
periplasmic chaperones and OM localised components commonly noting their association 
with maintaining membrane integrity (19, 69). However, no large scale high throughput 
screen had been performed in order to determine all the nonessential genes required for OM 
homeostasis. Shortly after commencing our investigations a series of publications were 
released utilising the same collection with alternative approaches, to answer similar question 
(199-201). In the midst of these publications we chose to continue our screen, but provide 
further insightful characterisation of the mutants identified. We have therefore characterised 
the mutations identified to provide mechanistic evidence for the means by which these genes 
contributed to barrier function. Our investigations predominantly focused around nonessential 
genes in the E. coli K12, strain BW25113, though we have also investigated a selection of 
these mutants in S. Typhimurium, to further explore the roles of these genes in a 
physiologically relevant human pathogen. Our investigations in E. coli K12 have highlighted 
potential secondary roles for genes of predicted function, with the identification of efflux 
defects in the yibP and yciM mutants. We have highlighted a series of mutations resulting in 
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the excessive production of membrane vesicles and potential periplasmic leakage, phenotypes 
which are of significant interest due to their wide ranging biological applications, in respect of 
recombinant protein production and vaccine development.   
Due to the nature of E. coli K12, we felt that further investigation in a physiologically 
relevant strain was required to confirm both the phenotypes and examine the roles of these 
genes in pathogenesis. By recreating these mutants in S. Typhimurium we have been able to 
demonstrate that in some instances the defects are consistent, highlighting the similar 
functions and mechanisms of OM homeostasis across different organisms. Investigations 
using the murine model of S. Typhimurium infection have provided further insight into how 
these proteins contribute to virulence, particularly highlighting how the route of 
administration can significantly affect the observed results. Our data is relatively consistent 
with that of orally dosed S. Enteritis bamB mutants (242). However, this study also indicated 
how complex in vivo infection experiments require careful interpretation; mild  attenuation in 
bacterial burdens can have a significant effect on lethality and the outcome of infection. 
Importantly, our investigations give promise for the potential use of these proteins as targets 
for future drug development.  
 
Biogenesis of membrane components  
 Despite the significant advances in our understanding of the biogenesis of key outer 
membrane components, including the identification of the BAM complex, Lpt and Lol 
pathways, the OM phospholipid transport pathway has remained recalcitrant to identification. 
The investigations presented as part of this study have provided significant insight into key 
questions regarding phospholipid transport.  
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Phospholipid transport 
Previous investigations on phospholipid transport have predominantly focused on the 
pathways and proteins responsible for retrograde trafficking and recycling of OM 
phospholipids. The identification of the Mla pathway, PldA and PagP proteins are responsible 
for recycling and degrading phospholipids. By either transporting these back to the IM or 
catalysing their degradation, through the removal of fatty acids and palamite, respectively 
(71-73). In contrast our investigations and characterisation of plpA has provided the first 
experimental evidence for the mechanisms of phospholipid transport to the OM, with specific 
regard to PG and CL are trafficked across the periplasm for insertion into the inner leaflet. 
Consistent with previous hypotheses, we have shown for the first time an inner leaflet 
localised lipoprotein, PlpA, is responsible for this function. Through lipidomic analysis we 
have confirmed the altered lipid composition of the OM in plpA mutants, is caused by the 
absence of PG and consequentially resulting in elevated levels of PE.  
Our collaborators have determined the NMR structure for PlpA, providing the first 
structure for a dual BON domain containing protein. Using NMR analyses and mutagenesis, 
we have been able to identify and confirm the roles of particular residues, critical to both 
stability of the protein and its’ function in binding PG. We confirmed PlpA binds PG and CL 
at one face of α helix 3. Site directed mutagenesis and random insertion sequences at these 
sites confirm these results with the abolition of protein function whilst maintaining structural 
integrity of the protein. In addition, we have confirmed the importance of other residues 
located in the BON1 and BON2 domains. 
This data provides the first experimental evidence for the role of BON domains in 
binding phospholipids emphasizing the need for further investigation into the functions of 
other BON domain containing proteins. Despite enhancing our understanding of phospholipid 
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transport, key issues remain unresolved, including how PlpA identifies phospholipids ready 
for transport from the IM and subsequently releases these into the inner leaflet of the OM? 
Does BON1 play a role in this aspect of function? We have shown several residues in this 
domain are critical to protein function, though none of these are required for substrate binding 
questioning how the interaction of BON1 and BON2 enables functionality, i.e. does the 
interaction of these domains initiate substrate binding or release at the membrane? Further 
investigations into the biochemical mechanism of PlpA function will aid our understanding of 
this process. 
Importantly, the identification of PlpA has highlighted the fact that the mechanism by 
which PE is translocated and inserted into the OM remains unknown, as PlpA was shown to 
only bind PG and CL. Therfore, an alternative pathway must exist for the transport of PE to 
the OM.  
Despite our investigations, with double mutations in plpA and mlaA-F, pagP and pldA 
providing an element of confirmation for the role of PlpA in maintaining inner leaflet 
phospholipid content, these studies have further emphasized that maintaining membrane 
stability is a highly complex process. These mutations could only counteract sensitivity to 
vancomycin but not to SDS. In the absence of the SDS suppressor mutant sequencing data it 
is impossible to draw conclusions as to the means by which resistance to this compound is 
restored. However, this data will provide further key insights as to the functions of this 
protein and the mechanisms by which Gram-negative bacteria maintain a selectively 
permeable OM. 
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The identification of the TAM complex 
Previous investigations have highlighted an array of proteins involved in the transport 
and biogenesis of AT proteins, including the role of periplasmic chaperones (including HlpA, 
SurA, DegP and FkpA) and the BAM complex components BamA and BamD (16, 100, 244). 
Though these investigations have failed to address the mechanisms by which AT passenger 
domains become surface localised. Until recently several theories have existed regarding the 
route of passenger doamn transport to the bacterial cell surface. These included BamA 
enabling the AT barrel to be held in a semi-folded conformation to allow an extended pore 
diameter through which the passenger domain could be transported and the hairpin model, 
requiring passenger domains to be extruded as a linear polypeptide before folding on the 
surface (90). Through collaboration with other groups we have identified and characterised a 
new OM secretion complex, termed the TAM complex (103).  
Our investigations into the components of this complex in S. Typhimurium 
contributed indirect supporting evidence for the role of this complex in AT passenger domain 
surface display, particularly regarding the heightened serum sensitivity of these mutants. 
However, our in vivo investigations failed to show significant defects in systemic infection for 
tamB mutants.  Although our investigations did not clarify the mechanisms by which TAM 
associates with BAM and AT precursors to aid in there secretion, these new findings need to 
be reconciled with the previous theories of AT secretion. Additionally, the role of ytfP 
(transcribed in the same operon as tamAB) in this complex has yet to be clarified. 
Interestingly, our investigations suggest a potential role for this gene product in resistance to 
innate immune responses, however this requires additional investigation to both confirm this 
hypothesis and determine the means by which this is mediated. Further investigation of this 
complex may provide key insights as to the fundamental aspects of AT biosynthesis. 
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Roles of S. Typhimurium autotransporters in virulence 
Numerous studies have investigated the role of AT proteins in virulence and the 
specific phenotypes they are responsible for. However, previous investigations on the ATs of 
S. Typhimurium have largely focused on only two of the five proteins encoded by S. 
Typhimurium viz. MisL and ShdA. While one study examined the potential for functional 
overlap between these two proteins, the study failed to account for the other type V proteins, 
namely ApeE, SadA and SapP. To address this issue, we have created a series of deletion 
mutants removing all ATs from S. Typhimurium. By examining the ability of these mutants to 
colonise and cause persistent infection in vivo, we have identified unique events that were 
otherwise unobservable in the single mutants, including the role of ApeE as factor for 
persistent colonisation of the liver.  
This investigation has highlighted a number of additional questions for further 
investigation, including how multiple deletions of AT proteins affects the transcriptional and 
translational regulation of the remaining ATs. Do ATs including SadA and ApeE have a more 
pronounced role in intestinal colonisation, in the absence of factors such as MisL and ShdA. 
How does the removal of these large surface structures affect immune recognition and 
responses to the bacteria? Future investigations directed at answering these questions will 
enhance our understanding of the role of S. Typhimurium AT proteins in virulence and their 
specific phenotypes. Additionally, experiments are planned to further investigate the substrate 
specificity of ApeE, to address its potential role in liver colonisation.  
 In addition to ApeE’s potential role in liver colonisation we have confirmed a role for 
this protein in the survival of Salmonella enterica serovars on tomato’s, providing biological 
significance to the previously known phenotype of Tween-80 degradation and utilisation as a 
carbon source.  Until recently this was the first description of a S. Typhimurium AT protein 
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participating in virulence outside of an animal model. Further investigations are planned to 
assess other potential substrates also highlighted during the BioLog screen of 2000 carbon 
sources. These studies will enhance the results presented here, and provide novel insights into 
the role of this largely ignored AT protein.  
Furthermore our investigations into the specific roles of SadA, have provided the first 
peer reviewed characterisation of a TAA from Salmonella (174). We have shown in contrast 
to other TAAs SadA is not required for serum resistance, though in the absence of other Va 
proteins, SadA is more critical. Despite sadA single mutants not being attenuated in the 
murine model, our in vitro investigations have suggested that this particular virulence factor, 
maybe associated with S. Typhimurium infection in other hosts, particular birds, cattle and 
pigs which demonstrate higher natural body temperatures consistent with temperatures shown 
to increase SadA expression, emphasizing the need for more investigation using alternative 
models.    
Key to our investigations, we have shown SadA is immunogenic and can afford 
limited protection against infection. We plan to further investigate the immunogenicity of 
other Type V proteins from S. Typhimurium, with the view to identifying suitable 
contributors to a multivalent vaccine. Whilst these proteins only induce a mild attenuation 
upon deletion, as shown with OmpD from S. Typhimurium which is a protective antigen 
(131), it remains possible they will induce a suitable protective memory based immune 
response against infection. 
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APPENDIX  
Appendix Table 1 – Primers used in this study 
Gene Disruption 
Name Sequence (5’→3’) Description 
Fwd 
apeE 
DW 
TGGTGCCAAACGTACCGGAT
TTAGTGCGACGCCAATGCGT
GTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to apeE 
Rvs 
apeE 
DW 
ACGGCACCATGACAAAATC
ATACCGCTGGTTAACCTCGC
GGGAATTAGCCATGGTCCAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to apeE 
Fwd 
bamB 
DW 
GCTTTCCGTTACCCTGCTCA
GCGGCTGTTCACTGTTTAGC
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamB 
Rvs 
bamB 
DW 
GGGCCACAAAACGCCCGTC
ATCGACATTAATCCAGTGCA
GATGGGAATTAGCCATGGTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamB 
Fwd 
bamC 
DW 
GCTTACTCAGTACAAAAGYC
GCGCCTGGCGAAGGTTGCGG
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamC 
Rvs 
bamC 
DW 
TTACTTGTTGAACGCTGCCT
GGAAGAACGGCAACCAGCG
CGTCGGGGAATTAGCCATGG
TCCAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamC 
Fwd 
bamE 
DW 
CGCTGTAAAACGCTGACTGC
TGCCGCAGCAGTACTCCTGA
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamE 
Rvs 
bamE 
DW 
CTTCGTCAACGCCGGTTTAT
CAATATTGGTTAACACGATG
GGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium bamE 
Fwd 
degP 
DW 
CTGGCTCTGAGTTTAGGTTT
GGCATTGTCGCCTCTGTCTG
CGTGTAGGCTGGAGCTGCTT
C 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium degP 
Rvs 
degP 
DW 
CACCACGCTGAATATTGAGC
GCCAGAACCGACGGCTTGCA
TGGGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium degP 
Fwd 
fkpA 
DW 
ACTACGATGGCCGTTGCTAT
GCACGCACCGATCACTTTTG
CGTGTAGGCTGGAGCTGCTT
C 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region in 
blue) with 40 bases homology to S. 
Typhimurium fkpA 
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Name Sequence (5’→3’) Description 
Rvs fkpA 
DW 
AGCCGCATCGGCAGGTTTAG
CATCCGCTTTCGGCGCTGGA
ATGGGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium fkpA 
Fwd hlpA 
DW 
GCTGCAGGTCTTGGTTTGGC
GATGGTAACGTCCGCACAGG
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium hlpA 
Rvs hlpA 
DW 
GCGGTGATGTCTTTCACATC
GCTGCTGTTGTAAGCAACGA
TGGGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium hlpA 
Fwd misL 
DW 
GCATCTACGTGGATGGTCAG
GATGGTGACGGTATTAACGC 
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to misL 
Rvs misL 
DW 
CAATGGTTTGCGCCCCGGCT
CCTCCAATATTATTTACTGC 
GGGAATTAGCCATGGTCCAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to misL 
Fwd plpA 
DW 
GCGTTGCTATTGCAAGGTTG
CGTCGCCGCCGCGGTAGTGG
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium plpA 
Rvs plpA 
DW 
CTGCCGCTTTACCTTCACGTT
CAGTCACCAGGCCCAGCAG
ATGGGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium plpA 
Fwd sadA 
DW 
TCGGTCTTAGCAGCATTATG
GTTTCTGCGGA 
TGCACTGGCGTGTAGGCTGG
AGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to sadA 
Rvs sadA 
DW 
GTCGTATTGGCGGCGATATC
GGTTGTGTTCT 
GGTTAATGCGGGAATTAGCC
ATGGTCCA 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to sadA 
Fwd sapP 
DW 
TACGATACCTGGACTTATTA
CGACAATCCTACCACCGCGC 
GTGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to sapP 
Rvs sapP 
DW 
ACACCAACGTTTGCAGACCA
GTCTTGATCAACATCACCGC 
GGGAATTAGCCATGGTCCAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to sapP 
Fwd surA 
DW 
GTATCGCCATGATCGCGAAT
ACCAGTTTCGCTGCCCCCCG
TGTAGGCTGGAGCTGCTTC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium surA 
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Name Sequence (5’→3’) Description 
Rvs surA 
DW  
GGCGCGCTGTTCTTGCATCC
AGGTCGCCGCTTCTTCTGAC
ATGGGAATTAGCCATGGTCC 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium surA 
Fwd tamB 
DW  
AGCCTCGGCGTGTTGATTTT
CATTGTGGTGTTACTGGCGA
GGTGTAGGCTGGAGCTGCTT
C 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium tamB 
Rvs tamB 
DW  
GCAAATCAAGTGCCTGATCT
ACGCCAGACACTGCTTCCAG
GGGAATTAGCCATGGTCCAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium tamB 
Fwd ytfP 
DW  
AGTTTACGACAGAAACAAG
GCAACAGTCACTGGATGACC
AGTGTAGGCTGGAGCTGCTT
C 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium ytfP 
Rvs ytfP 
DW  
CCAGTCACCGCTTTCAATCA
GAGTTAACCCATGAACAGG
ACGGGGAATTAGCCATGGTC
CAT 
For amplification of kanamycin resistance 
cassette (from pKD4, homologous region 
in blue) with 40 bases homology to S. 
Typhimurium ytfP 
Fwd pDOC 
tamA 
TAGGGATAACAGGGTAATTC
CAGGGGTGGGAATAGGGGA
TATTCAGGAGAAAATGTGGA
CCGGTCAATTGGCTGGAG 
For amplification of kanamycin resistance 
cassette (from pDOC-K, homologous 
region in Blue) with 40 bases homology to 
tamA (black) and I-SceI site (Green) 
Rvs pDOC 
tamA 
ATTACCCTGTTATCCCTATC
ATAATTCAGGCCCCAGACCG
ATATAAAACTGTAAACCAAT
ATCCTCCTTAGTTCC 
For amplification of kanamycin resistance 
cassette (from pDOC-K, homologous 
region in Blue) with 40 bases homology to 
tamA (black) and I-SceI site (Green) 
Cloning Primers 
Name Sequence (5’→3’) Description 
Fwd apeE 
pQE60 
CGCGCGAGATCTCATATGAC
CCAAAAGCGTACCCTGC 
For amplification of apeE, containing an 
NdeI site (Blue), for cloning into pQE60 
Rvs apeE 
pQE60 
GCGCGCGCTAGCAAGCTTCA
AAATCGGGCGCTAAACCCA
ACG 
For amplification of apeE, containing an 
HindIII site (Blue), for cloning into pQE60 
Fwd apeE 
frag MP 
GGGCATATGACCCAAAAGC
GTACCCTGC 
For amplification of partial apeE gene to 
produce a fragment containing NdeI site 
(Blue) for use in mega primer reactions 
Rvs apeE 
frag MP 
GGGCCATGGTTGGTTGCGCG
ATGGCCGCCGCC 
For amplification of partial apeE gene to 
produce a fragment containing NcoI site 
(Blue) for use in mega primer reactions 
Fwd 
apeES10A 
pQE60  
ATTACCGGTATCGCTAAGGG
CATCGCCAATCACCG 
Fwd primer for mega primer reaction to 
mutagenise apeES10A,  with alterations 
shown in blue 
Fwd apeE 
pET22b 
TCCATATGACCCAAAAGCGT
AC 
For amplification of apeE, containing an 
NdeI site (Blue), for cloning into pET22b 
Rvs apeE 
pET22b 
TCGAATTCCTGTTAGTGAAC
ATCCGG 
For amplification of apeE, containing an 
EcoRI site (Blue) for cloning into pET22b 
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Name Sequence (5’→3’) Description 
Fwd E. coli 
plpA pJH10 
TATAGAATTCATGAAGGCAT
TATCGCCAATCGC 
For amplification of E. coli plpA, 
containing an EcoRI site (Blue), for 
cloning into pJH10 
Rvs E. coli 
plpA pJH10 
CGGGGAGCTCCTATTTAATA
AACGTAAACGCCGTAG 
For amplification of E. coli plpA, 
containing an SacI site (Blue), for cloning 
into pJH10 
Fwd STm 
plpA 
pET17b 
and pQE60 
TATACATATGAAGGCATTTT
CGCCGCTCG 
For amplification of S. Typhimurium plpA, 
containing an NdeI site (Blue), for cloning 
into pET17b and pQE60 
Rvs STm 
plpA 
pET17b 
and pQE60 
GCCGAAGCTTTTACTTAATA
TACGTAAAGGCGG 
For amplification of S. Typhimurium plpA, 
containing an HindIII site (Blue), for 
cloning into pET17b and pQE60 
Fwd plpA 
pET17b 
and 
pET20b 
GGGAATTCCATATGAAGGCA
TTATCGCCAATCG 
For amplification of E. coli plpA, 
containing an NdeI site (Blue), for cloning 
into pET17b and pET20b 
Rvs plpA 
PET17b 
CCGGAATTCCTATTTAATAA
ACGTAAACGC 
For amplification of E. coli plpA, 
containing a EcoRI site (Blue), for cloning 
into pET17b 
Rvs plpA 
pET20b 
CCGCTCGAGTTTAATAAACG
TAAACGCCGT 
For amplification of E. coli plpA, 
containing a XhoI site (Blue), for cloning 
into pET20b  
Fwd sadA 
pQE60 and 
pET22b 
GGAAATTACTACTCACATAT
GAATAGAATAT 
TTAAAGTC 
For amplification of sadA, containing an 
NdeI site (Blue), for cloning into pQE60 
and pET22b 
Rvs sadA 
pQE60 
GCTACTAAGCTTTTACCACT
GGAAGCCCGC 
For amplification of sadA, containing an 
HindIII site (Blue), for cloning into pQE60 
Rvs sadA 
pET22b 
AGAGTTAATTTAGAATTCTG
TGAGTAGGCTG 
TGG 
For amplification of sadA, containing an 
EcoR1 site (Blue), for cloning into pET22b 
Fwd sapP 
pQE60 
CGCGCGAGATCTCATATGCA
CTCCTGGAAAAAGAAAC 
For amplification of sapP, containing an 
NdeI site (Blue), for cloning into pQE60 
Rvs sapP 
pQE60 
GCGCGCGCTAGCAAGCTTAC
CAGGTATATTTAACACC 
For amplification of sapP, containing an 
HindIII site (Blue), for cloning into pQE60 
Fwd sapP 
pET22b 
ACCCATGGACTCCTGGAAAA
AGAAACTT 
For amplification of sapP, containing an 
NcoI site (Blue), for cloning into pET22b  
Rvs sapP 
pET22b 
GAATTCCTGTAGTGGCTTGC For amplification of sapP, containing an 
EcoRI site (Blue), for cloning into pET22b 
 
 
 
 
 
Salmonella Typhimurium Check Primers 
Name Sequence (5’→3’) Description 
Fw apeE Check CAGGATAATACCGCGG Flanking (approx. 200 bases upstream) to 
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Flank ATCA apeE, to confirm the excision of apeE 
Rvs apeE Check 
Flank 
CTGTTAGTGAACATCCG
GCT 
Flanking (approx. 200 bases downstream) 
to apeE, to confirm the excision of apeE 
Fwd bamB Check 
Flank 
AGTTGCAGCTTAAGCA
AGCC 
Flanking (approx. 200 bases upstream) to 
STm bamB, to confirm the excision of 
bamB 
Rvs bamB Check 
Flank 
CAGACGGTTAAATAGC
GTGG 
Flanking (approx. 200 bases downstream) 
to bamB, to confirm the excision of bamB 
Fwd bamC Check 
Flank 
GTCGAACCCAATCCTATC
CC 
Flanking (approx. 200 bases upstream) to 
bamC, to confirm the excision of bamC 
Rvs bamC Check 
Flank 
CATTTCCTGCTACGCCTG
CC 
Flanking (approx. 200 bases downstream) 
to STm bamC, to confirm the excision of 
bamC 
Fwd bamE Check 
Flank 
GAACTGCTGGCGGCGT
AAAC 
Flanking (approx. 200 bases upstream) to 
bamE, to confirm the excision of bamE 
Rvs bamE Check 
Flank 
CCAGCGCGCCGAAAAA
TCGG 
Flanking (approx. 200 bases downstream) 
to bamE, to confirm the excision of bamE 
Fwd degP Check 
Flank  
CTTTATTCCGGAACTTC
GCG 
Flanking (approx. 200 bases upstream) to 
degP, to confirm the excision of degP 
Fwd fkpA Check 
Flank 
ATGGTAATCTCCTGGA
ACGC 
Flanking (approx. 200 bases upstream) to 
fkpA, to confirm the excision of fkpA 
Rvs fkpA Check 
Flank 
CAGTGAGGGTTCATCTT
TCC 
Flanking (approx. 200 bases downstream) 
to fkpA, to confirm the excision of fkpA 
Fwd hlpA Check 
Flank 
AGATGTACCGGATTAC
AGCG 
Flanking (approx. 200 bases upstream) to 
hlpA, to confirm the excision of hlpA 
Rvs hlpA Check 
Flank 
CACGGTACTTAGGATTC
ACC 
Flanking (approx. 200 bases downstream) 
to hlpA, to confirm the excision of hlpA 
Fwd misL Check 
Flank 
CATAGCGGTATCAGCAGC
AT 
Flanking (approx. 200 bases upstream) to 
misL, to confirm the excision of misL 
Rvs misL Check 
Flank 
CGGCTCTGTTGTTACCTG
AA 
Flanking (approx. 200 bases downstream) 
to misL, to confirm the excision of misL 
Fwd plpA Check 
Flank 
ACACCACAGCGCGCGCAT
TC 
Flanking (approx. 200 bases upstream) to 
STm plpA, to confirm the excision of plpA 
Rvs plpA Check 
Flank 
CCATGCTGGCGGAAGCGC
TG 
Flanking (approx. 200 bases downstream) 
to STm plpA, to confirm the excision of 
plpA 
Fwd sadA Check 
Flank 
AGTCCTCTGGAATGCC
GCTA 
Flanking (approx. 200 bases upstream) to 
sadA, to confirm the excision of sadA 
Rvs sadA Check 
Flank 
TTGTGCTTAGCGCTGAA
TGC 
Flanking (approx. 200 bases downstream) 
to sadA, to confirm the excision of sadA 
Fwd sadA Check 
Internal 
TGTGGGATGAAAGCAT
CAGC 
Internal approx. 400 bases inside the start 
of sadA gene 
Rvs sadA Check 
Internal 
ATCGCGGAGGCTTTAT
AACC 
Internal approx. 200 bases upstream of 
gene disruption end  
 
Salmonella Typhimurium Check Primers 
Name Sequence (5’→3’) Description 
Fwd sapP Check GCACTCTGGCAATCACT Flanking (approx. 200 bases upstream) to 
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Flank TCT sapP, to confirm the excision of sapP 
Rvs sapP Check 
Flank 
GAATTCCTGTAGTGGCT
TGC 
Flanking (approx. 200 bases downstream) 
to sapP, to confirm the excision of sapP 
Fwd surA Check 
Flank 
GCGCCGTCCGCACAGACG
AC 
Flanking (approx. 200 bases upstream) to 
STm surA, to confirm the excision of surA 
Rvs surA Check 
Flank 
CTACGGCCTCGGCACGCA
AG 
Flanking (approx. 200 bases downstream) 
to STm surA, to confirm the excision of 
surA 
Fwd tamA Check 
Internal  
CGAGTTGATGATGCGA
TTCG 
Internal to tamA, to check for complete 
excision/duplications of tamA  
Rvs tamA Check 
Internal 
GCGAAGAAACGTAAAT
CCGG 
Internal to tamA, to check for complete 
excision/duplications of tamA 
Fwd tamA Check 
Flank 
TGTTAAGCCGTTTAACGG
CG  
Flanking (approx. 200 bases upstream) to 
tamA, to confirm the excision of tamA 
Rvs tamA Check 
Flank 
GACCTGAATGTCTTTCA
GCG 
Flanking (approx. 200 bases downstream) 
to tamA, to confirm the excision of tamA 
Fwd tamB Check 
Flank 
CGAAGTTGATAACCGGAT
CG 
Flanking (approx. 200 bases upstream) to 
tamB, to confirm the excision of tamB 
Rvs tamB Check 
Flank 
AACGTACATCCATGCA
CTCC 
Flanking (approx. 200 bases downstream) 
to tamB, to confirm the excision of tamB 
Fwd ytfP Check 
Flank 
TGGCGTAAGCAATTTAGC
GC  
Flanking (approx. 200 bases upstream) to 
STm ytfP, to confirm the excision of ytfP 
Rvs ytfP Check 
Flank 
TAATACGCATCTGCACCT
CC  
Flanking (approx. 200 bases downstream) 
to STm ytfP, to confirm the excision of 
ytfP 
E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
aceE ACAGAAGTCGTGAAGAGAGC TCTCTTTAACGATACCCGCC 
aceF TATCGCTCAGGTGATGAACG GTAATACCCTAACCACCACC 
ackA GGTGTCATCATGCGCTACGC CAGCCGACGCTGGTTCCGG 
acrA AATGCCAGTAGATTGCACCG GCAATCGTAGGATATTGCGC 
acrB CGGATGACAAAGTGGAAACC CGTATGAGATCCTGAGTTGG 
ada TCACCAAAGAAGGCGATAGC   AGAGATAACCTTGCCGATGG 
aer GATGATTGCTGCGCAAATGC CAGAGCGATATCAGTGATGC 
afuB GCATAACCTGAATCTGAGGC ACACCATACAGATATCGCGC 
agaD CTGCGCGTAATGTTCAAAGC ATACGTCAGTAATGGCGTGG 
ampD CTGTTCCGCCTAAATCTTCC CGTTGAACAATACTCCCTGC 
aslA GCCTTACATATCAACTGCGC TATGCATGCGCATTTGCTGG 
asmA TGCTGGAGTTCTACAACTCC CTTGAGCGTTCCATAGTAGC 
aspC TGCTGTGGGTATCGTTTACC TGGATTTCTGGCAAAGTGCG 
asr ATTGCCAGCTCAAACCAACG AATACTATAGACGGGACGGG 
astB GTTCGATCAACTGTTGCTGG GTATTCCCGCTGAAATCACC 
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Gene Forward Reverse 
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atoA TAATTCGCGCTCATCGTTGC ATAAGCGCCATCTGCATACC 
atpA ACTGAGTGAACAACAGCTCG ATGCGATCCTGCGATTTACG 
atpB TAAAGGCGGTATTCTTGCCG AAAGCAACGCTTACTACGCG 
atpC CATCATGGAAGGCGAATACG CATCGTGAAATGGACAGAGG 
atpD ATCTCAGGTTTATCAGGGCG TAAACTCTTCGTGACCGTGC 
atpE GTTCGGTAACATGTATGCCG TCGATGGCTGCCATTAATGG 
atpF CGTCAACCYGATCTGATTCC AGTTGCTCACCACAAACTGC 
atpG AAATTGGCAGCTTCGAAGCC TTTGCACCTCAAGAGCATCG 
atpH ATTCTGGACGAAGCGAAAGC TTCAGTGCGATAGCGTAACG 
bglA TTTCAGTCAGCGTATCCAGC TCGCGTTAAGTCGAACATCC 
bglF AAATTACCCGCAAGCATGGC ATAACGCGATATCTTCCGGG 
bglJ TGCATGGATAAATAGCGCGC TGAGATGAAGCAACTGCTCG 
caiF TAGCTCACACTTATCGACGG   GACGAGTTACACTGGAAACG 
celC TGGGAGCCTTCTTTAACACC ATCTCCTGGAAATAACGCCC 
chaB TAAGCGAAGTCTCCTTGTGG  TTCAATGGCACCAAATGCCG 
cheA AAAGTGTTACGTGTCGTCGG  ACGCCTTTGATAAACGCTGG 
cheB  TACTGGCGAAACAGTACACC  ACAAATCCATAACCGCCTGC 
cheY TGTTGTTCCATTCTGTCGCC TCCATTTGATCCTGATGCGG 
chpA ACAGTAGCGTAAAGCGTTGG TTCTTCAAGGGTGTAAGGCG 
cmk GTCCATGTTTGACTCTCACC   ATAGCAACAACAACGCCACG 
coaE TGGCTATAAGGGTAAGAGCG  TCTTTCAACAGCTCAGTGCG 
cpxA TACCCTGCTCTATTTGCTGG TATCACCGTTTACTCTCCGC 
cpxR TAATGAACTGACTGCCAGCG CCACATTAAATCGTTGGGCG 
csiE ACTAACCCATGATCGCTAGC    GGTGCAAATTCTGCATTGCG 
cueR TATCTACAGTCTGTGGTCCC AGTCATTTAAACCAGCGCGG 
cusA TTTGTACCGAAACGCGTTGC CCAAGAAACAGACCAGTACC 
cusB AGGGTATCGATCTGGAAAGC TGGTTAGCGGATAAGTCACC 
cusS TATCTGCTGCGTTAACCAGG TCAGGGTGATTTAGTACCCG 
cvpA AATACGGTCTTGCCTGATGC AAATACATCGCTCACCAGCC 
cydB TGGTTCGTGGCTGAATATGG TTCCAGTTCACTGGTCTTCG 
cysB GATGGCAAATGGGTTGAAGG GCAAGACGTTGAACGATTGG 
cysE GCAATACGAAAGAAGTCCGC GCGATTATCTGATGTTCGGC 
cysE GCAATACGAAAGAAGTCCGC GCGATTATCTGATGTTCGGC 
cysI TGACACGTATCGATCTTGCC TTGATTCACCAGATGCAGGC   
dacB TGATAGGGCAAGTCTTCACC TGATGAAGACTGGGATGACG 
dapF GAAAGGTCCGCTCTATTTCC GAATATGATTACGTGCGCGG   
dcuR AACATTGCACTACCGTCACG CTGATCTACCCATTTGTGGG 
dedD TGATGACTGGTATTGTGCGC TTTATGCCTTTGCGGCATCG 
degP GGAACTTCAGGCTATAAAAC GAAGATGTATGGAGTTGTGG 
 
 
E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
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degQ GGCGCAGCCATTGCGCCCTC GGAACGGCAGCAGCATACC 
deoB TGACACCATCGATTACAGCG TTGTAAGTACCGGTGAAGCC 
dgoK TAGCATTGCGATCAGTTCGC ATGCTTTGCTCCCATTGTGG 
dksA CGGAAATTTCTGCTGAAGGC CGGGTCGATATCTTCTATGC 
dnaJ TGAAGACAAAGCCGCTATCG TCAGGCGTAATACCACAACC   
dpiA GATGTGGTGATTGAAGTCGC TTTGACTATCCCGATGCTGC 
dpiB TCCTAAGGAGTATTTCGGCG TTAATCCCTCTACCGTCAGG 
dppD TATGGCTGCTCTTGGTTTCC TCAATCATCGTCAGCAACCG 
dsbA CTGATTGAACCTTTACGCGC ACACCTGTAGCTGACTTACG 
dsbB GGTTTATGCAAATGGGCTGG   CACTGAATGCTAAAGAGGGC 
dsbD GGATAATCCACACGTTCAGC GGATAATCCACACGTTCAGC 
eda ATCCACGTAACACCAGAAGC TGACCAGTCAGAATGTCACG 
ego  TCCCTGTTCTGAAATTGCCG CACATTCCGGTAATCGAACC 
elaD ACTGGCGAATGATTTCACCG GTTACGCGGTTCTGAATACC 
emrA GCAAATCACCCGCAAATTGC   CCCGAAAGAAGTGATTACCC 
emrY AAATCGTTCAGCGTGTACCG TTTCAGCGCAGAACAACTGC 
envZ TGAGTTTGCGGTACTGAAGG ACACGAAGATTCTCGATCCG 
exbD TCAAAGACCAGCGAAGAAGC GTTCACCTTCACATCTACCG 
fabH CAAGTTCCTCAGCGAATTGC CAACAGATGCAGTCAACAGC 
fadD ACGTTGGCATTTAACCCAGC TTCAGTATCCAGGGCTATCG 
fadL ACTTGCAACATTCCAGCTGG GTGTATGAGCGCACAATAGC 
fadR GATCTCCATGATGGTTTCCC   AGAAGTCCTGAAGCATGTGC 
fbp TACTTCATGGCCTAACTGG TTGGAACGGTATTAGGGACG 
fcl TGATTATCGCTGTTGACCCG AAACTGGCCTGCTGTTATCG    
fdhE GATCCGATTCGCGTTAATGC CTTGTCATCAGTCTCATGCC 
fdx AGAACGTCAGGTCATTGACG GAAATTATTCGGCCTCGTCC 
fepA TTGCAATAGCGTAATGGCGC TCGAGACTGATGACAAACGC 
fepB TGATGGATTCGCATAAGCGC    GATGTTAGGGCGGATTAACG   
fepC TATTGCTTTAGTCGCACCGC CGGTGAATTACGTAATCGGC 
fepD TTGAGATGAAACGAGCGAGG TAAAGCCCATTACGTCAGGG 
fepE TCTATCGTCAGGATTGTGCG TGTTAAGCGAACTGAACCGC 
fepG TTATTGGCCTGATGATGCCG    GCTTAAGGTACGCAGTAACG 
fhuA AAGCGTGAAATACCGGATGG AATCAGACCGGTCACTTTCC 
fimB ATGGCGTTTGTATGGCAACG TGGCCTGAACTTCTTTACCG 
fimD GTAACAGAGTTGAATGCCGG TGTTAAATTGCTTCGCCGCG 
fkpA GACAACGCTTTATAGTACCC CTAATTTAATACAGCGGAGG 
fkpB TTCAACCTTGCCGATACTGC CCACATAGCGGTTATGTACC 
flgB TTGCGATGTGAGATTGCTCG AACATCGGCAACCTTTACGC 
flgC ACCTCAACGCAACACATTCC GCTGTTATCAATCTGTCCGG 
 
E. coli Checking Primers Sequence (5’→3’) 
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flgM ACAACGCGTCAATGTGATCG ACAGTAATTTCCTGCCAGCG 
fliG GAAAGCTGTACAGCAACAGG CTGATAACCTTGCTCATGGG 
frdA TACGCAGGAATCAAACAGCG CGTTGTTAACCATCATGCCG 
frdB AATGGCACGTAAAGAGTCCC TTTCGGTGCCAGTTCAAACC 
frdC  AACTGTGGTTTGTGCTACGC  GAATACGCGACCAATGAAGC 
frdD TTAACCTGATCACTCTGGCG TGATAAATTACCGCCACCGC 
frvR CGCACATAACGATTTACCGC AAGGCGGCATGAATTTCTCG 
fsaA TAAGAAATACGACCGTGCGG AAATGCTGGCAGGTTATGGC   
fumA ATTCTGCACTCGTGAACTGC AAATGCGGAAATGCTCCAGC 
fur TGTACCTGTACAATGTCCCG ACAACATCAGCAGTTTGCCG 
gadW CATAAGCTATACGCTGTGCG   CAATACTGACCCACATTCCC 
galU ATGAGCAAACGATAACGCGG TGAGCAAGGTAAATCCCTCG   
garP TGCAATATTCTCCAGCCAGG AACCGATATCCAGAAGACGC 
gcl GATGTCGGTAGTGTTGTTGC CGAGTTTATTACTCGCCAGC 
glcB GAAGAGATGGTGAACAACGG  AACGCAATTGCTACCTCTGG 
glgC CAAATTCTGCTCTCGGATCG ACAACAGCGTGATATGTCCG 
glnA AGGTCATTGCACCAACATGG AAAGCAGTCTCCTGAACAGG 
glnL GACGCAAATGCGTCTTATCC ATGATGACCGGAAGCATTGG 
glyA AGAAATCCGTTTCCGGTTGC TACGACAGATTTGATGGCGC 
gnd TATTGACCTGTGCTTGAGGC AACGCTACGTTGTTCGATGG   
gpmB GATGCAATATGGCAGGATCC TGCAGGAGTTTATCCTGACG 
gpmI CAGGAAAGGAGTATACCTGC TTTCAATTGTGCGAGCAGGC 
guaB GACGAACCGTTTGATTCAGG CACAGTTCGCAGTAAACACC 
hcaD CGATAATGCAGTCTCTGACG CCATATATTGGACCGTACCG 
hcp TCAATGGATTTCACCCTGCC AAATGGTGTAAGCACGCAGC 
hfq TGTGGTCTTACCTTGAAGGC TAGATGTGTACCAGTACCGC 
hisQ GCACTGAACAAAGCCTTTGC CACCAGTAAAGCGATAACCG 
hlpA GGAATGTAGTGGTAGTGTAG CCGGTGATGACGATATCGCC 
hofD CATGGTTTACTCGGTCATCC TTCATGATTACGTCAGCCGC 
hrpA ATGTTTGAATGGGCGATGCC TGGTTCCTCCTTATCGTTCC 
hscA GAACAGGCGAAAGATGAAGC  GCGTGTTCAATCTCGATACC 
hscB TGCAATTTCTGGACGGTACG AGTGAACAACAGATGGCAGC 
hslR AAGAGGATCAGCGGTTATGG CCATCAAACTTCAGCGTAGC 
hslR AAGAGGATCAGCGGTTATGG CCATCAAACTTCAGCGTAGC 
htrB ATGCGGTTGTGTAACACTGG ACATAGCAATCCGCTGTTGG 
hupA TTAGCTGAGTGCGAAGAACG TCTTCAGCAAATCCACTGGC 
hyfB GCCAACACAACATGCTTTGC ATCAGACCTGAAGATGTCGG 
hypD AGCGCGATGTCGATTTAACG AGAACAGCGGGTCAATAACG 
idnD TTACCTGCTGCGATACTACG TTCTACAGCAAGTTCTGCGC 
 
E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
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ihfB GCAAACTTCTCCAACAACGC  GTGTGCAACTTTGTTGAGCG 
intB CACATCGCTGTATGCAATGC TGGTTGTCTGGAGATTCAGG 
iscS GCGATCGACGTTAAGTTACG ACTTCCCTTTCACCCATTCG 
ispZ TTCCGGGAATTATCATGGCC CAACCACCAAAGATGTCACC 
JW0258 AGTAAGTTGGCAGCATCACC TGTCACACTGTACCGTAACG 
JW0530 TGTCACACTGTACCGTAACG ACCAACAGATGGCCATAACC   
JW5326 ACGACGGATATGTTCAGTCG GACTTGAACCGAAGAACACG   
JW5460 TCCTGCGGACTAAATTCAGC GGTTCCTGATGTACTAAGGG   
JW5675 ACCTTCGCGAACAAACTTGC AAGGAATGCTCTGTTCCTGC 
kch GCAACCGTGTTCTTGTTTGG CGCATATGGATTCATCTGGC 
kdpD TAAACTAATAGCCGCACGCG GTCGCGGATAAACTCAATCC 
kdpE TCTACAACTGGATGTCTGGG AGTTGTCCGCCTTATATGGG   
kilR TTGAAGTTCGGCTGATGTCC TCGGTAGTTACAACAGTGGC 
lamB TCCATATCCAGATCCCTTCC CTGCTGATAAACAGAGGACG 
ldcA TATTGGCATCCACTGCATCG ATTGTTGTGGCATCCAACGG 
ldcC ATCGTTGAAAGCGCAACTGC GATAGACTTCGCTTTGCAGC 
lhr CCGTATTGTCAAAGGCTTGC ATACAAGTCTGAAGAGCCGG 
lipA TGTTACAGCCAGATCACAGC CTCATAAAGAGTGACGTGGC 
lipB AAGCAGCAAAGGCAACTACC GTCTAATTGGAACGGAACGC 
lon TGGTCAAAGCAAACCGTTGC AGCAGTTATATCAGGCCAGC 
lpcA TACTTGTAGGAGGTCTGACC CAATTCGCACATGGGTAACC 
lpp TGAATCCGATGGAAGCATCC TAAAGCGTTGTATCGTCGGG 
lysR TGCCGACGAATAATTTGCGC ATTCCTGAAGCGGATGAACG 
macA CTGCTGAGAGATTCAGATGG GCCGAGAATATTCATCAGGG 
macB TGCGCAAGTGCATATTCAGC TCCACCATTCAGATGGATGG 
maeB CCGTCTAACTCGTTCATAGG TGGAGAGATATTCGCTGTGG 
malG TCAACTGTTAACCAACGGCG GGGATAACGTAAGTTGAGGG 
manB TGTAGAGGAATGACAGTCCG TTAATTGAAGTGCGCTCCGG 
manC TTCCCGCGAATATCATAGGC   CAGCTTTGCGAAACCTTTCC 
maoC TGAACTGTGACGGATTTCGC TGTTCTTGTTAGCAACCGCG 
mcrB AAGGCTGTATTGTCCTCACC TGATGCCAGGAATGATCTCG 
mdh CGGTAGGGTATATTGTCACC TTCGGTGGATAACAAACCGG 
menA TTACACACTGTTCTGGAGCG TATTTGTCCGCCAAACGACG 
menD AATTAGCGGCAATGTCGTGC AATCCATCGACGCTAATCGC 
menG ATTACTGGTGAAGCAAGCCC AAACAACTCACTGTCGCAGG 
metE TGAAAGTCCTTCACTTCGGC GCAGAGATTATCGTGTACCC 
mioC GATCATGCGTACCATCAAGC CTTATTAGGATCGCACTGCC 
mipA AATGTAAAGACCAGGCTCGC TAAACCGAGTTCAATGCCCG 
mltC AGATCTCCAAAGAAGCCTGG AAAGCACATTTGACCGTGCG 
 
E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
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mltD TTCTTCCGCACGATTTGTCC TCTCACGTACGAAACTACGC 
moaA CATAGCGAAAGTGTGGATGG TACCACTTGTACATCGTCGC 
mobA ATGTCATCCGTCAAATCCGC TGGTGTTTCCGTCATCAAGG 
mqo CCGGACGGCATAATATTACG TATCAGCATACGCCACATCC 
mrcA GATAATGTCGTTCTCCAGCG ATGGATTTGCTGGAAGACCC 
msbB TATGGATAAACCAGCAGGCC  AATCTGCTGCGCGATAAAGG 
mscL AATCTGCGCATTGAGCAAGG TGATCCCTTATTCCGACAGC 
mtlD TGGCAGGTCGTAAGTAATCC TCTACAGCATACTTCACCGC 
mtlR TACGCTGGAATATGGTCTGC AATACCCGATGAAAGCGTGC 
nagZ TCAATGACTATGCCACTCGC TAGGGTTGAAGATCACCTGG 
nanE TTTACCTACAACGTTGGCGC GATTATGCGGATTAAGCGCC 
nanR CAAGGCTATTTATGGTGCGG ACGTATAAACCGTCGATGCC 
ndh TGATGCGCTTCTTATCAGGC TTATTCACGGGAACACCTCC 
ndk TGGTTTCTGAATGGCGAACC TCCACTTCATCACCTGATCG 
nifU TCGCAGTTTCTTCAGGTTCC CAGAAATTGCAGGCTCTTGC 
ninE TGAATACCTCATCAGCAGGG ATGCAATGGTGGCAATCAGG 
nlpB GGTCTTGTGGCGACCGATAC CCTTATCCGAACTACGTCCG 
nlpC GATTGTGATGAGCAGTCACG   ATCTTCATGGTAACCGTCCC 
nohA TCACTTTACGGGTCCTTTCC ATAAATGCCGGAGCATGAGC 
nudH GCTTATTCAGAATGCTCCGG ACAACGTCGATCATGATCGG 
nuoA TTATCCTGGAGTCGTCAAGG ACGAAGTCACCATCTCAACG 
nuoB TATCTTCGACGTTGAAGCGC TGAACAGTAAAGGCATCCGG 
nuoC TCTATCGGCAAAGAACGTCG TCTGACTGTAGAACGTTGCC 
nuoE GCCTGCCAATGAATCTTTCC GCATTACACAGCAGGTAACG 
nuoF GCTGCTGCCAACTTGCTGCC GTCTACATGAATTGTAGCCA 
nuoG GCGCCATCAAATATTTCCGC TAACGGTTCTGGAACAGACC 
nuoH GCCGTACATCAAACTCAACC ACGATACGACCACGATAACG 
nuoI TCTCTGCATTGATGGTGACG CACGAACAGCACCATAATGG 
nuoJ TTCCGCATCAACTTCTCACG GAATGTACATCACCTGACCG 
nuoK TAACGATCAGGGTATCGACG GATGTTAAAGTCGCCTACCG 
nuoL ATCATGATTAACGCCTCCGC  TAGCCAGGGTAGTAACATGG 
nuoM TGCTGTTAAGTGAGAACGGC TAAGCCCAATAACCGAGAGC 
nuoN TTACATCGCGCTTACTTCGG ACGACTGCATTTCAGGAACG 
ompA GTAGACTTTACATCGCCAGG TATTGTCTGGCAACGTCTGG 
ompR  TGCGCACATTGGGTATAACG  TTGGAGTAGAGAGAGATCCC 
osmY GTGATGACATTTCTGACGGC CCATGAACAAACTCACCAGG  
oxyR ATTTGAGCCTGGCTTATCGC  ACAAATCGTCGGCATGAACG 
paaC GTTGGCAGTTTACATGCTGC ATCAAATGTTCCGTTGCCGG 
pal CAGATGGGCGTTTCAAAGCG CCTGAGCAAAAGCGGCCCAG 
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parC CTGCTTAAACCCTACGTTGG   ACCTGAAATCAGGTTAGGGC 
pcm TCAAAGGTATTCGCGTGACG AGCGAAACCAGTGACAAAGC 
pdxH CTACTGCATCTCAAACAGGG   ATAACGACTGCACCTTTGCC 
pepB TTTGTTAGTCTGGCTGGACG TGGATTCCAGTAGAGTACGG 
pfkA GAAATGGAAGACTCTCTGCC TTGCGGGTATATGTTGAGGG 
pfkB TCAAAGATTAGCGTCCCTGG  CATCATCCGTCATAGTGAGC 
pflC AGCAGGATTACGCAAACTGG GCAATGTTCAAATCGCTCGG 
pgi AATGCTTCACTGCGCTAAGG ACCTCACGGTATGATTTCCG 
phnG GAAATCCCGAATATGTCGCC TTCGTTCTTCGGCAATACCC 
phoQ CGAAGTGATCAAACTGACCG TCAACTTCGCTTTCCATCGC 
potF CCGAGCTATAGTCTCAAACC CATCGTAGGATTTGGTCAGG 
ppdC TGGAAAGTCAGTCATTGCGC TTAAAGGCGCTCTCTTTGGG 
ppiA GGCATAGCGGGATATGCCGC GACGCCTTCAAGACGGCGAC 
ppiB GATTCCACACACGTACATGC CCATGCTTCAAACAGATCGC 
ppk ATTAGCTGGTTTGCCGATGG  TTTAAACCGCGCGTCATTGC 
ppsA GCCGCATCATTCATTATCGC GTCGAAGAGAGCAGATTTGC 
priA CATTACGTTACCGCAAGAGC TCATTAATGCTCGGGAGACG 
priB GATGAATGTTGAAGCTCCGC GTATTAATGGACCGTGACCG   
proW GTGGTCGACGAGGACCAACA CAGTAATGCCTTTGCCCGGC 
pstS GTGACAAACCGTCATCTTCG   GAGAGACAATAATGCCACCC 
purA GGAAGAAGATGATCTCTGCG   TAACACTGTGTCGGATAGCG   
purD CGTGATGACGAAGTGATTGC TCAGGATATTCAGCCGTTGG 
purE GCATACGGAAGGTTCAATGG CTATCTCAGCGGTAATCACG 
pykA TTGAAGCGGGTCAAAGAAGC CGAAATCCAGCCGTATAAGC 
pykF TTTCAGCGTATAATGCGCGC AAAGAAGCATCGAACGCTGG 
pyrC TAACCAGCAACCTGCTTACG CATAACGTACCGATACGTGG 
pyrI AAGCGCAGTTTGTTCTTCGC TAAGTGGCGTTTACGGTTGC 
qor AGCCTGCTGTTTGTTGAAGG   TTGTGCGGATGATCACAACC 
rbfA TCATCGAGATCCAACGTACC CATCAGAAGTATCGGTACGC 
rcsA ATCTTCCAGGATACTCCTGC CGATGAAGGTGAATGATCGG 
rcsB AGTGACTTTGCTGCGTTAGC TCAGTGCAAATGCCAGATGC   
rdgC TCGTTTCAATAGTCTGCCGG TCGAACAACCCGATCTTTCG 
recA ATGCATTGCAGACCTTGTGG GTTTACGTCGCAGTTCTTGC 
recB AAGGCATGGCTATTCTGTCG GATTTCACTGACACAGGTCG 
recC CAGAAACCAGTACCAACAGC GTTTCTGCCTGACTTAAGGG 
rep TGGATTCACGATGAACTCCG GCCAGAGATGACATTACAGG 
rfaC GTGATCCGTTTGATTACCGG   GTAAGTAGCACGAAATGGCG 
rfaD GCAATTAGCATCCTTGCACC   GAGGCATAGGAATAGCTTCG 
rfaE TATTCTGGAACTACTGGCGC GGGCCTTGTATAAGGAAAGG 
 
 
 
 
224 
 
E. coli Checking Primers Sequence (5’→3’) 
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rfaF GGCTTATCACAAGAAAGGCC TTGCCACAGGAATAACTCGC 
rfaG ATTTGGTGCAACGGATCACG TCACTCAGGCGATGAATAGC 
rfaH TGATTTCCAGATGCGGATCC   ACTGATCGAAACTGATGCGC 
rfaP GGGTACGCGCATTATATTGC CAGCCATGCATTATCCATC 
rfaQ AGCACGTCAAAGTAAGTGCG TGGTATGGGACTTAACTGGC 
rfaY CTAAACCGTGGCACAAATGG GGTATAACGACTTCTCTGGC 
rfbB ACAACGAGTTAGCAGTAGGG AACTCCGGTTCTGATTCTGC 
rfbD CTTATGTTGCTGATCGTCCG AGCGGGTAATAGATCATCGG 
rffA AACTCAATGCGACAGATGCG GTACTGGGCAACGTATTTGG 
rffC CTCCATCAACCAGATGTACC TCGGCATGATCACTTCATCG 
rffH TGACCTGATCACCTTTGTCG CAACTTCACCTTCTACCAGG 
rhaR TTCTCTTTCACTGCGTACGC TGTGTTACTCTCGACACTGG 
rhaT AAATGCCCGAGATGTGAAGC TGCGCAATATCTTCTCCAGC 
rimK GCAACTGGCGGAATATTACC AGACACCGTCGAAATTCTGC 
rimM TTCTACCAGGTTGTTGTCGC TTGATTCGTTGCCAGTTCGC 
rmf AGATGGTTAAAGTGCTGGCC ATTCACTGGTCAGGTACTGC 
rnfC AATGTATTCAGGCGTGTCCG  GCTTGCGTAGTTTGAGTACG 
rnk CGTCTTCCATAAACCAAGGC GCCGCCATAATCAGAAATCC 
rnt  TACGGTTATCGCGTTTGTGG  GAAGGGTCTGGATTATCTGC 
rpe TGAACAACAAGCGCATCTGG  TACGTACCTGTTCTTCTGCC 
rpiA ATACCCAGACCGTTGTATGC CGGCAATATGAACGTTTGCG 
rpiB TTGTGAACAATGGCGAGTGG ATCGCCTGCTGAATATTGCC 
rplA CTGGTATCAAGTCTGGTTCC TCTATCCGTCGCTATTCAGC 
rplI AACTACATCACCGAAAGCGG TCCTTATCAAGTTCAGCCGC 
rpmE AGTCAAAGGTACGAGGAAGC TGAAAGAGTTCGACCTGAGC 
rpmE2 GGAGATAACCTCCATTCTCG GTTGGCCTCAAATGAACAGG 
rpmJ  ACCTTTATCTGCCTGATCCC ACGGCATGCTTATGATCAGG 
rpoN CGTTAAGCGTGTATACCTTGGC GTAACAAATTCGCGCAGTGCCG 
rpoS CCATAACGACACAATGCTGG GTGTTAACGACCATTCTCGG 
rpoZ CAGAAATGAGCCATTACGCC TAGTCGAGTTTCATCTCGGC 
rrmJ TCGGTCAAACCATTACTGCC AGAGTAATCCACCTTACGGC 
rsd ATTCGCCGATTTGTAGTGCG ATGAAGCAAGAGACGATCGC 
rseA ACGCATGGCAATAACCTTGC ACAATTGTGCAAGAGGACGG 
rstB TGGGAATTAGCTACCCATGC CTTGCGAAAGGTTATCGACC 
rtn TCAGCCGCAGCTAATAAACC GAAATTAAACGCGTACCGGG 
rusA ATCCCTGGCGTATGTAATGG CCAGAACGCCAATTACAAGC 
sbcD GAGCTTCATCTTCTACGACC ATACAGCGCCAGACAAATGG 
sbm TCACAAAGTCCTTCGTCAGG TCAACAACATGCCAAAGGCC 
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secB AGAGATGATCAAACGCAGCG CGAGATCGCTTTCAAGATGG 
secG GTGACTGAATTTGCACACCG TGACAACCATTCCTCAGACC 
sfsB TCAACGCGATCGTTAATCCC CTTTATGCATGTGCCAGAGC 
slyA TGTAAGGGCAATCCTGTTGC TGTTCTTGGTGGTTTCCTGG 
smpA GCTTCACGGTCAGAGTAAAC GAGCTTCGCAGGCAACGAGC 
smpB ACTGATACATTTGCTCCGCG GATTTATGAGCGCCATGACC 
soxR  ACATAACCCAGGTCCATTGC GTATACCGTTCAGGATTGCG 
sprT AACACCTTCTGGGTGTATGC GATTGCAGATCAACAACGCC 
srlR GCAATTACCGGTATGCATGC TAAACAGCATCACATCGCGG 
stpA TCGGTGTATGTAGTAGCTGG TCAACCCTTGCCGTTAATGC 
sucB GAAGTGTTGCAGCAGTTTGC CGTTAAACGTCACATCAGGC 
sucD TCTGGTTAACATCTTCGGCG   ATTTACCCTGATAGCGCAG 
sufI CAAAGATCAGGTTCGTGAGC TTGGATCAGGGAGATAGAGC 
surA GCGGTATATGACAACGCAATC CGGAGGGTGAGCGGCAAAC 
surE ATTCGAACAAGCAGCTGTCG ATTCGCGCCACCATATATGG 
talA ACGTGGCGCACATTATTACC CAAACTGTAGAGCAGCATCG 
tap AACAGGCGAGTCGTTTAACG  CGCTGTGCTGATTAGATTCC 
tatA ATGTACGTCAGGGACAATCG   TCAGACTGTCCTGAAACTCC 
tatB GCAATGAGCGATGATGAACC ATCATCGTTGAACCTTGCGG 
tatC TAATGAAGCTGCGCATGAGG CAACAGGACGAATACTGACG 
tatD ATCGGTGTCTTCTTCTCACG CGAAAGACATTGTCGATCCG 
tatE TCATTATGGCGGAAGTGACG GTTCGACGAAATGAAAGCCG 
tbpA TAAATCAGCGTGGTTTGCGC AAGGTCATTGCACACAGACG 
tfaD TATCTCCCGAAAGAATCCGC GTTGTGCACAATAGCTTCGG 
tig AGTGATGCCGCTATAATGCC CTGCTGTACCGATTGTAACC   
tktA CGCTCAGTCTCAGTATAAGG AGCAATTGAGCAGGGAAACC   
tolB CAGGCACCGGTTGCCACGGG GCAATTGCCATAACAGGCAG 
tolC CCGCGATAAAGTGTTTCTCG TTCAGCGCATTGTTGTACGC 
tolQ CAACGCCGAGAATACTTTGC GCAACAGCACCAGCAGTACG 
tolR GCAACACTGCAAATGGTTGC AAGATGACATGCAGCACTGC 
tonB TTGAAAGGGCGAAGATCTGC AATGACTTTCTTACGGCCGG 
tpiA  TGCACTGCGTTATGTTGTCG ATGCTGGCAGAAGAAGTACC 
treA TCTTCGCTAATCACGAACCC CTTACCCGTAGAAATGACGC 
trmU GTGTGTAGCGGGTTAATTCG TATGCATCAGTGGATTGCGC 
tsx ACTCTGCTTACATCACCTGG CAGGCCTACGTTATTTCAGC 
tufA TGGTATGCTCAAAGGTCAGG   CATGCTTCCATTGCCAATGC 
tufB ATTACCTCAGCCTTCCAAGC GGCAAACCAAATCGAAACGC 
ubiC CCACTTCATGCGATTGTTGC CACAACGCCCATAATGTTGG 
ubiE AGCCAGGATGAAGAGTATCG ATTCGCCCAGTACATCAACC 
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E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
ubiF GTACTCGTTCATCTGACAGC GATTCTGATTCCGGCATTCC 
ubiG CGCATAATCCAGATAGGAGC ATATCAGTCAGCGAGTGTCC 
ubiH GTGTTTATGGTCAGGATCGC TACGAGAGAGAATGTCCTGC 
ubiX TGAATGCTCGGTGTTCAACG    GGTCTTATGCCATCTTGACG 
ugpA  GATTGTGGATGAAGAGCTGG AGCTGTTAAGCAACATCCGC 
uidB TATCATCACCGAATACGGCG TGAAATCGAGCAATCCTCCC 
uvrY GTCACATTTCATCGTAGGGC TCAATTTGCTGGATCTGGGC 
uxuR CGTTGTAGGCCGGATAAGGC CCAGGAAGAATGAGTACTAAC 
vacJ CGTATAGCTAAAGCGTAGCG TACGTCTAGGTCATTGTCGG 
wbbJ TATATGGGATAAAGCCGCCC TTAGCCACGACCCTTTAACC 
wcaD TTCTCGCGTCGATAACTACC CGAAGCTGATATCTTCCACC 
wza TCTCATCAACGACTGCATGC GAGACAGTTGATGTTCTGCG 
wzzB GAAGAGCTTAAGGATGTGGC AGAAAGTGGGTGAAGAAGGC 
wzzE TTGTGCTGATTACCCTTGCC GCAGTGACGCAAACTTTAGC 
xapR GTTTACAATCGTGCGCTTGC CAAAGATTCGAACCTGCAGC 
xdhA CTATTTCCCATCCTGATGCG TAAATGTCGTTGCAGAGCCG 
xylF AATTCACAAGTGTGCGCTCG CACACAGCACTTTCATCAGC 
yadM GAGCAAGGCAATGTCATTGG ATGTAGCGGTACAAGTACCC 
yaeD ATAAGCGTACTCTTACCCGC GTTAAAGAGCAGTTGCGACG 
yafC CTATTACGTCAACCCTTCCG TAAACACAATGCGACTCCGG 
yafP TCTACGACGACTCCTTTACC  ACTTATGTAAGCTCCTGGCG 
yagE GTAAGTGTCTACCATGTCCC TAATCAGCACCTCTTTGCCG 
yagT CCCATCATCATCAACATCCC CTTCAATCTTATCGAGCCCG 
yagV TCCTTTATTACCCGCAACGG ATGATTTCCAGCCGTTACCG 
yagY ATGAATATAGAGCGGGACGC AGGATGGTTTCACCTTCTCC 
yagZ TCCATTGAGATAACCTGCCC TATACCCATCGGCGTAATGC 
yahL CGCGGTGATGTGAAATATCG AGAGATGGAATGCCAGTTGG 
yahN TTCAGCGGCATAGACATTGG GTTTGGCTATTCAGGATGGG 
yaiO AGAGGGAATTATCGCTACCG TTTCGCACCTCATCATCTGC 
yaiP AATTCTCGGCTACGAAACCC GGCGTTCGAGCATTATAACG 
yaiT TGTCCACATTCGGACTTAGG CTACGCAGAGAGATAACTCC 
yaiY CTCACAACGAAGATTCACGC CTGGCATTCAACTGGAAAGC 
ybbK ATCCTTCGCAGGAATAAGGG   CAGGATGGCAAACATTACCC 
ybcI TACAGGTTGTTGCCTGATCC TCACCTGCGTAAACTTTCCG 
ybcN CGGCATAATTATGTCACCGG GGATTCTTACCTGGCATTCC 
ybdF GACCATGTTCCATCTGATGG   ATGGGCTGTATTGCAGTAGC 
ybeB GAGCGCCATTGATATCAACC ATATCGAGGGTGACAATGCG 
ybeD TCTGAAAGCCAGCTATGTGC TATATCACAGCGAGGAGAGG 
ybeY AAATCAGGCTTACGTCACGC GCGTATCTTCGTCGATAAGG 
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E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
ybgC CAGAAGGTTCTTTGGCAAGG GTCCGCTGGATAATAATGGC 
ybgF CTCCGGAATACAACATCTCC TACCAACTGAGCTAACGACC 
ybgI ACGTCACGTAATAGTTGCGC TCAATAAAGCGAGACTCCGG 
ybgQ ATCGTATTAGGTTCAGCCGC GTTCCAGACGTTGAATAGGG 
ybgT CAATGTGGGATGCAACTTCC CTTGCCAAAGAACCTTCTGC 
ybhD ATGTTCCGCTAACAGGAACG TCACCACATCTCGGTATACG 
ybiO ACTTGTAGGACGGATAAGGC TGAAGAGAGCAAAGGCTTCG 
ybiU TAACAGCTGACCTCTCTACC AACGCGTGATCGACTTTAGC 
ybiW GCTTTAATGCCGACGAAACC TGTGAATGATTTAGCCCGGC 
ycaI GATCGCGCCAATATTTACGG CAAGAAGTGGCTTAAGGAGC 
ycbF TGCAGAGCGAAATGTTGTCC AACGGCGTTCCTGTAATACG 
ycbR TGAATGATGGTACAACGGCC TCGAAACGAGACAAATCGGC 
yccW TTCGTACTGTGTGGTGTAGC TATCGTCCTCCATCACTACG 
ycdK TTTCTTCAATACGCCGCTGG ACTGCGTAATGCTCAATCCC 
ycdP AGCCTGATGATCGAGAATCG TCGTCAACGGTGATATCACG 
ycdQ GCATCAGGCTATTTCTTCGC CGCTTTGCCAGTAATAACCC 
ycdS TGCCGTATTCCTGAAGATCC AGCCAGGCAAATTGTTCACG 
ycdZ TATCTGTTACCCTGGTGTGG ACGAACCTGTTATGCTGTGC 
yceP GAATTAATCGCGTATCGCCG AATTCTCCAGGAAACGTGGG 
ycfF GGTTTATGTTGTCGTCAGGC TAACGGGTTCTTGCCTTTCG 
ycfJ TTAATCGACGTACACTGGCG TTATGTCAACGACAAGCGCG 
ycfK TATCTTGCACAGCTTGCTGC TAGAATCTGGCGGAATGACG 
ycfM AACCTTCAGCATCCTCAACG GTGATAAAGCCCGATACTGG 
ycfS AGAACGCGATCGCTTAATGG CGGTACAATCAGTGCTAACG 
ycgY TCCGCTTTCACATCAGAACG ATGCTGGATTTGATCTGCCC 
ychE CAAAGCTGACACCTTTCAGC ACATGATGGTGAGGAGAAGC 
yciM TATTTCCACATTGCTGGCGG GTTAACGTCATGACCAGACC 
yciT CTCTGCGATCCATAATCTCG ATTCCGTGAAATCTGCTCGC 
ycjU TGTCTTTCCCTCTGTTCTGG CATTCATTCGTTTGCCGTCG 
ycjZ GGAGGGAAATAGATCACTGC AACTCCGAACACTACGTTCG 
ydaT TGTCCAGCAATTGAACGTGC AGGATGGTTCAACATCAGCC 
ydcP CTTGATCTGTGCGTTGATGG AATGTGGATCATCAGCTGCG 
ydcS CCTTACAGACGGCATAATGC ATACTGACGCCATCTACTGC 
ydcX GATGGATAAGGGCAAGTTGC ATCTTCCCGACTTAACTCCG 
yddM TAAAGTGGTGCCGAAAGTCG AACGTGTAGGCCTGATAAGC 
ydeU ATAACAGCGGTGTGATGTCG TCCACAGCAAGTTTATCCGC 
ydfP TGTCCCTATAACATTGGCCC GAAGAAATTAGCCCTTGGGC 
ydfQ GCCTTACAGGACAAAGAACG TCAGCAGATTTCTGTTGCGC 
ydfR ACAACAGGTGTTGCCTATGG TACGATCACCAGCATTCAGC 
228 
 
 
E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
ydgI AATTCTCTGGCAACTACGGC AGTACTTCATCGGCAAACGC 
ydhM TCGTCAGACTGGCAAATTCC TTGCCTGGGCAGAAATTTGC 
ydhP TATCGTCCTCGGTTTGATCG GTGAACTGGGAATTCGTAGC 
ydhQ ATTTCGACCGTTTGCAGAGC TCTGGTCGTTGAACCTATGG 
ydiK CGACGAGTAAATCGTTTGCG ACCGTGAGCTAATAGTAGGC 
ydjE  AAGACAATGATCCGTCAGGC ATTACCGATGGTTGTCGTGG 
ydjI GCTATGCCAATCGTTATCCG  GCGGCATCTTTACCAATACG 
yeaY ACGAATGCAACAGCTTTCCG GAGATTGATAACGGTCAGGG 
yebB GGATAGATATCCAGCGAAGG TGCCACGTTAGTCAGAATGC 
yebU AGGCAAACACTTCCTGTTGC GTTAACGTTCGATCACCTGG 
yecT GGTATTGAGACTGTAGAGCG CGATTTATCTGGGAAGTGCC 
yedV TATTACACTGACGCGCAAGG  TTAATGACGACATCACCGGG 
yedW  GCGGCATTAACCAAAGAAGG GACTAACATCCATCATCCGG 
yeeF TAGCAAATAGTGCGATCGCC AGAGCACCACAAATTAGCCC 
yeeU TCTGTACCGGTAAATACCGC GTGTGTCATTCAGTGTGAGG 
yegI ATAACCTCCCGTCACTAACG TCAGCAATGAACTGGCTACG 
yegN TTGTCTGGGTGCTGAATAGC AGGTCATTTCACTGACTCCG 
yegP GCCGAACAGTCATTTATCCG TCTGATGACAGGTCAGATCC 
yegT CGATTGGATATCGGCTATGG AGGTATCGTCGGTGAATTCG 
yehB TTGCTGGTAAATCGCAGTGG CCTGAACAACCAAGTTGTGC 
yehK ATGAGCTTCCGTTCTCTTCG GCGCATTAGTTGTTTGAGCG 
yehM ATTATGTCCACCGCTGAAGC TACTGTTGATCCACTCAGGG 
yeiA AAGCATGTACGGTTATCGGG TCCGCATTCGGTCATAAACG 
yeiW CTTAACCAGCAGCAGTTTGC CGCTCTATACCAACACTTCG 
yfbV CCCGCTGAGTTGTGAATTTG GTAACGTTCAGCATTTGCCG 
yfcQ CTCAGTACCAATATCACCGG GCAACGTTCAAATCCTGACG 
yfeU GTGAAGAAACGGATTGCAGC AACTGACGTTTGTTCTGGGC 
yfgA AGCCATCGACATTAAAGCGG TGAGTTTGAACGCTTCTGCC 
yfgC TCGAGCATAAAGACCTTCCC TTCTGGCGCATCAATTCACG 
yfgL GCGCGTAGTGCATGGGAAGC CAACGCACGCTATATTCGCG 
yfgM CGTCTGCGTGATGAATTACC ATAGAAGTTGCCAATGCCGC 
yfhG TTGCCAGGGATTGTATTCGC GCATACCGTCCATTTCATCC 
yfhM TCCTACAAACCATGTCGTGG AGAGGCCAGAGTTTATCTGC 
yfiM ACAGCGAGAGAAAGAACTGG CTATATTTGGTGGTTCGGCG 
yfiR GCCAACTGCATGAAGTATGG AGTGTTTCAGTTGCTGCAGG 
yfjD CTATATTGTGCTGCTGTGGG ATACGCTGAATGGTCGTACG 
yfjN AGTATCGAGTTGCTGCTTGG ATTTCCAGCGTAACGAAGCG 
yfjQ TAGGTGCCATACTCGATACG GTCATGAGAGATTCTCCAGG 
yfjR GATGTGAAGCTTAACCGTGC ATCAGACGAACCACTTTGGC 
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E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
ygaM CTTTCTGGGTTACCACATCG GCGCATGATTCGTATTTCCG 
ygaT TGGCTACGAAATGAGCATCG   TCCGTTCCATTTCGAGATCG 
ygaU TCTGGAGAATCGTCATCACC GTCATCAGGCGTTTCATACG 
ygaW CTTATAGCGTTACCTCACCC ACCGCTCTGGTAATTCATCC 
ygbE TGAACTGCGCAACTTTACGG TTAGTTTACCCATCCTGCCC 
ygbT CAACTTCAGGTTGGTGTTCC ACTACATTGCCTTCTTCCGC 
ygcO CAGCGTTATCAGCATGTTCC CTGATGGTGCAGATATTGCC 
ygdD GCTGGCAAATAACGTGATGG CTGTAACATGCCGACAATGG 
ygdQ TTCTGATCCAGTAGCCATCG GACGTAATCACTGGAACACC 
ygeA TGTGGGCATTACTTTCTGGC TATTTCGGTGGTTAACCCGC 
ygeF ATCAGAAGCTGCGAATTCGG TTCCTCTGTGATGTGTCTCG 
ygeI ACTGAGAGTGAAAGCCATCG TTAGAGCAAGAGTTGCTGGC 
ygeP CAGCAGTAAGACTTCCTTCC TCCGATTTGACAGCAACTCC 
yggC TTCCCAGTTCTGGCATTACC CTAGGATAAGCGAAACGTGG 
yggD ACGTTAACCGTGTGTACTCG GAGATATTCCCAGAAGGTGG 
yggL TAAACGCCGTATCGTTCAGG   ATTGCCGTCACTGAAAGTGC 
yghB TTTAGCGGGACCTTGATTCG ATTACCGTCTGCATAAGGCG 
ygjR GACCTCAATATGAAGCACGG GGAATACGTCTGCGTATTCC 
yhaC ACAATGTACTTGCTCAGCCG TTTATTCATGCCGGATGCGG 
yhaK GATCGATCGCATCCATAACC TTTACGCGGTAGCTTCATCC 
yhbE CTGTTTGCTAAAGCAGACGG TAAGCGTGTTCAGGTTCTCG 
yhbG  GACGGGTAATGCTTATCTGC GAGTGTCGATTTGCTCAAGC 
yhcB TAAGCGCCTTCAGGTATTGC CCGACACTTAACGCTAATGC 
yhdP GTAGCTGAAGCCTTGAAAGG TTGTAGGCCTGATAAGACGC 
yhdV ATCCGCCGTTGCTTTAAAGG   GAAAGCAGCGAAATAACGCG 
yheL GCATTAACTGACGATCTGGC ACCAGCTGGTTAACTGTTGC 
yheM ACGAATTTGACCTCGTACGG  ATAAGGTCTTCGTTCAGGGC 
yheN AGATCTGGTTACCCAAACGC AGTGGCAATGTAATCACGCG 
yhfW TACTATCGTCGTGGTCATGC TCATCAGGTCGTTCATCTCC 
yhiI TGCGTGTTTCATTTACGGCC CATTGCCCTGTTCAATGACG 
yibP  GTTCCGCTGATTTACGTTGG TGAATCAACACTTCGTGCCC 
yidL AATAGCCTTGTTGCGATCCG ATCCCGCAGTTTCAGAAAGG 
yihF TCCGGCGATGTTTGTTAACG TGTTACGCTGTGTTATCCGG 
yjbB TCCTTACAACAAACAGGGCG TGAGTAAAGGTCACGCTACG 
yjdB AATGCAGTCCATCTTCGTCG ATGCGCTGAATTACAACCGG   
yjfR TTCCACATGGATAGAGTGGG GCTCAACGACTTTCTCAACG 
ykfA TTTAAGGTGTATCACGGCGG  GTCCTCACTGAATACACTGG 
ykgE  AACATCGGGCATAAATGGGC  GAGAGCTGGTACAGATAAGC 
ykgG GCCGGTGCTCATGCGGCAAG CATAACAATGACGGAACGGG 
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E. coli Checking Primers Sequence (5’→3’) 
Gene Forward Reverse 
ylaC TCATTAACCCTGGTGTGACC GTGTTCTCACCAGCATATCC 
ylcE GCAAGCCGATTTGATACTCC ACTACAACGCACCTGAAACC 
ylcG CACTAAAGCAGGTTTCTGGC ATGATTATTAGCCGCCCACG 
ymdC GGATGCCTATCTCAATAGCC ACATTACACCGCACATCACC 
ymfM TCGTTCAGCAATCGAAGACG TGATATTCATCCACCACGGC 
ymfP ATCTGTATCACCTGAACGGC GCGGTTTATCAGTTCAGTGG 
ynbA TGAACTGGATTTAGTCCGCC ATCAGAAACCCAGCCAAAGG 
ynhG TCAATTTCGATGTGCGTCCG TCAGGCTGCTAAAGATGACG 
yniC TGACCGCATTAATGCCTTCC TTGGCAAATACCGCACAAGC 
ynjI TGATCAAGCCAAACGTACGC  AGGTGAGCAAACCAACTACG 
yoaC GTGTTCGCCCTTTGATTAGC TTCACTCACCCATGAACAGC 
yobG TTCGTTAGTCCGTGAACTGG TCCATACCAGTGCTATCAGC 
ypdF ATTCCGTCGTATATGGTCGG ACCTGTCGATTCATTCAGGC 
ypdI GAGAAATCAGAGAGCAACGG GGTAATGAACTAGTGACGGG 
ypfH GTGATGCGCAGTTATGTACC   CGAAGAAGTAAGCTGAGTGC 
yphH ATGGGATGTATATCCTGCGG ATGTGCTCGTTGTTCATGCC   
ypjB GTAACGCTGTTATTGCTGGG CTTAAGCCAAGTAGTACGCG 
ypjC CGTGGCTATGCTCATTAACC AGCACCAATTCAGTCACTGC 
ypjF ATGTCCTAAGCTGGATGTGG TTGGTGTTGTCCTTACACCG 
yqaA GCTTCCTCTTGTTGATGTGG ATGGTGACCATATGTGCAGG 
yqaD AATTATGATGGGTCCACGCG ACATGGCGATGCTCATTTCG 
yqeJ CATCCGTGGTTATACTTCCC TCGACTCATGGATTTGCACC 
yqiG CAAAGCTCGTATGGAATCCC TATGATACGGGTACGATCCG   
yraP GGCATTGACCGGCTATGACG TCGGATGCGGCGTAAACGCC 
yrbI GTATTGCCGATGTGATGACG CAATCGATAGCTTAGTGCCC 
yrfD TCGTTATCTGTAAGCTGCGG GCGGTATAGGCCATAAATCG 
ytfM TGTTAAGCCGTTTAACGGCG GACCTGAATGTCTTTCAGCG 
ytfN CGAAGTTGATAACCGGATCG AACGTACATCCATGCACTCC 
ytfP TGGCGTAAGCAATTTAGCGC TAATACGCATCTGCACCTCC 
znuB TTCTCACGATCTGCATCTGG ATCACTTTGGCATAACGCCG 
zur CGACAAGGCAACATAACACC GAATAAAGATGAAGCCGGCG 
zwf AGATATTACGCCTGTGTGCC CTGCGCAAGATCATGTTACC 
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